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Abstract
Type 2 diabetes has reached epidemic proportions worldwide. The resulting in-
crease in chronic and costly diabetes related complications has potentially catas-
trophic implications for healthcare systems, and economies and societies as a
whole. One of the key pathological factors leading to type 2 diabetes is insulin
resistance (IR), which is the reduced or impaired ability of the body to make use
of available insulin to maintain normal blood glucose levels.
Diagnosis of developing IR is possible up to 10 years before the diagnosis of
type 2 diabetes, providing an invaluable opportunity to intervene and prevent or
delay the onset of the disease. However, an accurate, yet simple, test to provide
a widespread clinically feasible early diagnosis of IR is not yet available. Current
clinically practicable tests cannot yield more than a crude surrogate metric that
allows only a threshold-based assessment of an underlying disorder, and thus
delay its diagnosis.
This thesis develops, analyses and pilots a model-based insulin sensitivity
test that is simple, short, physiological and cost efficient. It is thus useful in a
practical clinical setting for wider clinical screening. The method incorporates
physiological knowledge and modelling of glucose, insulin and C-peptide kinet-
ics and their pharmaco-dynamics. The clinical protocol is designed to produce
data from a dynamic perturbation of the metabolic system that enables a unique
physiologically valid assessment of metabolic status. A combination of a-priori in-
formation and a convex integral-based identification method guarantee a unique,
robust and automated identification of model parameters.
In addition to a high resolution insulin sensitivity metric, the test also yields
a clinically valuable and accurate assessment of pancreatic function, which is also
a good indicator of the progression of the metabolic defect. The combination
xx ABSTRACT
of these two diagnostic metrics allow a clinical assessment of a more complete
picture of the overall metabolic dysfunction. This outcome can assist the clinician
in providing an earlier and much improved diagnosis of insulin resistance and
metabolic status and thus more optimised treatment options.
Test protocol accuracy is first evaluated in Monte Carlo simulations and sub-
sequently in a clinical pilot study. Both validations yield comparable results in
repeatability and robustness. Repeatability and resolution of the test metrics
are very high, particularly when compared to current clinical standard surrogate
fasting or oral glucose tolerance assessments. Additionally, the model based in-
sulin sensitivity metric is shown to be highly correlated to the highly complex,
research focused gold standard euglycaemic clamp test.
Various reduced sample and shortened protocols are also proposed to enable
effective application of the test in a wider range of clinical and laboratory settings.
Overall, test time can be as short as 30 minutes with no compromise in diagnostic
performance. A suite of tests is thus created and made available to match varying
clinical and research requirements in terms of accuracy, intensity and cost. Com-
parison between metrics obtained from all protocols is possible, as they measure
the same underlying effects with identical model-based assumptions.
Finally, the proposed insulin sensitivity test in all its forms is well suited for
clinical use. The diagnostic value of the test can assist clinical diagnosis, improve
treatment, and provide for higher resolution and earlier diagnosis than currently
existing clinical and research standards. High risk populations can therefore be
diagnosed much earlier and the onset of complications delayed. The net result
will thus improve overall healthcare, reduce costs and save lives.
Chapter 1
Introduction
The number of people with diabetes is increasing rapidly due to aging popula-
tions, and an increase in the prevalence of obesity and sedentary lifestyles. The
resulting increase in diabetes related complications has catastrophic implications
on healthcare systems and on entire economies and societies. Understanding the
underlying metabolic disorder allows identification of those at risk of developing
diabetes up to 10 years earlier, and this would provide an invaluable opportunity
to intervene and prevent or delay the onset of the disease. This chapter discusses
the overall prevalence of diabetes, its development and underlying problems, and
its clinical classification and diagnosis.
1.1 The Diabetes Epidemic
Type 2 Diabetes is a disease that has reached epidemic proportions. An estimated
171 million people were diagnosed worldwide in the year 2000. This number is
expected to rise to 366 million by 2030 [Wild et al., 2004]. About the same
numbers are estimated to have undiagnosed diabetes or pre-diabetes [Hossain
et al., 2007; Wild et al., 2004], effectively doubling those numbers. In New Zealand
it is estimated that by 2021, 250,000 people will have diabetes and 500,000 more
will have pre-diabetes, resulting in about 15% of the population directly affected
by the disease [PriceWaterhouseCoopers, 2001].
The total diabetes related health expenditure in the USA in 2002 was US$ 132
billion, second only to all cancer types combined [Kleinfield, 2006]. These costs
are incurred primarily by treatment of chronic long-term complications, such as
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Figure 1.1 Cases of Diabetes in 2000 and estimated numbers for 2030 with the projected
percentile increases [Hossain et al., 2007; Wild et al., 2004]. Largest increases are seen in
developing countries.
eye damage or blindness, renal failure, nerve damage in limbs leading to amputa-
tion, hypertension and cardiovascular disease [ADA, 2006]. As a result, diabetes
is the third most common cause of death in the USA.
One of the underlying causes of this epidemic is a worldwide obesity epidemic
and increasingly sedentary lifestyles [Hossain et al., 2007]. It is estimated that
worldwide 1.1 billion people are overweight, 312 million of those obese (BMI >
30), a number that has tripled in the past 20 years [Hossain et al., 2007]. An
estimated 155 million children are overweight or obese. The greatest threat of
obesity is on populations in China, the Middle East, Southeast Asia and the
Pacific Islands, as is shown in Figure 1.1, mainly due to changing dietary habits
[ADA, 2006; Hossain et al., 2007]. Whereas the disease was seen as a problem of
developed countries in the past, it is the developing countries that now have the
most rapid rise in prevalence [Hossain et al., 2007; Wild et al., 2004].
Typically, type 2 diabetes is not recognised early enough to intervene before
permanent damage has begun to occur, and is thus often diagnosed only when
treating its symptoms or complications at later stages [ADA, 1998; Gastaldelli
et al., 2004; Kleinfield, 2006]. This late diagnosis is due to the nature of the
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disease development, where noticeable symptoms do not arise until significant
irreversible damage has occurred [ADA, 1998]. With accurate early diagnosis,
pre-diabetic states can be identified up to 10 years earlier [Martin et al., 1992],
which can significantly reduce the onset of further damage and complications.
Unfortunately, the need for preventive diagnosis and treatment is not recognised
sufficiently by health expenditures [Hogan et al., 2003; Kleinfield, 2006; PriceWa-
terhouseCoopers, 2001].
1.2 Development of Diabetes
The complete name of the disease is Diabetes mellitus. Diabetes is derived from
the greek word for “passing through”, and mellitus from the latin word “honey”,
referring to the excessive sugar in the urine of the patients [Dobson, 1776]. Di-
abetes combines a group of different metabolic disorders, which have different
origins, but all resulting in hyperglycaemia or high blood glucose levels [ADA,
2006]. Insulin is needed by the cells as a mediator for glucose uptake. High
blood glucose levels are mainly caused by a deficiency or a resistance to available
insulin.
The three main recognised types of diabetes are type 1, type 2 and gestational
diabetes mellitus (GDM), the latter occurring temporarily during pregnancy. As
only the first two are lasting disease states, and a persisting GDM after pregnancy
is classified as type 2 diabetes, GDM will not be described in detail. Type 1
and type 2 diabetes represent significantly different metabolic conditions with
different pathologies.
1.2.1 Type 1
Type 1 diabetes is characterised by a significant, often sudden deficiency of in-
sulin. It is caused by an auto-immune disorder destroying the insulin producing
β-cells in the pancreas and has a strong genetic pre-disposition. This type of di-
abetes is commonly known as juvenile-onset diabetes, but can also strike adults
and is not linked to obesity [ADA, 2006]. About 10% of people with diabetes
have type 1 [ADA, 2006].
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The destruction of the insulin producing β-cells resulting in type 1 diabetes
can occur very rapidly over weeks or months. However, it can also take many
years, and sometimes a minimal insulin secretory function can remain intact.
Treatment is mainly by regular insulin injections, taken multiple times per day
for the rest of the patients’ lives. If glucose levels are not kept within a tight range,
long-term complications can occur. Despite the difficulties, many type 1 diabetic
individuals have lived long healthy lives through frequent glucose monitoring and
tight glycaemic control.
1.2.2 Type 2
Type 2 diabetes is characterised by a resistance to insulin in the majority of
individuals. The development of type 2 diabetes is a more gradual process than
in type 1 diabetes. It starts with the pre-diabetes stages of impaired glucose
tolerance (IGT) and impaired fasting glucose (IFG), before a clinical classifica-
tion of diabetes is made [ADA, 2006]. The progression of the disease is often
undiagnosed and untreated for many years, until first health complications start
to appear.
The risk of developing type 2 diabetes has a partial genetic pre-disposition,
but is strongly affected by increased body weight and obesity, which significantly
increase insulin resistance [Ferrannini et al., 1997; Hossain et al., 2007; Kahn
et al., 2006b; Petersen and Shulman, 2006]. Weight reduction and lifestyle change
to a healthier diet and increased exercise have been shown to greatly decrease
insulin resistance and the prevalence of developing type 2 diabetes [Camastra
et al., 2005; McAuley et al., 2002; Tuomilehto et al., 2001]. However, these
interventions are difficult to implement in some patients, necessitating other forms
of treatment.
The development of insulin resistance and reduced β-cell function in the pro-
gression to type 2 diabetes is shown in Figure 1.2. A gradual decrease of insulin
sensitivity (increase of insulin resistance) is seen. This decrease is initially ac-
companied by a compensatory increase in pancreatic insulin secretion to maintain
normal glucose levels. When the pancreas cannot keep up anymore with the in-
creased demand, it begins to exhaust itself. The result is a further increase in
basal plasma glucose levels. It is not fully understood if the primary underlying
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Figure 1.2 Progression of β-cell function (solid) and insulin sensitivity (dashed), opposite
of insulin resistance, in the development from normal glucose tolerance (NGT) to impaired
glucose tolerance (IGT), resulting in type 2 diabetes [Ferrannini, 1997]. The x-axis indicates
blood glucose concentration 2 h post oral glucose challenge, a diagnostic criteria of diabetes.
problem is insulin resistance or a defect in β-cell function [Ferrannini and Mari,
2004]. However, it is well accepted that both factors play an important role in
maintaining glucose balance [ADA, 2006; Schinner et al., 2005].
Treatment of type 2 diabetes consists first of lifestyle changes to increase in-
sulin sensitivity, followed by, or combined with, medication to enhance insulin
sensitivity or stimulate the pancreas. In later, or more extreme stages, insulin
replacement therapy, as in type 1 diabetes, is required to maintain normogly-
caemia.
1.2.3 Insulin Sensitivity
Insulin resistance, a decrease in the body’s sensitivity to insulin, is the main
underlying problem in the pathogenesis of type 2 diabetes. Insulin sensitivity is
not a discrete metric that can be assessed with a simple, well defined test. Rather,
it is a concept to quantify the body’s ability to reduce blood glucose levels with
insulin. This definition is very broad and includes many underlying physiological
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Figure 1.3 Overview of the physiological effects measured by insulin sensitivity tests. De-
pending on the design of the test, it can measure either one, a combined effect of two, or all
three of these effects. The dashed lines indicate a mediated or enhanced effect.
effects that contribute to the whole body response.
The main effects contributing to insulin dependent glucose uptake are shown
schematically in Figure 1.3. The three primary effects are the sensitivity of tissue
cells to bind insulin (peripheral sensitivity), the effect of insulin on the liver to
suppress glucose production (hepatic sensitivity), and the ability of the pancreas
to respond with insulin secretion to an increase in glucose concentration (β-cell
or pancreatic function). These effects may also be time-varying and are different
in fasting or perturbed states [Scheen et al., 1994]. Depending on the structural
design of the chosen method to assess insulin sensitivity and its assumptions, one
or more of these effects can be combined in the assessment, thus yielding varying
results requiring different interpretations [Radziuk, 2000].
The cellular defects of IR are not fully understood, but it is clear that there
are genetic and environmental factors influencing them [ADA, 1998; Petersen and
Shulman, 2006]. It is assumed that there is a downregulation of the insulin bind-
ing receptors, which is caused by an increased intracellular lipid content [Petersen
and Shulman, 2006; Schinner et al., 2005], in line with the findings of increased
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IR in obesity [Camastra et al., 2005; Kahn et al., 2006b]. Another finding is that
IR is caused by inflammation, as the proinflammatory cytokine TNF-α produced
by adipose tissue seems to induce IR [Hotamisligil, 2006; Shoelson et al., 2006].
Other inflammatory markers, such as IL-6, Leptin and C-reactive protein (CRP)
have been correlated with the incidence of type 2 diabetes [ADA, 1998; Herder
et al., 2006; Shoelson et al., 2006]. Overall, systemic inflammatory markers are
strongly associated with type 2 diabetes and its complications.
Insulin sensitivity can be treated primarily by a lifestyle change. Increases in
exercise, healthier diet [Duncan et al., 2003; McAuley et al., 2002; Nishida et al.,
2002; O’Gorman D et al., 2006; Tuomilehto et al., 2001] and weight loss [Camas-
tra et al., 2005; Ferrannini et al., 2005, 1997] are proven to increase sensitivity
and thus reduce the prevalence or impact of type 2 diabetes. Other treatments
include sensitivity enhancing medication, such as thiazolidinediones (Rosiglita-
zone), biguanides (Metformin) or sulfonylureas (Glyburide) [Kahn et al., 2006a].
Finally, if β-cell function is strongly diminished, additional insulin therapy can
be provided as needed [Kahn et al., 2006a].
1.3 Diagnostic Criteria
The general diagnosis of diabetes, as recommended by the American Diabetes
Association [ADA, 2006] is by any of three criteria:
1. Symptoms of diabetes (polyuria, polydipsia, unexplained weight loss)
plus plasma glucose concentration any time of the day ≥ 11.1 mmol/l
(200 mg/dl).
2. Fasting plasma glucose (FPG) ≥ 7.0 mmol/l (126 mg/dl).
3. 2-h post OGTT glucose ≥ 11.1 mmol/l (200 mg/dl) during an oral glu-
cose tolerance test (OGTT) (75 g glucose content dissolved in water).
People with elevated glucose levels that do not meet the criteria for type 2
diabetes are classified with impaired glucose tolerance (IGT) or impaired fasting
glucose (IFG). These conditions are defined as follows:
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• IFG: Fasting glucose between 5.6-6.9 mmol/l (100-125 mg/dl).
• IGT: 2-h post load OGTT glucose between 7.8-11.1 mmol/l (140-199 mg/dl).
These thresholds do not directly measure the underlying disorders of IR and
impaired β-cell function, but are only surrogates that can be easily measured clin-
ically. Many insulin resistant people have normoglycaemic levels due to increased
compensatory pancreatic function. Hence, they would not meet these criteria and
would not be screened until their β-cell function begins to deteriorate in the later
developments, as shown in Figure 1.2 [ADA, 2006; Gastaldelli et al., 2004].
In a long-term follow-up study by Martin et al. [1992], it has been shown that
10 years ahead of the formal diagnosis, people that developed type 2 diabetes
had a 60% lower mean insulin sensitivity than those that did not develop the
disease. Additionally, in another study it was found that IR is the strongest
predictor of type 2 diabetes and cardiovascular disease risk in obese individuals
[McLaughlin et al., 2007]. An early diagnosis of IR could therefore recognise this
defect and allow early treatment to delay or prevent the onset of complications.
Unfortunately, the existing accurate tests are too complex to be feasible in a
wider clinical setting, and the often used clinical surrogate tests are too crude
[ADA, 1998]. A simple, accurate test would thus be especially useful to test high
risk groups, such as the offspring of type 2 diabetic individuals, or to monitor the
direct effect of treatment on IR, as specifically noted by the ADA [ADA, 1998]:
[...] lacking a clinically practical test for insulin resistance or a way
to follow it longitudinally in a clinical setting, it is impossible for the
clinician to know whether a given treatment is specifically alleviating
insulin resistance and preventing its associated conditions.
1.4 Preface
The goal of this research is to develop a test that is able to accurately assess
insulin sensitivity without the complexity of existing accurate tests. It should be
simple, short and cost efficient to be useful in wider clinical settings, enable early
diagnosis of IR, and allow frequent monitoring of treatment. This goal has been
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targeted by researchers for several decades, but a satisfactory solution has not
yet been found.
This goal is pursued in this thesis by systematically analysing the physiology
and previously developed tests and models, to determine the key aspects that need
to be captured. With the design restrictions of a short clinical test, an optimal
protocol can be engineered to minimise the impact of confounding factors that
can affect the test outcome. More specifically, detailed knowledge of metabolic
behaviour is combined with smart modelling and algorithms to achieve this goal.
A brief overview of the thesis includes:
Chapter 2 reviews current methods of insulin sensitivity testing used in research
and clinical settings. Key aspects of each method are discussed and com-
pared. The methods are finally put in perspective and compared to define
the design restrictions for a better and simpler protocol.
Chapter 3 presents the insulin modelling and identification methods required
for such a test. It systematically addresses the physiology and modelling
of insulin and the estimation of insulin secretion rate using C-peptide. The
result is a new and optimised insulin system model and fitting method.
Chapter 4 presents the glucose modelling and identification methods required.
Physiology and modelling of glucose are described, and an optimised glu-
cose/insulin pharmaco-dynamic model presented. The result is a new and
optimised overall metabolic system model and fitting method that is appli-
cable to a short clinical protocol.
Chapter 5 validates the insulin models and methods developed on data from
the literature and obtained from other studies. The physiological validity
of each model is shown.
Chapter 6 validates the overall model-based metric of insulin sensitivity against
gold standard euglycaemic clamp test data.
Chapter 7 presents the proposed protocol for the new test developed and esti-
mates its expected accuracy in a Monte Carlo analysis applying all identified
sources of variability.
Chapter 8 presents the clinical pilot study to validate the protocol clinically.
The design of the study is described and its results are discussed.
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Chapter 9 optimises the protocol in terms of test duration, sample numbers and
timing. This task is achieved by testing protocol performance on sample and
time-reduced data sets from the pilot study. Shorter and simpler versions
of the protocol are proposed with the expected difference in variability.
Chapters 10 and 11 summarise the key aspects of the thesis and present pos-
sible future improvements and applications for this research.
Chapter 2
Review of Current Methods
Soon after the discovery of insulin by Banting et al. [1922], it was evident that
some people needed more insulin than others to achieve normal blood glucose
levels. Thus, a first approach to assess this sensitivity to insulin was proposed by
Horgaard and Thayssen [1929], followed by others, such as Andres et al. [1966];
Himsworth [1936] and Shen et al. [1970]. In the past 40 years in particular, a
great deal of research has focused on the development and validation of more
accurate, simpler and/or more physiological methods [Ader and Bergman, 1987;
Ferrannini and Mari, 1998; Scheen et al., 1994].
This chapter gives an overview of the state of the art in insulin sensitivity
testing. A variety of methods are included, differing by application. More specif-
ically, there are those used mainly in research to assess the effects of treatment or
medication on insulin sensitivity, and there are tests that are clinically focused,
designed to screen populations and diagnose diabetes, or the risk of develop-
ing the disease. The test methods are compared in terms of their accuracy and
practicality for diagnosis, focusing on reported issues or problems that might be
improved in a new test. Tables summarising all of the tests described are given
in Appendix A.
2.1 Overview
A detailed description of insulin sensitivity is found in the previous chapter. Tests
that measure insulin sensitivity can be divided into two main types, based upon
their design:
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1. Direct tests
2. Surrogate tests
Direct assessments usually involve the oral or intravenous administration of glu-
cose and/or insulin, and a subsequent sampling of these molecules to determine
their pharmaco-dynamic interaction. Another localised direct method is to use
the arterio-venous (A-V) difference technique, by comparing these concentra-
tions at the in- and outflow of certain tissues or organs to determine their glucose
uptake [Scheen et al., 1994]. Surrogate tests are empirical methods, mostly re-
gression models, that are designed to correlate well with certain gold standard
test metrics. They can use data from a dynamic test or just a fasting sample, the
latter of which makes them very attractive for screening purposes. When using
fasting metrics, it is to be noted that these metrics only quantify the sensitivity
during a fasting state, which can be different to that observed during the dynamic
or hyperglycaemic state used in other tests [Scheen et al., 1994].
One of the difficulties in assessing insulin sensitivity with a dynamic test
is to separate observed results between the different effects influencing them, a
task that cannot always be achieved. The contribution of the pancreas, or β-
cell function, can be isolated by sampling C-peptide concentrations, which are a
good indicator of pancreatic insulin secretion [Pacini and Mari, 2003]. Hepatic
sensitivity, defined as insulin’s effect in inhibiting endogenous glucose production
(EGP), can be measured with the additional use of glucose tracers [Caumo and
Cobelli, 1993], or isolated by suppressing EGP completely [DeFronzo et al., 1979].
Additionally, some physiological effects are not always accounted for in certain
tests, such as non-insulin dependent glucose uptake [Zierler, 1999] or saturation
of glucose uptake [Natali et al., 2000; Prigeon et al., 1996], and are thus lumped
into the measured insulin-dependent result, skewing or biasing the result.
Other factors that can affect the measured results are effects that are not
identified or hard to measure in vivo. These effects include for example the
gut absorption rate, if glucose is ingested orally [Radziuk et al., 1978], or the
counter-regulatory response to hypoglycaemic glucose concentrations [Monzillo
and Hamdy, 2003].
All of these factors have lead to different approaches to test insulin sensitivity.
However, they do not necessarily measure the same effects, even if they might
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correlate well. Their respective use is therefore mostly limited to certain appli-
cations. The more accurate, mostly intravenous and more intense/invasive tests
are only viable in a research setting. In contrast, fasting, or the briefer oral dose
tests, are ideal in clinical settings due to their simplicity. However, because they
may measure different effects and have different levels of accuracy and resolution,
there is no consistent test useful across this range of application requirements.
2.2 Comparative Statistics
Before discussing the different methods to test insulin sensitivity and how they
compare, it is important to point out some aspects and limitations of commonly
used comparative statistics and performance metrics. In particular, this section
defines the comparative and accuracy metrics and terms used in this thesis.
2.2.1 Correlation Coefficient
The similarity between two tests is commonly expressed as a correlation coeffi-
cient. The correlation coefficient is a measure of the linearity of the relationship
between two data sets [Salkind and Rasmussen, 2007] and is always a value be-
tween r = −1 and r = 1. A value of r = 1 or r = −1 indicates perfect linearity
with a positive or negative slope, respectively. The closer the correlation is to
r = 0, the less linear the relationship. Note that the lack of a linear relationship
does not imply a lack of a relationship, but only that the direct linear association
between values is weak.
Different correlation coefficients can be calculated depending on the data
distribution. For normally distributed data, the parametric Pearson product-
moment correlation coefficient can be used. Otherwise, non-parametric coef-
ficients, such as the Spearman’s rank correlation coefficient are better suited
[Salkind and Rasmussen, 2007].
The correlation coefficient is very sensitive to outliers, which is illustrated in
the example shown in Figure 2.1. In this case, two different tests were performed
on n=10 individuals [Caumo et al., 2000]. The data set includes one highly insulin
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Figure 2.1 Correlation plot between two different test metrics on n=10 individuals from a
study by Caumo et al. [2000]. The solid line represents the linear relationship calculated with
all samples, resulting in a Spearman’s correlation r = 0.89. If the high outlier (diamond) is
taken out, this relationship is strongly reduced to a Pearson correlation r = 0.63 (dashed line).
sensitive outlier. If this subject is included, the distribution of the data set is
not normal and the Spearman correlation coefficient has to be calculated, which
results in a high correlation of r = 0.89. Without this subject, the distribution is
normal and the Pearson correlation coefficient is used, resulting in a correlation
of r = 0.63. This limitation is explicitly mentioned by the authors [Caumo
et al., 2000], but that level of detail is usually not provided, making comparisons
difficult.
Sample size also has a large impact on calculated correlation coefficients, as
visualised in Figure 2.2 on data from a study by Mari et al. [2001]. Correlating the
full data set of n=91 individuals results in r = 0.77. If the individual subgroups
are examined separately, correlations drop to r = 0.59 in the lean (circle), r = 0.73
in the obese (square) and r = 0.49 in the type 2 diabetes (triangle) subgroups.
This drop shows that linear relationships might not be transferable if different
subgroups are compared separately, indicating that the relationship both changes
and grows weaker. Overall, this example shows that a relationship calculated from
one subgroup cannot necessarily be extrapolated to another subgroup. Therefore,
comparison between studies should be considered critically.
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Figure 2.2 Correlation plot between two different test metrics on n=91 individuals from a
study by Mari et al. [2001]. The full data set correlates n=0.77, but correlations and slopes of
regression lines differ if subgroups are regarded individually. The subgroups are lean (circle,
solid line), obese (square, dashed line) and type 2 diabetes (triangle, dash-dotted line).
Correlations in data sets with smaller sample sizes are usually worse than in
larger groups because. This is because the ratio between the y-axis data range
to the x-axis data range is larger. This effect can be seen in reverse for the obese
subgroup (square) in Figure 2.2, in which the regression line is longer than in
the other two subgroups, yielding a higher correlation coefficient. Note that the
smaller coefficients for the lean and type 2 diabetes subgroups are thus due to
their shorter ranges and larger y/x ratios. Keeping these aspects in mind allows
the reader to more critically assess and compare reported values.
A correlation coefficient is thus highly dependent on the sample size and
distribution. A large sample size is more robust to outliers and yields much
more significant correlation coefficient. An equally distributed smaller sample
size might result in the same correlation, but any outlier can significantly reduce
this correlation coefficient. Hence, it is harder and less reliable to compare results
with relatively small sample sizes and/or significant outliers.
Statistical significance of the correlation is usually calculated with hypothesis
testing and given as a p-value, with a significance threshold commonly defined
as 0.05 [Petrie and Sabin, 2005]. A correlation is thus only considered valid if its
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significance level is smaller than the threshold where the null hypothesis is being
tested. The range of acceptable correlations in biological and medical research
studies differs to that in engineering, due to the more variable nature of biological
and physiological system behaviours across subjects and tests. A correlation of
r = 0.5 is thus normally considered relatively strong, if significant. Correlations
between r = 0.6 to r = 0.8 would be considered very good, with values over
r = 0.9 being extremely rare.
2.2.2 Test Accuracy
Test accuracy cannot really be determined in absolute terms, as only an effect is
measured and the true underlying value is not known. Instead, when assessing the
outcome metrics of a test, they are usually correlated to a gold standard test that
is known to be highly repeatable. In this case, the accepted gold standard is the
euglycaemic-hyperinsulinaemic clamp [DeFronzo et al., 1979]. This comparison
is sometimes difficult, as not all tests measure exactly the same effects, but is
mostly done nonetheless [Ferrannini and Mari, 1998; Radziuk, 2000].
Accuracy of an insulin sensitivity test is usually defined as its accuracy in
repeatability for the same subject. A highly repeatable test can yield consistent
and comparable results and allow effective monitoring of interventions. In con-
trast, natural variability in insulin sensitivity can be captured and interpreted as
test inaccuracy or a lack of repeatability. In validation studies, the accuracy of a
test is usually given as the coefficient of variation, defined as the standard devia-
tion SD divided by the mean over all subjects in the cohort, CV=SD/mean. This
value thus provides a combined measure of the natural variability and systematic
or assay variability of a given test. The most repeatable test, the euglycaemic
clamp, has been shown to have a CV= 6% − 10% [DeFronzo et al., 1979; Mari
et al., 2001; Monzillo and Hamdy, 2003].
2.3 Intravenous Tests
Intravenous tests utilise an injection or infusion of glucose and/or insulin to cause
a perturbation of the metabolic system. The accuracy of these tests is generally
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better than for oral dosed tests, as the system is more controlled and the unknown
gut absorption rate is bypassed, minimising error or variability. These tests are
usually more invasive and often take longer to perform. They are thus used
primarily in research settings, and are too costly and intense for a wider clinical
use.
2.3.1 Euglycaemic/Hyperglycaemic Clamp
The euglycaemic-hyperinsulinaemic clamp method was first presented by De-
Fronzo et al. [1979]. The idea behind the test is to infuse insulin at a constant
rate and glucose at a variable rate to “clamp” the plasma glucose concentration
at a normal fasting concentration, typically around 4.6 mmol/l [e.g., McAuley
et al., 2001], although any reasonable level may be used. An example glucose
and insulin concentration profile for this test with the respective infusion profiles
is shown in Figure 2.3.
Due to the high dose infusions of insulin and glucose, hepatic glucose pro-
duction and pancreatic insulin secretion are almost completely suppressed, and
it is assumed that the glucose uptake rate now equals the glucose infusion rate.
For this assumption to hold, a steady state needs to be achieved, which can take
between 2-3 hours [Ader and Bergman, 1987]. A closed loop system with glucose
sampling every 10 minutes, and a continuous adjustment of the glucose infusion
rate [DeFronzo et al., 1979; Ferrannini and Mari, 1998] is therefore required to
reach and hold this euglycaemic steady state [Bergman et al., 1985]. Measured
insulin sensitivity represents mainly peripheral sensitivity, as endogenous glucose
production (EGP) is almost completely suppressed.
The insulin sensitivity index, ISI, is then defined as the mean glucose infusion
at steady state, M , divided by the mean insulin concentration I at steady state:
ISI =
M
I
(2.1)
The physiological hypothesis of Equation 2.1 is thus straightforward. At a steady
euglycaemic or fasting level, the infused glucose M over one hour is assumed to
be removed by the average plasma insulin present over that hour, since a steady
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Figure 2.3 Example of a two hour euglycaemic-hyperinsulinaemic clamp from a study by
McAuley et al. [2002]. Shown are glucose concentration (upper left), insulin concentration
(upper right), glucose infusion rate (bottom left) and insulin infusion rate (lower right).
fasting glucose level was maintained. This ratio is assumed to hold since EGP is
suppressed at the supra-physiological insulin infusion rates used.
Due to the clamping of the system and the relatively high infusions, the
metabolic system is well controlled and the assessment highly repeatable, which
make this method the current gold standard. The test is also very flexible, as it
can be performed at different glycaemic or insulinaemic levels to study changes
in metabolic effects at these states, or in combination with tracers or other drugs
to assess their effect on glucose uptake.
Information about β-cell function can be obtained with the hyperglycaemic
clamp, in which a step increase in clamped glucose concentration is introduced
to trigger first- and second-phase insulin secretion. Indices commonly used are,
for the first-phase secretion, the incremental insulin concentration area under
the first 8-10 minutes after the step increase, and for the second-phase the mean
insulin levels after the first secretory peak has faded [DeFronzo et al., 1979; Pacini
and Mari, 2003]. Unfortunately, insulin sensitivity and β-cell function cannot be
obtained simultaneously and require a longer or separate test protocol.
The main drawbacks of the clamp method are the intensity and length of the
test. It takes between 2-6 hours to perform, with considerable safety wind-down
times. In addition, highly trained medical personnel must be involved full-time,
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increasing cost and making widespread use infeasible. Special equipment, such as
calibrated pumps, a heating box to arterialise venous blood and a glucose meter
are also required. The infusion rates are also supra-physiological, with steady
state insulin concentrations of around 100 mU/l, where normal fasting levels are
only ∼5-10 mU/l. Overall the test is very complex and intense for both the
subject and clinical personnel.
Regarding the test’s physiological accuracy, the assumption that all glucose
uptake is mediated by plasma insulin is not completely correct. In particular,
tissue uptake is dependent on insulin in the interstitium, which is considerably
lower than the concentration in plasma at steady state [Yang et al., 1989]. Addi-
tionally, non-insulin dependent uptake, such as the constant uptake by the brain
and the central nervous system [Zierler, 1999], is not separately accounted for
and included in the measured uptake. The test also yields different results if per-
formed at different infusion rates, which suggests a saturable peripheral glucose
uptake [Natali et al., 2000; Prigeon et al., 1996] that will lead to an underestima-
tion of the actual sensitivity. Dose dependency of the result also means that ISI
values cannot be directly compared if different insulin infusion rates are used.
Nonetheless, these effects most likely only introduce a shift in the result and do
not affect the overall accuracy in repeatability at those inputs.
Overall, the test is highly repeatable with a reported CV= 6% − 10% [De-
Fronzo et al., 1979; Mari et al., 2001; Monzillo and Hamdy, 2003]. It also offers
a steady state assessment of a wide range of possible metabolic states, as the
glycaemic level can be clamped at any reasonable value. Other tests are thus
always judged in their performance by their correlation to the clamp metric ISI.
2.3.2 Insulin Tolerance Test (ITT)
The Insulin Tolerance Test (ITT) is one of the first proposed tests to measure
insulin sensitivity in vivo [Horgaard and Thayssen, 1929]. A bolus of insulin is
injected (0.1 U/kg) and the decay rate of glucose measured at 10-40 minutes after
the input. The insulin input is relatively large, translating to 8 U for an 80 kg
individual. Insulin sensitivity is defined as the decay rate constant of a single
exponential decay. It can be calculated from the time needed to reduce glucose
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concentrations by half (t1/2):
KITT =
ln(0.5)
t1/2
(2.2)
The test is relatively simple and short and has been shown to perform well,
with good accuracy in repeatability (CV= 6% − 9%) [Gelding et al., 1994;
Monzillo and Hamdy, 2003] and comparability to the clamp (r = 0.81 [Bonora
et al., 1989; Gelding et al., 1994]) and the IVGTT (r = 0.76) [Lindheim et al.,
1994], but not to the fasting surrogate HOMA-IR (r = 0.44) [Inchiostro, 2005].
Disadvantages include a high risk of hypoglycaemia due to the sudden drop in
glucose induced by the relatively large insulin input [Ferrannini and Mari, 1998].
In particular, inaccuracies may be introduced by the counter-regulatory response
triggered by hypoglycaemia. This effect can be reduced by applying a shortened
version, which takes samples up to 15 minutes post injection [Inchiostro, 2005],
avoiding the counter-regulatory response that starts at ∼20 minutes [Monzillo
and Hamdy, 2003]. Due to concerns over safety and the relatively large insulin
dose, it is primarily a research tool.
2.3.3 Intravenous Glucose Tolerance Test (IVGTT)
Direct Assessment
Assessing glucose tolerance by an intravenous injection of glucose is a practice
that has been used for a long time. In particular, a large number of studies
discussed this approach in the 1920s-40s [Greville, 1943; Lozner et al., 1941;
Orr-Ewing, 1931]. Before the invention of the insulin assay, this decay could
only be measured, but not separated into insulin-dependent and independent
components. A common practice was to inject a bolus of glucose, or use a fast
infusion, and assess the decay rate, defined as the slopeKG of the logarithm of the
glucose concentration curve as measured over 1-3 hours [Greville, 1943; Lozner
et al., 1941]. This method is comparable to that used in the insulin tolerance
test (ITT) and can be applied with no further computer analysis of the data.
Measured sensitivity is the combined effect of peripheral and hepatic sensitivity.
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An improvement can be made by relating KG to the increase in insulin con-
centration, as described by Galvin et al. [1992]. This approach was validated in
its 40-minute version against the clamp with good correlation of r = 0.85 and a
CV=21% in the overall range of subjects studied (n=30, wide range of glucose
tolerance). The performance and resolution was not satisfactory in subjects with
low insulin sensitivity, which can be attributed to the small relative increase in
insulin concentration in these subjects. It also does not allow any assessment of
β-cell function.
Minimal Model Based Assessment (Semi-Direct)
The Minimal Model (MM) of glucose kinetics was presented by Bergman et al.
[1979] as a simplified description of the glucose kinetics observed during an
IVGTT protocol. By fitting the model parameters to match IVGTT data, meta-
bolic information about the glucose metabolism can be obtained [Bergman et al.,
1981; Pacini and Bergman, 1986]. The model differentiates between glucose up-
take at basal insulin (SMMG ) and glucose uptake at increased insulin (S
MM
I ).
Additionally two metrics of first- and second-phase insulin secretion can be de-
rived. Insulin dependent uptake is mediated by insulin action in a site remote of
plasma, and represents both peripheral and hepatic sensitivities. The model thus
incorporates a minimal description of the most important physiological aspects.
It was also the first use of mathematical models and computers for testing insulin
sensitivity.
The original protocol includes a bolus injection of glucose (0.3 g/kg body
weight) and frequent blood sampling for 180 minutes, with a total of about 22
samples assayed for glucose and insulin concentrations. Both arms are cannu-
lated, one for injection and the other for sampling. A heated box is used to
arterialise venous blood at the site of sampling [Bergman et al., 1985]. The
model is fitted to the data with a non-linear least squares algorithm, estimating
three model parameters.
The method has been used very widely in research studies, and is recognised
as a reasonably accurate alternative to the slightly more intense clamp procedure.
Reported accuracies vary between CV= 14%− 30% [Ferrannini and Mari, 1998;
Monzillo and Hamdy, 2003; Scheen et al., 1994]. Correlation between Minimal
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Figure 2.4 Example of an insulin-modified IVGTT on a healthy individual, from Mari [1998].
Shown are the resulting glucose concentrations (left) and insulin concentrations (right). Glucose
is administered at t = 30 min and insulin between t = 50− 55 min.
Model SMMI and clamp ISI varies greatly between r = 0.44 − 0.92 [Bergman
et al., 1987; Coates et al., 1995; Finegood et al., 1984; Foley et al., 1985; Katz
et al., 2000] depending on the subgroups and populations studied, and potentially
the specific protocols used. Note that this wide range of correlation casts some
doubt on the tests accuracy and/or robustness.
Accuracy has also been found to be significantly diminished in subjects with
low insulin sensitivities, such as obese and type 2 diabetes individuals, leading
to frequent identifiability problems [Cobelli et al., 1986; Donner et al., 1985;
Finegood et al., 1984]. To overcome some of these problems, protocol variations
were proposed to increase the otherwise weak insulin signal. These variations
include infusing tolbutamide to trigger a pancreatic response [Beard et al., 1986;
Yang et al., 1987] or injecting insulin 20 minutes after glucose input [Finegood
et al., 1990; Quon et al., 1994a]. These modifications improved accuracy, but
problems in accurately and repeatedly identifying the parameters still persist.
Numerous studies have been performed since to find better fitting approaches to
this non-convex problem [Erichsen et al., 2004; Krudys et al., 2006; Pillonetto
et al., 2002; Vicini and Cobelli, 2001]. An example of the data from an insulin-
modified IVGTT on a healthy individual is shown in Figure 2.4.
More complex modifications were proposed to improve test performance.
These enhancements include the addition of glucose tracers to separate the ef-
2.3 INTRAVENOUS TESTS 23
fects of glucose production and utilisation (Hot MM) [Cobelli et al., 1986], an
enhanced two-compartment minimal model (2CMM) [Caumo and Cobelli, 1993],
or a circulatory model [Mari, 1998]. All of these approaches yielded mostly bet-
ter fits, but at a cost of considerably increasing complexity. While this increased
complexity is not a big problem in physiological research studies, it renders the
test impractical for use in wider clinical settings [ADA, 1998].
When directly compared with clamp derived measurements, the MM-method
seems to overestimate SMMG and consequently underestimate S
MM
I [Cobelli et al.,
1998; Mari, 1997]. This issue was identified as an undermodelling problem. A
proposed solution was to use a two-compartment description [Cobelli et al., 1999],
as glucose kinetics during the first 10 minutes are strongly affected by systemic
mixing rather than uptake. In addition, the estimation of SMMG is not very ac-
curate and its estimation is only possible from the portions of the data with
low insulin concentrations. Unfortunately, these portions are either in the early
20 minutes, which are mostly affected by mixing, and after 100+ minutes, which
is primarily affected or contaminated by counter-regulatory triggered EGP [Cal-
legari et al., 2003; Ferrannini and Mari, 1998]. Shortening the test to 90 minutes
was shown to improve parameter estimation in the face of these issues [Callegari
et al., 2003].
Overall, the test is still very accurate and allows the assessment of different
effects through the addition of tracers and different model variations. Unfortu-
nately, well known modelling and identification problems make the results less
reliable. Finally, its length and intensity limit it to a research-only application.
2.3.4 Continuous Infusion of Glucose with Model Assess-
ment (CIGMA)
This test consists of a relatively low dose infusion of glucose over 60 minutes
(5 mg/kg/min) to mimic a postprandial state. Glucose and insulin are then
sampled during the final 15 minutes, over which a near steady state is attained
[Hosker et al., 1985]. The test data are then compared to known physiologic data
using a model of whole body glucose homeostasis that accounts for all key inputs
and clearances. Accuracy in repeatability is within CV= 17% − 21% [Hosker
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et al., 1985; Nijpels et al., 1994] and reported correlations to the clamp vary
between r = 0.66 [Nijpels et al., 1994] and r = 0.87 [Hosker et al., 1985].
As the glycaemic state attained during the test is very physiological, the esti-
mated sensitivity is likely a very accurate match to the true combined peripheral
and hepatic sensitivity. Due to the administration of only glucose, the test is
not applicable to type 1 individuals, nor is it very accurate in individuals with a
weak pancreatic insulin response [Ferrannini and Mari, 1998]. These limitations
make it less useful or reliable in clinical situations, although the relative simplic-
ity, safety and potential physiological accuracy make it appealing in research and
some limited clinical settings.
2.4 Oral Tests
2.4.1 Surrogate Assessments
The protocol of an oral glucose tolerance test (OGTT) has a clear advantage
over intravenous tests. In particular, it is less invasive and the administration of
glucose through the gut is very simple, does not require a venous administration,
and is more physiological. An example of the resulting concentrations is shown
in Figure 2.5.
Figure 2.5 Example of a 75 g oral glucose tolerance test (OGTT) [Matsuda and DeFronzo,
1999]. Shown are the resulting glucose concentrations (left) and insulin concentrations (right)
for normal, impaired glucose tolerance (IGT) and type 2 diabetes individuals.
A standard OGTT consists of a rapid ingestion of a 75 g or 100 g solution of
glucose, followed by timed blood samples for 2-3 hours [Pacini and Mari, 2003].
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Blood glucose levels, and sometimes insulin or C-peptide concentrations, are sam-
pled at least hourly, including a fasting sample. The glucose concentration drop
during the following hours is an indicator of the body’s ability to take up glucose.
This indicator of insulin sensitivity usually combines all three effects, peripheral
sensitivity, hepatic sensitivity and β-cell function.
Due to its simplicity, it is the current method of choice for a clinical diagnosis
of diabetes and recommended by the American Diabetes Association [ADA, 2006].
It is important to note that any of these surrogate measures do not strictly mea-
sure a physiological effect, but only give surrogate indications of the actual effect.
In particular, the OGTT measures the body’s ability to remove a glucose load,
which is dependent on insulin sensitivity, but does not measure insulin sensitivity
directly. The interpretation of the sampled data varies between tests, sometimes
including insulin values, but not always. Some commonly used calculations are
described here.
2-hour Glucose
The glucose concentration sampled two hours after glucose ingestion is the most
often used indicator of impaired glucose tolerance, as it does not involve any fur-
ther calculations. It is one of the metrics used as a criterion for the diagnosis of
type 2 diabetes (11.1 mmol/l), recommended by the American Diabetes Associ-
ation (ADA) [ADA, 2006]. Its correlation against the clamp has been found to
be good at r = 0.74 in a large population (n=188) covering all levels of insulin
resistance [Ferrannini et al., 2005]. The repeatability is debatable, with various
studies reporting changes in diagnosis in 30% − 65% of subjects after a repeat
test [Ganda et al., 1978; Ko et al., 1998; Levy et al., 1999; Riccardi et al., 1985].
Its simplicity still makes it the test of choice in clinical practice [Monzillo and
Hamdy, 2003].
Matsuda
In the study by Matsuda and DeFronzo [1999] the authors propose an index of
insulin sensitivity derived from an OGTT on n=153 subjects with a wide range of
glucose tolerance, and validate it against the clamp. Their idea is to incorporate
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fasting levels (G0, I0), as well as the mean glucose and insulin concentrations
(G30−120, I30−120) during the final 90 minutes of a 120-min OGTT. The formula
they derived is defined:
ISIMatsuda =
10000√
I0×G0×G30−120×I30−120
(2.3)
Their reported comparison to the clamp is good at r = 0.73 in the whole group,
but diminishes to r = 0.66 for impaired glucose tolerance (IGT) cohorts and
r = 0.54 in diagnosed type 2 diabetes individuals. Good correlation was found
in some studies, ranging from r = 0.66 − 0.86 [Chiu et al., 2001; Kirwan et al.,
2001; Soonthornpun et al., 2003; Stumvoll et al., 2000], but not all, with r = 0.21
found by Kanauchi [2002] in n=113 Japanese subjects covering a wide range of
glucose tolerance.
Stumvoll
In a similar study by Stumvoll et al. [2000], the authors propose a more empirical
linear regression model, including glucose concentration at 90 minutes (G90) and
insulin concentration at 120 minutes (I120), as well as the subject’s BMI. The
formula they derived on n=104 nondiabetic subjects is defined:
ISIStumvoll = 0.226− 0.0032×BMI− 0.0000645×I120 − 0.00375×G90 (2.4)
In their validation against the clamp, they achieve a high correlation of r = 0.79
across all subjects. They also derive formulae to estimate β-cell function that
are well correlated to the clamp derived metrics. The correlations found in other
studies were not as high, with a range of r = 0.51 − 0.69 [Chiu et al., 2001;
Kanauchi, 2002; Mari et al., 2005; Soonthornpun et al., 2003]. An advantage of
this index is that it does not require all the samples taken during a standard
OGTT, but only two timed values. It thus reduces time and personnel require-
ments, making wider use somewhat easier.
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Others
Other indices have been derived with similar performances to those described
above, including different combinations of glucose and insulin samples taken from
an OGTT. Common ones are those by Gutt et al. [2000], Cederholm and Wibell
[1990], Kanauchi [2002], Soonthornpun et al. [2003], Avignon et al. [1999] and
Belfiore et al. [2001]. Indices of β-cell function have also been derived, usually
included some ratio of incremental insulin over incremental glucose concentrations
[Pacini and Mari, 2003].
2.4.2 Model-Based Assessments
In spite of the reasonable performance reported for the surrogate metrics dis-
cussed in Section 2.4.1, they are not based on a physiological explanation. To
measure physiological effects with an OGTT, some studies have proposed models
with varying complexity to directly measure insulin sensitivity from OGTT data.
OGIS
The Oral Glucose Insulin Sensitivity index (OGIS) was presented by Mari et al.
[2001]. It was derived by assuming a physiological representation of the glucose-
insulin interaction during an OGTT. The model parameters were then estimated
in that study on a population of n=104 subjects with different degrees of glucose
tolerance, from which a mean set was chosen to provide a universally applicable
formula. Two different versions are proposed, for use with a 120 or 180 minute
test. Correlation to the clamp was good at r = 0.77 in the whole group, but
worse in the individual subgroups, moving down to r = 0.49 in type 2 diabetes
individuals. Even if the direct correlation to the clamp is not much better than
in other tests, the approach does have a physiological basis that allows a more
comparable assessment of metabolic status.
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Oral Minimal Model
The Oral Minimal Model (OMM) was proposed by Caumo et al. [2000] for use
with meals and Breda et al. [2001] for an OGTT. It combines the original MM
by Bergman et al. [1979] with a description of the rate of glucose appearance in
plasma, Ra, to estimate the same MM parameters from an orally administered
glucose load. This approach allows a direct measurement of IR during a more
physiological state, and has been followed up with considerable research and val-
idation efforts. Validation using a meal input against the IVGTT was performed
in healthy individuals with good correlations of r = 0.89 [Caumo et al., 2000] and
r = 0.75 [Dalla Man et al., 2002], an example of which is shown in Figure 2.6.
The OGTT version was validated against the clamp, resulting in a correlation
of r = 0.81 [Dalla Man et al., 2005b] and yielding accuracies in repeatability of
CV= 12% − 15% in another study [Breda et al., 2001]. The results were also
validated with tracer studies and resulted in good linear comparisons with cor-
relations of r = 0.96 [Dalla Man et al., 2005a] and r = 0.86 [Dalla Man et al.,
2004] for the meal and OGTT comparisons, respectively. With the addition of
C-peptide sampling and the C-peptide MM, this method also yields pancreatic
secretion metrics [Breda et al., 2001].
Figure 2.6 Example of a meal tolerance test from Caumo et al. [2000]. Shown are the
resulting glucose (left) and insulin (right) concentrations after ingestion of a standardised meal
with approximately 75 g carbohydrate content.
2.5 Fasting Tests
Fasting tests rely solely on fasting blood samples to obtain information about
the state of insulin resistance. They are very attractive, as no input of glucose
or insulin is required and the time and stress involved for the individual and the
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medical personnel are minimal. The derivation of the different calculations is
sometimes purely empirical, while others are based on linear approximations of
physiological model descriptions. The accuracy of many of these fasting surrogate
tests can be improved by sampling two or three times and using the mean value
[Wallace et al., 2004b]. Some of the most commonly used fasting metrics are
described here.
Fasting Plasma Insulin (FPI)
Fasting plasma insulin concentrations are often used to diagnose insulin resistance
[Ferrannini and Mari, 1998; Monzillo and Hamdy, 2003]. High concentrations are
usually a good diagnostic indicator of insulin resistance in normoglycaemic indi-
viduals, and correlations in the range of r = −0.37 to r = −0.59 have been found
when comparing to the clamp test ISI [Ferrannini and Mari, 1998; Kang et al.,
2005; McAuley et al., 2001; Ruige et al., 2006]. Only some of the variability in IR
is seen in the insulin concentration, as this value also depends on other factors,
such as insulin secretion, clearance and distribution [Monzillo and Hamdy, 2003].
In subjects with type 2 diabetes, fasting insulin levels tend to become very high,
but then decrease over years as the pancreas exhausts. This behaviour results in
inaccurate assessments of IR with this test value [Kang et al., 2005; Monzillo and
Hamdy, 2003].
Fasting Plasma Glucose (FPG)
High FPG levels are often used as a first screening indicator of impaired glucose
tolerance [ADA, 2006]. The problem is that IR is apparent many years before glu-
cose levels rise, and compensated by higher endogenous insulin secretion. FPG is
thus only a valid indicator if the state of impaired glucose tolerance is significantly
progressed. Nonetheless, when compared to the clamp, reasonable correlations
of r = 0.50− 0.59 are achieved [Kang et al., 2005; Lewanczuk et al., 2004]. FPG
is an ADA recommended criterion for screening IGT and type 2 diabetes [ADA,
2006].
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Fasting Plasma I/G ratio
A logical conclusion from just using FPG or FPI is to use the ratio of both.
This ratio is commonly used in large screening studies, but does not necessarily
perform better than the individual metrics, when compared to the clamp, with
correlations reported in the range of r = −0.41 to r = −0.68 [Hanley et al., 2003;
McAuley et al., 2001]. Note that the index assesses insulin resistance, which is
equivalent to the reciprocal of sensitivity, thus resulting in a negative correlation.
Homeostatic Model Assessment (HOMA-IR)
The HOMA-IR index (also called just HOMA) was derived from a physiologi-
cal whole body glucose-insulin model, developed on known physiological data
[Matthews et al., 1985]. It is the same model used in the assessment of CIGMA.
The authors proposed a simplified linear equation to approximate the computer
model:
HOMA− IR = G0×I0
22.5
(2.5)
A new, more accurate solution of the original computer model was presented
as HOMA2 [Levy et al., 1998], but the approximated formula of Equation 2.5 is
still widely used, due to its simplicity. The index assesses IR, which is equivalent
to the reciprocal of sensitivity. Comparison to the clamp and IVGTT are thus
negative. Many studies have used HOMA-IR so far to assess IR, and correlations
against the clamp vary widely between r = −0.19 to r = −0.94 [Bonora et al.,
2000; Mari et al., 2001; Mather et al., 2001; McAuley et al., 2001; Ruige et al.,
2006]. However, most results reside within r = −0.4 to r = −0.6 depending
on the subgroups used. One example of this variability is seen in the study by
Mari et al. [2001], in which the overall population achieved r = −0.75, but the
type 2 diabetes subgroup only r = −0.19. Even so, the index is considered a
reasonable indicator of IR, and has been widely used to date due to its simplicity
and comparability across studies.
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A separate HOMA index of β-cell function, HOMA-%B, can be calculated
similar to above:
HOMA−%B = 20×I0
G0 − 3.5
(2.6)
McAuley Index (ISIMcAuley)
The McAuley index was developed as an empirical regression model on data
from n=178 clamp tests on normoglycaemic individuals [McAuley et al., 2001].
Different surrogate indicators of IR were used to find the most useful predictors.
The equation derived by the authors includes fasting insulin and triglyceride (TG)
concentrations, the latter of which is often increased in type 2 diabetes:
ISIMcAuley = e
(2.63−0.28×ln(I0)−0.31×ln(TG)) (2.7)
The correlations against the clamp are not significantly different to other fasting
metrics, as assessed in various studies with r = 0.48−0.61 [McAuley et al., 2002;
Oterdoom et al., 2005; Ruige et al., 2006].
HbA1C
The use of glycosylated hemoglobin levels, HbA1C, has been proposed in some
studies as a marker to screen and diagnose diabetes [Bennett et al., 2007; Drou-
maguet et al., 2006; Peters et al., 1996]. HbA1C levels represent a 2-3 month
average of blood glucose levels and are thus not affected by short term changes or
incomplete fasting states, which is a significant advantage in screening applica-
tions. The performance of this approach was compared to the ADA-recommended
guidelines, the 2-h OGTT [Bennett et al., 2007; Peters et al., 1996] and a fast-
ing glucose value [Bennett et al., 2007; Droumaguet et al., 2006]. Performance
was found to be similar, with comparable sensitivities and specificities as these
other metrics. However, it also offered the advantage of a higher intra-individual
repeatability, with assay accuracy within CV= 2% − 4% [Barr et al., 2002]. It
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could thus be the most reliable of the fasting metrics for screening purposes.
Others
Further fasting indices include QUICKI [Katz et al., 2000], which is essentially a
log-transformed HOMA-IR, and similar metrics proposed by Hanson et al. [2000]
and Belfiore et al. [1998] that do a different calculation with fasting glucose and
insulin values. All of these indices perform well in some studies and not so well
in others. They are mostly good indicators if used for broad screening purposes,
but do not achieve the necessary resolution to monitor frequent changes in IR,
or to provide significant early warning or diagnosis.
2.6 Method Comparisons
Comparing the different methods is a difficult task as they do not always measure
the same physiological effects or have the same units. As discussed, the three ef-
fects, peripheral sensitivity, hepatic sensitivity and β-cell function all contribute
to the overall whole body sensitivity and response to glucose. Some of the more
complex tests, as the clamp, IVGTT, or the OMM, can differentiate between all
three effects if performed with tracer labelled glucose and C-peptide sampling.
This flexibility is an advantage over simpler tests for physiological research stud-
ies in which the effects of drugs on each individual aspect can be assessed. In
contrast, the high intensity, duration and cost involved, make them infeasible for
wider clinical studies or any reasonable form of population screening.
In a clinical setting, factors such as simplicity, safety and time are much more
critical. In addition, the amount of training necessary for the performing medical
personnel is important, as it cannot be expected that every general practitioner
will undergo lengthy and costly specialised training to be able to offer such a
test. In this typical clinical setting, much simpler, and less intense and costly
surrogate tests, such as an OGTT or fasting assessments are desirable. The loss
in repeatability and reliability is often acknowledged as a necessary compromise,
or simply not acknowledged and used nonetheless. The consequence is that a
state of resistance can often only be diagnosed when the state is significantly
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progressed and irreversible damage has already begun to occur.
Another aspect to be considered is the different settings each test is performed
in. Insulin sensitivity can be different in a fasting state, in which the system is in
equilibrium, than in an intravenous perturbation [Ferrannini and Mari, 1998]. It
can then be different again for a more physiological oral perturbation [Ferrannini
and Mari, 1998]. In fact, oral glucose triggers insulin-stimulating gastrointestinal
hormones, that are not present in an IV input [Breda et al., 2001]. The supra-
physiological concentrations achieved during a clamp test have been shown to
result in different results, as saturation effects become evident and significant
[Natali et al., 2000]. Other differing effects are seen in test performance if insulin
is injected or stimulated using drugs such as tolbutamide, which is necessary in
insulin dependent diabetes subjects to increase the insulin signal [Quon et al.,
1994a].
All the tests described in this chapter, except the HbA1C, require a fasted
state to yield reliable results. This aspect can potentially confound results if not
adhered to, which probably makes the HbA1C value the most robust analysis.
An early diagnosis of IR is still not possible with this assessment, as an elevated
HbA1C is only seen after significant β-cell damage has occurred.
As a general observation it can be said that intravenous tests have the highest
repeatability, as they are the most controlled tests. The highest repeatability is
seen in the clamp, due to the suppression of all endogenous glucose and insulin
output, thus reducing any unknown dynamics. The IVGTT triggers unmodelled
regulatory responses that negatively affect model fitting [Cobelli et al., 1998;
Mari, 1997]. The source of these problems is evident and can be addressed in
improved fitting algorithms and fine-tuning of the protocol, rather than via more
complex modelling or clinical exercises [Lotz et al., 2006a].
Oral tests are more variable, due to the additional transport path involved in
the administration of glucose. The gastric absorption rate cannot be measured
without tracers and can be very variable. Any estimation of this rate involves
simplified assumptions and thus results in a larger introduced variability in the
overall test result. A larger number of samples used in the calculation of the
metric can reduce variability by capturing the dynamic response more completely.
Hence, the composite indices perform better than using just an OGTT 2-hour
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Figure 2.7 Comparison of different insulin sensitivity tests and the target area for a better
clinical test. The points are plotted according to the test’s intensity and accuracy in terms of
repeatability (CV in percent). Intensity is a composite symbolic measure of cost, duration and
overall stress involved.
post load glucose sample. The fasting tests also show reduced performance for
similar reasons, as only one sample is taken. Note that the repeatability of a
fasting test can be improved by using the mean of 2-3 samples, instead of only
one [Katz et al., 2000; Wallace et al., 2004b], but at a cost of increased intensity.
Nonetheless, even with a perfect test, varying results would be seen as insulin
sensitivity has been shown to vary with times of day and night [Bolli, 1988;
Van Cauter et al., 1997].
When designing a new test to measure insulin sensitivity that is repeatable,
accurate and feasible in a clinical setting, the positive aspects of the different
methods described can be exploited. In particular, improvements in the protocol
and algorithms can be made to prevent sources of error identified in previous
approaches. In Figure 2.7 the accuracy in repeatability of insulin sensitivity tests
is plotted against the test intensity, with intensity being a composite measure of
cost, duration and overall stress involved. Thus, this figure clearly highlights the
design space and goal region for any clinically useful, yet accurate, test.
The overall goal of this research is to develop a new clinical insulin sensitivity
test to match or exceed the target defined in Figure 2.7. Important test aspects
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that contribute to meeting this goal include:
• Duration: Duration can be minimised by developing a fasting test or by
using an intravenous administration. Orally administered glucose takes 30-
60 minutes to peak, rendering a short accurate test impossible.
• Simplicity: Special equipment (pumps, heated box, realtime test adjust-
ments) or tracers should be minimised and preferably eliminated. The test
should also ideally require no specialised procedures and need a minimal
amount of samples.
• Cost: Cost is a logical consequence of duration, simplicity and number of
samples.
• Accuracy: By incorporating physiological knowledge about the kinetics of
glucose and insulin, the test protocol can be optimised to minimise known
sources of error, such as systemic mixing, counter-regulatory responses,
EGP, or saturation effects. By also sampling C-peptide, β-cell function can
be estimated in addition to insulin sensitivity.
• Safety: To maximise safety, any dosing should be as low as possible, while
still providing a clear signal. This approach also improves physiological
accuracy by reducing saturation effects.
• Robustness: The robustness of the protocol should be such that possible
sources of experimental error, both computational and ergonomic/systemic,
are minimised. The data analysis algorithm should not require manual
analysis, input, or fitting.
2.7 Summary
Many different approaches to measure insulin sensitivity have been proposed to
date, varying in complexity and accuracy. Tests that measure sensitivity directly
use intravenous or oral administration of glucose and include sampling of glucose,
insulin and C-peptide to capture the dynamic metabolic response to that per-
turbation. The more repeatable tests, such as the clamp or the IVGTT are only
36 CHAPTER 2 REVIEW OF CURRENT METHODS
used in research settings, as they are too complex, intense and costly for regular
or widespread clinical application.
Simpler, but less accurate, surrogate metrics vary from calculations derived
from OGTT data to using only one fasting sample. These assessments are pri-
marily derived from empirical regression models and do not have the resolution
to give more than a high/low result. Nonetheless, they are the only clinically
feasible tests to date to gain widespread clinical usage and acceptance.
A clinically useful test that is repeatable and that provides a good resolution
to monitor small changes in sensitivity would enable earlier and more accurate
diagnosis of insulin resistance. Such a test could be engineered by considering the
good aspects of available accurate research tests, while reducing their intensity,
and also avoiding errors identified in their methods. This engineering task is the
primary goal of this research.
Chapter 3
Insulin Modelling and Identification
To assess insulin sensitivity to glucose uptake, physiological models of the key
metabolic pharmaco-dynamics (PD) are required. These dynamics can be cate-
gorised as the kinetics of insulin, glucose and their pharmaco-dynamic interac-
tion. Endogenous insulin secretion can be estimated indirectly in this process by
modelling C-peptide kinetics.
The modelling goal of this chapter is to attain pharmaco-kinetic (PK) models
of insulin, that are physiologically valid, yet simple enough to be identifiable with
a short, simple test and limited blood sampling. The physiology and modelling
of insulin and C-peptide are discussed. Appropriate identification methods that
can be applied within the proposed test protocol are presented for each model.
The identification methods are presented with each specific model as they are
inter-related and specific.
3.1 Insulin Kinetics
3.1.1 Physiology
Insulin is a hormone secreted by the pancreas, that plays a very important role
in regulating carbohydrate metabolism. It enables glucose uptake by muscle
and adipose tissue cells, regulates storage and release of glucose in the liver,
and promotes fat synthesis and storage [Guyton and Hall, 2000; Jefferson and
Cherrington, 2001]. It also has several other effects, including anti-inflammatory
effects [Dandona et al., 2006; Hansen et al., 2003], that are not the focus of this
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thesis and are well discussed in the relevant literature.
The insulin hormone is a polypeptide, composed of 51 amino acids with a
molecular weight of 5808 Daltons (Da). It is produced by the β-cells within
the islets of Langerhans of the pancreas [Guyton and Hall, 2000]. The pancreas
secretes insulin into the portal vein, where it first passes through the liver and
subsequently enters circulation. From there it is distributed to interstitial fluid,
where it binds to cell-membrane receptors to activate glucose uptake [Jefferson
and Cherrington, 2001], as shown in Figure 3.1.
Figure 3.1 Schematic of insulin binding to receptors on tissue cells to activate glucose uptake
(taken from www.betacell.org [2004]).
Secretion of insulin by the pancreas is bi-phasic in healthy individuals [Guy-
ton and Hall, 2000; Jefferson and Cherrington, 2001]. The first phase consists
of pre-produced and stored insulin and is secreted as a burst immediately after
plasma glucose concentrations rise significantly. After approximately 10 minutes,
a second phase secretion starts, which is a rise in the steady production rate to
meet the body’s metabolic need [Guyton and Hall, 2000; Jefferson and Cherring-
ton, 2001]. Note that this response to glucose matches the behaviour of a PID
controller, which has consequently also been used as an approach in closed loop
control of diabetes [Chase et al., 2006; Chee et al., 2003; Steil et al., 2006].
Clearance of insulin by the body is mainly accomplished by the liver, ac-
counting for up to 80% of total clearance [Duckworth et al., 1988; Ferrannini
and Cobelli, 1987b]. After secretion into the portal vein, insulin passes through
the liver, where approximately 50% is extracted and stored or degraded (first
pass extraction), before insulin even reaches the systemic circulation [Duckworth
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et al., 1988; Ferrannini and Cobelli, 1987b]. This mechanism allows for a fast
response and control of circulating insulin. Further clearance is taken over by
the kidneys, as a function of glomerular filtration rate (GFR) [Duckworth et al.,
1998], and through cellular degradation after binding to enable glucose uptake in
the periphery [Guyton and Hall, 2000; Jefferson and Cherrington, 2001].
Insulin was first isolated from a dog pancreas by Banting et al. [1922], and
was soon produced commercially to treat diabetes [Jefferson and Cherrington,
2001], mainly by extracting pork, beef or fish insulin, which are very similar to
the human molecule. The first genetically engineered insulin (Humulin) appeared
on the market in 1982. Presently, most insulins sold are genetically engineered
human insulins or analogs, that provide a wide range of half-times in the blood
plasma following subcutaneous injection. The goal is to better mimic first or
second phase pancreatic insulin response.
In this study, insulin is assumed to be human insulin, or equivalent, as ad-
ministration is intravenous and no delay in action is required. The remaining
kinetics can thus be modelled physiologically. A physiologically accurate model
should thus include the main volumes of distribution, the main mechanisms of
transport between these volumes, and the dominant irreversible losses to the liver
and kidneys.
To summarise the physiology to be modelled: Insulin is initially secreted into
the bloodstream by the pancreas and cleared by the liver, and to a lesser extent,
the kidneys. Through transcapillary transport, insulin is diluted into interstitial
fluid, reaching tissue cells where it binds to activate glucose uptake. In this final
process, insulin is internalised and degraded by the cell.
3.1.2 Modelling
The fundamental goal in modelling insulin kinetics is to develop a physiologi-
cal insulin kinetics model that includes all major physiological pathways. Only a
model that is physiologically valid can provide a useful diagnostic outcome, where
physiological validity in this modelling work is achieved when all structural com-
ponents are derived from actual physiological mechanisms, and the identified
parameter values lie in a physiologically justifiable range.
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Equally important, it must also be both identifiable and simple enough to
be useful in clinical applications proposed with limited measurements. These
requirements imply a model to which simple, but accurate, parameter estimation
techniques can be applied. Identified parameters can then provide a diagnostically
relevant outcome.
3.1.2.1 Background
Many different insulin modelling approaches have been pursued since the late
1960s, analysing insulin kinetics with one to three compartment models with dif-
ferent losses and physiological explanations [Frost et al., 1973; Hovorka et al.,
1993; Jones et al., 1984; McGuire et al., 1979; Sherwin et al., 1974; Silvers et al.,
1969; Tranberg and Dencker, 1978]. Physiological explanations for the compart-
ments and their parameters differed depending on the parameter values identified
using clinical data.
In the pioneering work in this field by Sherwin et al., an IV bolus of insulin
and a constant infusion is fit by different models ranging from one to four com-
partments [Sherwin et al., 1974], as shown in Figure 3.2. The authors concluded
that a three compartment model is necessary to accurately reflect the kinetics
of the decay curve, and they propose a model with compartments representing
plasma, hepatic plasma and extravascular fluids. Sherwin et al.’s model also
contains inputs to the hepatic and plasma compartments, and irreversible losses
from the plasma compartment. Due to the large number of parameters and the
limited sampling resolution available, this model is difficult to identify uniquely.
Other studies have examined simplifying this model to two compartments as
two exponentials can describe the observed plasma insulin decay sufficiently well
within measurement error [Ferrannini and Cobelli, 1987a; Turnheim and Wald-
hausl, 1988]. These studies typically unify the plasma and hepatic compartments,
as shown in Figure 3.3, approximating them as fast exchanging relative to other
dynamics [Frost et al., 1973; Polonsky et al., 1986a; Tranberg and Dencker, 1978].
These simplifications allow easier identification, but the assumed transport paths
are not always physiologically accurate and thus do not give an accurate rep-
resentation of the complete observed kinetics. Ferrannini and Cobelli [1987a]
concluded, after a detailed review of modelling efforts to that date, that a two
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Figure 3.2 The three models analysed in the pioneering work by Sherwin et al. [1974].
compartment model with irreversible losses to both compartments would provide
the best compromise in physiological accuracy and identifiability. However, a
model would only be useful if combined with an identification method capable
of providing a unique solution [Ferrannini and Cobelli, 1987a]. To date, such a
method of uniquely identifying all the parameters has not been presented.
Figure 3.3 Three two compartment models with varying locations and interpretations of
irreversible losses [Frost et al., 1973; Polonsky et al., 1986a; Tranberg and Dencker, 1978].
Due to these identification problems, most recent studies have employed a
mono-compartmental description, with a single linear loss and an input term
[Bergman et al., 1985; Carson and Cobelli, 2001; Toffolo et al., 2006, 1995].
Combined with the physiology of a delayed, remote site of insulin action, this
description results in a basically two compartment description, without a back-
42 CHAPTER 3 INSULIN MODELLING AND IDENTIFICATION
flow into the plasma compartment. A form of this simplified kinetics model has
been successfully used in glycaemic control studies in the ICU [Chase et al., 2006,
2005a; Wong et al., 2006a]:
d
dt
I(t) =
−nI(t)
1 + αII(t)
+
u(t)
VP
(3.1)
d
dt
Q(t) = −kQ+ kI (3.2)
This model is a reasonably accurate representation of insulin kinetics. It
has been particularly useful in control applications with limited knowledge of
the actual insulin concentrations. However, it does not necessarily adhere to
mass conservation laws and thus lacks important physiological knowledge that is
absolutely required for a detailed physiological test.
3.1.2.2 Model Structure
The proposed insulin kinetics model shown in Figure 3.4 is derived from Sherwin
et al.’s three compartment model [Sherwin et al., 1974]. However, it is reduced to
two compartments by integrating the hepatic and plasma compartments, as the
transport between these compartments is very fast [Ferrannini and Cobelli, 1987a;
Sherwin et al., 1974]. The decay of an IV injection of insulin has been shown to
follow a double exponential decay curve sufficiently well in several studies [Carson
and Cobelli, 2001; Ferrannini and Cobelli, 1987a; Turnheim andWaldhausl, 1988],
further justifying this reduction.
The model in Figure 3.4 consists of a central or accessible compartment repre-
senting the plasma space and fast exchanging tissues, such as the splanchnic bed,
and a peripheral compartment representing the interstitial fluid. These compart-
ments are further described as plasma and interstitial spaces, with distribution
volumes VP and VQ, respectively. Transport between them is bi-directional and
each compartment has a clearance pathway. The plasma input, u(t), represents
the appearance of insulin into the model.
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Figure 3.4 Initial structure of two compartment insulin kinetics model.
The differential equations describing the amounts of insulin in the two com-
partments are dependent on the fractional turnover rates k1 − k4 (min−1), the
amount of insulin in both compartments, i(t) and q(t) in mU and the model input
u(t) in mU/min:
d
dt
i(t) = −(k1 + k3)i(t) + k2q(t) + u(t) (3.3)
d
dt
q(t) = −(k2 + k4)q(t) + k1i(t) (3.4)
Reformulating Equations 3.3-3.4 in terms of concentrations, with I(t) = i(t)/VP
and Q(t) = q(t)/VQ yields:
d
dt
I(t) = −(k1 + k3)I(t) + k2
VQ
VP
Q(t) +
u(t)
VP
(3.5)
d
dt
Q(t) = −(k2 + k4)Q(t) + k1
VP
VQ
I(t) (3.6)
where VP and VQ are given in litres and the concentrations I(t) and Q(t) in mU/l.
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This formulation includes the main pathways of insulin, but still combines
some separate physiological processes into single parameters. Specifically, the
hepatic and renal clearances are combined in k3. It also allows for differing
transports between the compartments by allowing an independent estimation of
k1 and k2. The model can still achieve a good fit to clinical data, but estimated
parameters could be non-physiological and therefore may not be accurate for
prediction or model-based clinical testing.
To make the model description more physiological, the following equivalent
model formulation is suggested, with explicit choices of transport and mass con-
servation fully enforced:
d
dt
I(t) = −nKI(t)−nL
I(t)
1 + αII(t)
− nI
VP
(I(t)−Q(t))+uex(t)
VP
+(1−xL)
uen(t)
VP
(3.7)
d
dt
Q(t) = −nCQ(t) +
nI
VQ
(I(t)−Q(t)) (3.8)
where the parameters nK , nL, nC are in min
−1, nI in l/min, xL as a fraction and
αI in l/mU.
The irreversible clearance of insulin from plasma is mainly taken care of by
the liver and the kidneys. The liver clears as much as 80% of the total losses
[Ferrannini and Cobelli, 1987b] and can vary widely depending on concentrations
and individual state. Studies have also shown a saturation of liver clearance
at higher concentrations [Ferrannini et al., 1983; Thorsteinsson, 1990], due to
the mechanism by which insulin is cleared, namely binding to liver cells and its
resulting degradation. The liver clearance can thus be described by the param-
eter nL, which includes a Michaelis-Menten saturation term with the saturation
parameter αI [Thorsteinsson, 1990].
At low insulin concentrations the kidneys clear insulin mainly by glomerular
filtration (GFR), a constant rate dependent on blood flow [Despopoulos and
Silbernagl, 2003]. At higher plasma insulin concentrations, mainly postprandial
or during exogenous input, kidney clearance has been measured to be about twice
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GFR [Samnegard and Brundin, 2001; Zavaroni et al., 1987]. This additional
clearance appears to be by peritubular excretion [Rabkin et al., 1984]. Clearance
by the kidney can thus be described in this model by a separate parameter nK ,
and is assumed to be linear. Although it could be time-varying between 1-2 times
GFR, it is assumed constant in this study, allowing any variation to be captured
by nL. The parameter k3 in Figure 3.4 is thus split into the renal and hepatic
clearances nK and nL.
Transcapillary transport from plasma to interstitium has been studied by oth-
ers and found to occur mainly via diffusion in vivo in dogs and humans [Castillo
et al., 1994; Gudbjornsdottir et al., 2003; Rasio et al., 1967; Sjostrand et al.,
1999; Steil et al., 1996; Yang et al., 1989]. In this model a passive transport
by diffusion alone is assumed, due to a large amount of evidence that it is the
primary and/or dominant mechanism. Transcapillary diffusion is concentration
driven and bi-directional, and is described in this model by the diffusion constant
nI , defined by the volumes and k1 and k2 from Equations 3.3-3.4:
nI = k2VQ = k1VP (3.9)
This relationship implies the fixed ratio k1/k2 = VQ/VP , a relation that will
hold in general for any pair of fractional turnover rates between two compart-
ments, provided the transport is passive. For example, this passive transport
could be in the form of diffusion or convective exchange of fluid between the
compartments. Finally, Equation 3.9 also enables equal transport and thus en-
forces mass conservation, where independent identification of k1 and k2 might
not.
The irreversible loss from the peripheral interstitial compartment is believed
to occur mainly due to binding of insulin to the cells and its subsequent degra-
dation [Conn and Goodman, 1998; Jefferson and Cherrington, 2001]. The rate at
which insulin is degraded at the cells is described by nC , which is equivalent to
k4 from Equation 3.4.
The input u(t) to the plasma compartment is split into separate exogenous
and endogenous inputs, described with uex(t) and uen(t), respectively. Exoge-
nous inputs are typically known. In contrast, endogenous secretion is less well
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known, but can be estimated using the population model of C-peptide kinetics
by Van Cauter et al. [1992].
The final formulation of the model is shown in Figure 3.5. The model now
has 6 parameters and cannot be uniquely identified by a double exponential,
unless constraints are applied to reduce the degrees of freedom. This process
could include physiological a-priori identification of less critical parameters and
fitting of more dominant parameters. The identification approach could also vary
depending on the application and given data density.
Figure 3.5 Final structure and formulation of the two compartment insulin kinetics model.
The key differences between this model and previously proposed models are
the physiological plausibility of all parameters and the diffusion constant between
the compartments, that fixes the gearing ratio of the transport between the com-
partments and enforces strict mass conservation. This aspect has not always
been strictly maintained in previous models [Eaton et al., 1984; Sherwin et al.,
1974]. One simplification made from the more complex three compartment struc-
ture is the combination of the hepatic and plasma compartments into one, as a
separate identification of both would not be possible in a clinical setting. Over-
all, the model has physiological validity and is simple enough for use in clinical
applications.
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3.1.3 Model Identification
Unique identification of all the model parameters in Figure 3.5 is difficult if all pa-
rameters are variable. Commonly used non-linear recursive least squares (NRLS)
approaches are starting point dependent and computationally intense [Carson
and Cobelli, 2001]. Used correctly, a wide range of starting values should be
employed to enable an identification of the global minimum ([e.g. Thorsteins-
son et al., 1987]). To overcome this issue, other methods have been proposed,
such as Bayesian approaches employing a-priori known parameter distributions
to bind parameter estimation to a physiological range [Carson and Cobelli, 2001;
Pillonetto et al., 2002]. Nonetheless, with a rising number of parameters, unique
identification becomes difficult and often a wide range of parameter combina-
tions can result in a comparable quality of fit to clinical data, even though the
parameter values are not necessarily physiological.
3.1.3.1 A-priori Information
A commonly used strategy to overcome this limitation is to reduce the number
of parameters by exploiting known a-priori physiological information to fix pa-
rameters to constant values or introduce relationships between them [Carson and
Cobelli, 2001; Hann et al., 2005b; Hovorka et al., 1993]. As the insulin sensitivity
test is meant to only require plasma samples, parameters governing interstitial
concentrations, such as nI and nC are difficult to identify directly. To improve
identifiability, cellular clearance nC is thus linked to nI to achieve a fixed steady
state concentration gradient γ between both compartments:
γ =
Qss
Iss
(3.10)
This concentration gradient has been studied by a variety of researchers by
measuring lymph concentrations of insulin and comparing them to plasma con-
centrations [Castillo et al., 1994; Steil et al., 1996; Yang et al., 1989]. These
studies have reported mean values of γ = 0.34 − 0.6. In recent studies, mea-
suring concentrations directly at muscle tissue with a new microdialysis catheter
technique [Gudbjornsdottir et al., 2003; Sjostrand et al., 1999, 2000], Qss/Iss
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gradients of 0.4− 0.6 have been measured during euglycaemic clamps. The ratio
γ = 0.5 is chosen as a consistent mean value of the above mentioned studies. The
choice of this value has an effect on estimated insulin sensitivity, as described
in more detail in Chapter 7. By fixing this constant subject-independent value
across individuals, the bias introduced by this effect is only systematic and equal
in magnitude across all individuals, thus not introducing added variability.
Cellular clearance nC can thus be calculated as a function of nI and VQ using
steady state assumptions of Equation 3.8:
0 = −nCIssγ +
nI
VQ
Iss(1− γ) ⇒ nC =
nI
VQ
(
1
γ
− 1
)
(3.11)
Saturation of hepatic insulin clearance, described by parameter αI , is difficult
to estimate and would require specialised multi-dose tests to estimate correctly.
A mean value found in studies investigating this effect is αI = 0.0017 [Ellemann
et al., 1987; Thorsteinsson, 1990]. As the insulin sensitivity test proposed here
is designed for low, physiological concentrations after a fasting state, hepatic
saturation is not very likely and this value can potentially be set to αI = 0.
A further option to reduce the number of parameters to be identified is to
exploit kinetic similarities with other substances, in which the kinetic parameters
are uniquely identifiable. Two examples of substances with similar molecular
weights to insulin are inulin and C-peptide [Clark, 1999; Rasio et al., 1967]. Due
to similar molecular sizes, it can be assumed that these substances share similar
distribution volumes and passive kinetic transport rates. As both substances
are only cleared by the kidneys, their kinetics can be described by an identifiable
two compartment model with four parameters [Eaton et al., 1980; Sturgeon et al.,
1998]. A C-peptide kinetics model that is identifiable with a population approach
has been presented by Van Cauter et al. [1992] and is used in this study to identify
insulin parameters with similar physiological characteristics. After these steps,
the few remaining unknown parameters can be identified with a convex integral-
based fitting approach [Hann et al., 2005b; Lotz et al., 2006a], or alternatively
using only fasting information and steady state model analysis.
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3.1.3.2 A-priori ID with C-peptide Information
C-peptide is secreted by the pancreas in equimolar amounts to endogenous insulin
[Rubenstein et al., 1969]. The kinetics of C-peptide were initially studied by Faber
et al. [1978] and Eaton et al. [1980], analysing decay curves of IV injections of C-
peptide. Eaton et al. presented a two compartment model of C-peptide kinetics
that accurately described the observed data. Unlike insulin, C-peptide is not
cleared by the liver or degraded by the cells, thus simplifying the kinetics to be
modelled.
Van Cauter et al. [1992] developed population parameters for Eaton et al.’s
model, enabling identification without the need of analysing the C-peptide decay
curve in every individual [Van Cauter et al., 1992]. This population model has
been successfully validated in a variety of studies [Hovorka et al., 1998; Jones
et al., 1997; Toffolo et al., 1995]. The error in estimated C-peptide secretion
from the population model compared to individually estimated parameters is in
the range of 10% − 20% [Hovorka et al., 1998; Toffolo et al., 1995; Van Cauter
et al., 1992], showing a very narrow range across broad ranges of individuals and
groups.
Given the knowledge of the respective clearance sites of the two peptides
and a similar molecular weight of 5808 Da (insulin) [Guyton and Hall, 2000] and
3021 Da (C-peptide) [Clark, 1999], the assumption can be made that insulin and
C-peptide share certain passive characteristics. Transcapillary transport rate and
distribution volumes of inulin (5500 Da [Rasio et al., 1967]) and insulin have also
been shown to be comparable [Rasio et al., 1967; Steil et al., 1996; Yang et al.,
1989], leading to the assumption that they could be similar in C-peptide. This
assumption enables the use of the validated C-peptide parameters to describe
shared portions of the insulin kinetics model. This approach thus reduces the
number of parameters to be estimated, making the overall proposed model more
readily identifiable.
Insulin kinetic model parameters that can adopt values of similar C-peptide
parameters are the distribution volumes VP and VQ, the transcapillary diffusion
rate nI , and the renal clearance nK . All of these parameters are assumed to
be similar in insulin and C-peptide, given their shared molecular properties and
the common mechanisms of renal clearance [Despopoulos and Silbernagl, 2003].
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Hepatic and cellular insulin clearance rates, nL and nC , remain to be estimated,
as C-peptide is not cleared by the liver and does not bind to the cells.
The insulin model parameters VP , VQ, nI and nK are thus calculated from
the method proposed by Van Cauter et al. [1992], in which the amplitudes and
time constants of a double-exponential decay are estimated patient specific as
functions of the individual’s age, sex, weight, BSA, BMI and diagnosis of type 2
diabetes. The formulae derived in that study to calculate these parameters are
shown in Table 3.1. From the four decay parameters, representing the system
response to an IV injection, the kinetic parameters of the insulin model used in
this research can be calculated as shown in the table.
Table 3.1 Steps to calculate kinetic population parameters of C-peptide model, as proposed
by Van Cauter et al. [1992]. Step 6 relates these parameters to insulin model parameters used
in this thesis.
Steps Normal Obese NIDDM
1. Short half life t1/2-short [min] 4.95 4.55 4.52
2. Fraction F = A/(A+B) 0.76 0.78 0.78
3. Long half life t1/2-long 0.14× (age[yr]) + 29.2
4. Plasma volume VP Female: VP = 1.11×BSA + 2.04
Male: VP = 1.92×BSA + 0.64
(BSA =
√
height[cm]×weight[kg]/3600)
5. C-peptide kinetic parameters k2 = F × (b− a) + a
k3 = a×b/k2
k1 = a+ b− k2 − k3
with:
a = log10(2)/t1/2 − short
b = log10(2)/t1/2 − long
6. Insulin kinetic parameters VQ = VP×k1/k2
nI = VQ×k2
nK = k3
3.1.3.3 Integral-Based Fitting
Parameters left to be identified from data are the hepatic clearance related param-
eters nL and xL. They are identified using measured data and an integral-based
fitting method. The fitting method uses the integrals of the differential equa-
tions to reduce the nonlinear estimation problem to a set of linear equations that
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can be easily solved by minimising the L2-Norm between the measured and es-
timated values. The method has the dual advantages of being convex and not
starting point dependent. Equally important, parameters can be defined as step-
wise constants for different time segments to enable identification of time varying
parameters if required [Hann et al., 2005b; Lotz et al., 2006a].
Equation 3.7 is integrated in a chosen time interval t ∈ [t0, t1], obtaining the
following expression:
I(t1)− I(t0) = −nL
∫ t1
t0
I(t)
1 + αII(t)
dt− xL
∫ t1
t0
uen(t)
VP
dt
−
∫ t1
t0
[
(nK +
nI
VP
)I(t) +
nI
VP
Q(t)− uex(t)
VP
− uen(t)
VP
]
dt (3.12)
where the analytical solution of Equation 3.8 can be used to express Q(t) as
a function of the measurable plasma insulin I(t) and the kinetic parameters of
Equation 3.8.
Q(t) =
nI
VQ
∫ t
0
I(τ)e
−(nC+
nI
VQ
)(t−τ)
dτ (3.13)
Thus, given nI , VQ and nC from other steps, a single linear equation for nL
and xL can be obtained for each numerically evaluated integral in Equation 3.12.
Integrating over several time steps provides several such equations, and the prob-
lem is reduced to solving the following set of linear equations:
A¯
{
nL
xL
}
= b¯ (3.14)
where constraints can be added to the least squares solution to keep the parameter
within known physiological ranges.
To best compute the integrals in all time intervals, the profile of I(t) needs
to be approximated by interpolating between discrete measurements. Linear
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interpolation is sufficient in longer term data [Hann et al., 2005b] or control trials
[Wong et al., 2005]. However, the dynamic nature of the impulse response to a
bolus insulin injection requires an exponential decay curve to be fit. This task
can be done by fitting a double exponential curve to the data. In a situation with
limited sampling, this can be done by first estimating the slow exponential with
later samples in the data and then back-calculating the fast exponential using
the earlier samples, as shown schematically in Figure 3.6.
Figure 3.6 Schematic of the stepwise approximation of the discrete data samples with a
double-exponential decay. Step 1 approximates the slow exponential from all samples >10 min-
utes after insulin input. Step 2 approximates the fast decay using samples <10 minutes after
insulin input. The combined curve is obtained in Step 3 by adding both exponentials. The
estimated curve is a good match of the experimentally sampled data.
The resulting approximation errors of any reasonable approximation to the
true curve can be shown to be very small due to the integrations over several
time intervals [Hann et al., 2005b]. More specifically, integral functions have the
advantage of being robust to noise in the measured data, by effectively providing
a low-pass filter in the summations involved in numerical integration. Hence,
the dominant sources of bias will be due to model, rather than computational or
methodological error.
This integral-based approach effectively matches the area under the measured
response curves for each interval considered. This approach is in contrast to stan-
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dard, well accepted methods that typically use gradients to directly match the
response trajectory. Given the multiplication and summation operations used in
the numerical integration, there are several analogies to a digital filtering iden-
tification process that could possibly be made. More importantly, this approach
converts a computationally intense, non-convex problem into a much simpler con-
vex problem, offering several advantages in speed and the quality of the results
[Hann et al., 2006, 2005b].
3.1.4 Summary - Insulin Kinetics
Insulin kinetics have been discussed and a physiological model proposed that
includes all main kinetics. The model is physiologically valid, yet simple enough
to be applicable in a clinical setting. An identification method is proposed, that in
a first step identifies most parameters a-priori with information from a C-peptide
population model, and then identifies the hepatic clearance with an integral-based
fitting approach. The overall method is robust on typically seen clinical sampling
profiles. These identification steps are summarised in the schematic in Figure 3.7.
Figure 3.7 The overall method of identifying the model parameters from clinical experimental
data and a-priori C-peptide kinetics information, as described in Section 3.1.3.
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3.2 Insulin/C-peptide Secretion
3.2.1 Physiology
C-peptide (connecting peptide), just like insulin, is produced by the β-cells lo-
cated in the islets of Langerhans in the pancreas [Despopoulos and Silbernagl,
2003; Guyton and Hall, 2000]. In fact, C-peptide is seen as a by-product of insulin
production, as both peptides originate from the precursor Proinsulin, which splits
into insulin and C-peptide, thus producing equimolar amounts of both [Ruben-
stein et al., 1969]. More specifically, C-peptide is a single chain of 31 amino acids,
connecting the A and B chains of insulin in the Proinsulin molecule, as shown in
Figure 3.8.
Figure 3.8 Splitting of Proinsulin into C-peptide and insulin [Chevenne et al., 1999].
For a long time the physiological role of C-peptide was unknown and it was
merely seen as a waste product of insulin production [Wahren, 2004]. More recent
research has indicated a biologically active role, in binding to cell membranes
and activating intra-cellular signalling pathways, resulting in improved renal and
nerve functions [Wahren, 2004]. These effects are not critical for this research and
do not affect the modelling approach, as its function does not affect its appearance
or degradation significantly.
As C-peptide is only cleared by the kidneys, it has a longer half-life than
insulin (∼2-5 times longer). This difference results in higher concentrations of
C-peptide in the peripheral circulation and less fluctuations in its concentration
than insulin. Hence, the kinetics of C-peptide are easier to capture in both
measurement and model.
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Due to its equimolar secretion and longer half-life, plasma C-peptide concen-
trations independently reflect pancreatic insulin secretion. In fact, the slower,
less variable clearance by a single route (rather than three) makes it a more re-
liable measure of endogenous insulin secretion than the plasma concentration of
insulin itself. Therefore, models independently linking C-peptide kinetics and
insulin kinetics can be used to determine and capture endogenous insulin secre-
tion [Eaton et al., 1980; Faber et al., 1978; Hovorka et al., 1996; Polonsky et al.,
1986b; Van Cauter et al., 1992].
3.2.2 Model Structure
The kinetics of C-peptide were first analysed by Faber et al. [1978] who adminis-
tered synthetic human C-peptide and measured the dose-response plasma decay
curve over time. They concluded that a three component exponential equation is
necessary to describe its kinetics. Eaton et al. [1980] later described the kinetics
of C-peptide with a two compartment model and calculated kinetic parameters
assuming a double-exponential decay. Eaton et al. [1980] also show that a three
compartment model does not significantly improve accuracy of the data fit, as the
fast decay rate is too fast to estimate accurately with practical clinical sampling
limitations.
A smaller two compartment model was thus proposed that describes C-
peptide distribution and degradation. The kinetic parameters of C-peptide clear-
ance were derived for each subject using this model from the decay curve observed
after a bolus injection of biosynthetic human C-peptide. The model is shown in
Figure 3.9.
The primary compartment is described as the accessible, central (intravas-
cular) compartment, which represents blood plasma and fast exchanging tissues.
The peripheral (extravascular) compartment represents interstitial fluid. The
concentrations C(t) and Y (t) are the C-peptide concentrations at time t, in the
intravascular and extravascular compartments respectively. Parameters k1, k2
and k3 are fractional transport rates, where k3 represents an irreversible loss
from the central compartment via the kidneys. The input rate to the intravas-
cular compartment S(t) consists of either endogenous C-peptide secreted by the
pancreas or C-peptide administered exogenously, depending on the specific clini-
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Figure 3.9 Two-compartment C-peptide model by Eaton et al. [1980].
cal test. Note that the endogenous component of S(t) equals endogenous insulin
secretion uen(t).
The differential equations describing the dynamic system in Figure 3.9 are
defined:
d
dt
C(t) = −(k1 + k3)C(t) + k2Y (t) + S(t) (3.15)
d
dt
Y (t) = k1C(t)− k2Y (t) (3.16)
where the parameters and variables are as defined above.
3.2.3 Model Identification
To estimate the C-peptide, or insulin, secretion rate S(t), the C-peptide model
kinetic parameters for a given individual have to be known. These parameters
can be estimated by fitting the model to the individually measured data from a
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bolus intravenous injection of C-peptide. The identified parameters and model
can then be used to deconvolute the input rate of endogenous secreted C-peptide
given clinical data [Eaton et al., 1980; Hovorka et al., 1996; Polonsky et al., 1986a;
Van Cauter et al., 1992].
3.2.3.1 Population Parameters
As an individual estimation of kinetic parameters is not feasible in a short clin-
ical test, an alternative method to estimate the kinetics has to be applied. A
population regression model was presented by Van Cauter et al. [1992], in which
they analysed the decay curves of 200 subjects including 111 normal subjects (71
males, 40 females), 53 obese subjects (19 males, 34 females), and 36 individuals
diagnosed with type 2 diabetes (20 males, 16 females). Population based kinetic
parameters are defined from this study as a function of gender, height, weight,
age and diagnosis of diabetes. This method thus allows a-priori identification of
kinetic parameters. The formulas to calculate the model parameters as proposed
by Van Cauter et al. [1992] are shown in Table 3.1 on Page 50.
3.2.3.2 Estimation of Secretion Rate
Estimation of the C-peptide secretion rate S(t) is performed with an integral-
based method, previously employed in real-time parameter identification in gly-
caemic control trials in the critically ill [Chase et al., 2005a; Wong et al., 2006a]
and in fitting long-term retrospective insulin and glucose profiles [Hann et al.,
2005b; Lotz et al., 2006a, 2005a, 2006b]. To best compute the integrals in all
time steps, the profile of C-peptide is approximated using linear interpolation be-
tween data points, which introduces no additional error over model error [Hann
et al., 2005b].
C-peptide secretion rate S(t) is thus estimated as a time-varying step func-
tion, with stepsize of 1 min. Therefore, during any given 1 min time interval
t ∈ [t0, t1 = t0 + 1], S(t) is assumed constant. Integrating Equation 3.15 in the
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interval [t0, t1] yields:
∫ t1
t0
C˙(t)dt = −(k1 + k3)
∫ t1
t0
C(t)dt+ k2
∫ t1
t0
Y (t)dt+
∫ t1
t0
S(t)dt (3.17)
Solving Equation 3.16 analytically for Y (t) yields:
Y (t) = k1
∫ t
0
Cest(τ)e
−k2(t−τ)dτ (3.18)
where Cest represents the interpolated C-peptide values estimated from the dis-
crete measurements. Combining Equations 3.17 and 3.18, and solving for the
assumed constant secretion rate S0,1 in this time interval yields:
S0,1 · (t1 − t0) = Cest(t1)− Cest(t0) + (k1 + k3)
∫ t1
t0
Cest(t)dt
−k2k1
∫ t1
t0
∫ t
0
Cest(τ)e
−k2(t−τ)dτdt (3.19)
where S0,1 is the only unknown given the population model values for k1 − k3.
Repeating this process for the intervals [t1, t2], [t2, t3], . . . [tn−1, tn], results in a
1-min stepwise constant secretion profile S(t). This estimated S(t) is constrained
to be non-negative. Smoothing the estimated stepwise constant profile with a
zero-phase 3-point moving average is done to avoid overfitting to noisy data and
interpolated measurements [Hann et al., 2005b]. This last step is not required
in frequently sampled data, but results in a more physiological profile between
more sparsely sampled data.
Using the same model and Van Cauter et al.’s parameter estimation method,
estimation of secretion rate has previously been proposed by deconvolution [Eaton
et al., 1980] and a more elaborate constrained regularisation method [Hovorka
et al., 1996]. The main drawbacks of these methods, in comparison to the meth-
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ods presented here, are the individualised method adjustments required for each
subject, including knot placements for cubic spline interpolations [Eaton et al.,
1980], and a separate step to find the optimal proportionality constant in each
subject [Hovorka et al., 1996]. All of these extra steps introduce time, computa-
tional complexity and intensity, and human variability into the results.
In contrast, the integral-based method described is a single step, computa-
tionally convex and fast method that only requires linearly interpolated data. By
constraining the linear least squares estimation to physiologically valid non-zero
values and smoothing the estimated secretion rate to remove the effects of noise,
the resulting profile is physiologically accurate and the effects caused by noisy
data are reduced [Hann et al., 2005b]. The secretion rate of insulin, which equals
that of C-peptide, can thus be estimated robustly from C-peptide concentration
samples during a short clinical test.
3.2.4 Summary - C-peptide
C-peptide is secreted in equimolar amounts to insulin and its kinetics can be
identified uniquely with more certainty than those of insulin. The C-peptide,
and consequently also insulin, secretion rate can be estimated from a well val-
idated population model of C-peptide kinetics, applying a novel integral-based
estimation method. The estimation method enables robust and physiologica-
lly valid estimation of pre-hepatic insulin secretion rate from sampled C-peptide
concentrations. The steps involved in the method described in this section are
summarised and shown schematically in Figure 3.10.
3.3 Summary
The insulin model derived in this chapter enables a physiological and accurate
description of the relevant metabolic dynamics of the hormone. The model is
physiologically valid, meaning that all its structural elements and identified pa-
rameter values are derived and explainable from physiological mechanisms. Addi-
tionally, it is useful for application in a clinical setting as the parameter values can
provide information about the metabolism. The estimation methods proposed,
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Figure 3.10 The overall method of estimating pre-hepatic insulin secretion, which is equiv-
alent to C-peptide secretion. Sampled C-peptide concentration data is approximated linearly,
and in conjunction with a population model of C-peptide kinetics, the secretion rate is estimated
with an integral-based method, as described in Section 3.2.3.
employing a-priori information and parallels with C-peptide kinetics, combined
with a robust and convex integral-based estimation of hepatic clearance rate,
enable a fast and physiological identification of all parameters.
The estimation of endogenous insulin secretion through C-peptide kinetics is
a well validated accurate approach [Hovorka et al., 1998; Van Cauter et al., 1992].
The population model of C-peptide kinetics [Van Cauter et al., 1992] enables an
a-priori identification of C-peptide kinetic parameters without additional tests
required. The integral-based estimation of a stepwise constant secretion of insulin
is robust and simple, as it does not require manual data analysis and intervention.
Overall, the models and methods presented are well suited for application in a
clinical insulin sensitivity test.
Chapter 4
Glucose Modelling and Identification
To derive a model-based metric of insulin sensitivity, a pharmaco-dynamic model
of the interaction of glucose and insulin is required. The model must include
all other, non-insulin dependent glucose clearance and uptake mechanisms to
improve its physiological validity.
The modelling goal in this chapter is to obtain a glucose PK and PD model,
that includes the key glucose uptake mechanisms, and is physiologically valid, yet
simple enough to be identifiable with a short, simple test and limited blood sam-
pling. Previous model-based approaches are discussed to improve overall method
performance and robustness, and reduce possible sources of methodological error.
An appropriate identification method that can be applied within the proposed
test protocol is presented.
4.1 Physiology
Glucose is a monosaccharide used as the main, and thus most important, source
of energy in the body. It is oxidised in the cells to provide ATP, which in turn
provides energy to the cell [Guyton and Hall, 2000]. The body uptake of glucose
is through carbohydrates in food, which are broken up in the alimentary tract
and released into plasma mainly in the form of glucose. Glucose in plasma is
transported to the cells for use as energy, and if available in abundance, stored
by the liver and the cells for future use.
The molecular weight of glucose is 180 Da, which is small enough to diffuse
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rapidly within plasma and body fluids, its main site of action [Guyton and Hall,
2000]. The uptake by cells in the brain and the central nervous system is by
diffusion alone, as they are highly permeable to glucose. In contrast, muscle and
adipose tissue cells control a majority of the total uptake and require insulin
binding to cell receptors to activate or mediate glucose uptake [Despopoulos and
Silbernagl, 2003; Guyton and Hall, 2000]. Hence, glucose uptake in this form is
referred to as “insulin-mediated” versus “non-insulin-mediated” uptake in other
organs.
Excess circulating glucose is stored in the liver and cells in the form of glyco-
gen, a large polymer of glucose, which is created by a process called glycogenesis
[Guyton and Hall, 2000; Zierler, 1999]. If glycogen stores are saturated, further
glucose is converted into fat and stored in the liver and in fat cells in the adipose
tissue. These processes can be reversed in times of energy demand. Glucose can
be rapidly released from glycogen by a process called glycogenolysis, and if the
glycogen stores are used up, fat is metabolised with amino acids to form glucose
in a process called gluconeogenesis [Guyton and Hall, 2000; Zierler, 1999].
The combined processes of glycogenolysis and gluconeogenesis are commonly
also described as endogenous glucose production (EGP) [Zierler, 1999]. EGP is
tightly regulated by the body to keep plasma glucose levels as constant as pos-
sible. External appearance or input of glucose, through meals or intravenous
injection, immediately results in a rapid inhibition of EGP [Caumo and Cobelli,
1993; Jefferson and Cherrington, 2001]. Low plasma glucose has the contrary
effect, stimulating glucagon secretion by the pancreatic α-cells, which activates
glycogenolysis and thus rapidly increases glucose concentrations in plasma. Over-
all, these processes operate in a balance with insulin-mediated glucose removal
to maintain normal blood glucose levels or glucose homeostasis. In type 2 dia-
betes this balance in glucose homeostasis does not function optimally anymore,
resulting in high blood glucose levels.
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Figure 4.1 Hormonal control of glucose metabolism to store or release glucose on demand
(taken from www.endocrine.com).
4.2 Modelling
4.2.1 Background
The kinetics of glucose have been described in similar ways as insulin, with one to
three compartment models [e.g., Bergman et al., 1979; Carson and Cobelli, 2001;
Cobelli et al., 1984; Insel et al., 1974]. As glucose is a smaller molecule than
insulin, with a molecular weight of 180 Da (compared to insulin with 5808 Da)
[Guyton and Hall, 2000], it distributes in the body much more freely and rapidly.
Well perfused organs in the splanchnic area, primarily the liver, are known to take
up or store glucose very rapidly, further adding to the difficulty in measuring these
kinetics to create accurate models.
A three compartment model was used to fit glucose kinetics in an early study
by Insel et al. [1974]. The model incorporated insulin-dependent and insulin-
independent glucose losses, and was identified using data from various dose-
response and glycaemic clamp tests with the help of glucose tracers. They con-
cluded that the fast compartment was impossible to identify from sampled data,
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as equilibration between this compartment and plasma was too fast. The losses
were assumed to occur from the fast and medium exchanging compartments, not
accounting for peripheral losses, thus limiting its validity.
Later attempts by Cobelli et al. [1984], Jacquez [1992] and Overkamp et al.
[1997] resulted in more physiological modelled losses and explanations for the
model parameters. However, identification of these models still required compli-
cated and costly multi-tracer experiments and further user imposed parameter
constraints. These aspects limit their use to very specialised research studies
and render them impractical for control or clinical use. Some of these modelling
attempts are shown schematically in Figure 4.2.
Figure 4.2 Two three compartment glucose kinetics models developed by Insel et al. [1974]
(above) and Cobelli et al. [1984] (below).
As the fast equilibrating compartment was found to be too fast to identify
accurately (time constant 0.6 min [Cobelli et al., 1984]), it was proposed to com-
bine the fast and the medium compartment [Cobelli et al., 1984]. This merger
is similar to the assumption made in modelling insulin, resulting in an acces-
sible compartment representing plasma and fast exchanging tissues and a slow
compartment representing interstitial fluid. Similar two compartment models
had been proposed earlier by Radziuk et al. [1978], in which the losses of both
compartments were equalised to enable identifiability, and later by Caumo and
Cobelli [1993] and Hovorka et al. [2002]. These latter models contain constant,
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as well as glucose dependent and insulin dependent losses, and more complicated
dynamics, allowing an estimation of endogenous glucose production by deconvo-
lution [Carson and Cobelli, 2001; Caumo and Cobelli, 1993]. Again, these models
require the use of glucose tracers to be uniquely identifiable and are thus imprac-
tical for clinical or widespread screening use. For reference, the model presented
by Caumo and Cobelli [1993] is shown in Figure 4.3.
Figure 4.3 Two compartment model of glucose kinetics proposed by Caumo and Cobelli
[1993].
The simplest description of glucose kinetics is by using only one compart-
ment, with the best known model being the ‘Minimal Model’ of glucose kinetics
proposed by Bergman et al. [1979]. The model is described by the following
equations:
dG(t)
dt
= −SMMG (G(t)−Gb)−G(t)X(t) G(0) =
D
VG
(4.1)
dX(t)
dt
= −p2X(t) + p3(I(t)− Ib) SMMI =
p3
p2
(4.2)
where G(t) is plasma glucose concentration, Gb fasting glucose, D the glucose
dose, VG the volume of distribution, X(t) remote insulin effectiveness, I(t) plasma
insulin concentration, Ib fasting insulin, S
MM
G glucose effectiveness at basal in-
sulin, SMMI insulin sensitivity, p2, p3 transport rates defining delay in insulin
effect.
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This approach assumes fast equilibration between the compartments and thus
equivalent concentrations throughout the body. Losses are possible by insulin-
independent pathways (brain, liver, kidneys) via the parameter SMMG (min
−1), de-
noted as glucose effectiveness at basal insulin, and by insulin-dependent (mainly
muscle and adipose tissue cells), as mediated by remote insulin effectiveness X(t)
(min−1). The variable X(t) in this model accounts for the combined delay in in-
sulin transport to the periphery, as well as the insulin sensitivity of the cells, thus
combining transport kinetics and action dynamics.
The Minimal Model is widely used, mostly combined with an IVGTT to
assess insulin sensitivity in research studies [Bergman et al., 1985, 1981]. Its
main advantages are simplicity and thus practicality. However, numerous studies
have questioned the validity of its derived parameters, and the question was
postulated as to whether it is “too minimal” [Caumo and Cobelli, 1993; Caumo
et al., 1996, 1999; Quon et al., 1994b; Regittnig et al., 1999]. In particular,
studies have shown that the estimation of SMMG is imprecise and usually results
in a significant overestimation of its contribution, with the consequent result
being a significant underestimation of SMMI [Caumo et al., 1999].
The reason identified for this problem by Caumo et al. [1999] is that glucose
kinetics should be described by two compartments to describe the fast decay
during the initial 30 minutes after a glucose dose and the slower decay thereafter.
When fitting the Minimal Model to IVGTT data using accepted methods, the
model tries to match the initial fast decay with a single exponential, resulting
in an overestimation of the slow decay that follows [Caumo et al., 1999; Quon
et al., 1994b]. Despite this problem, the model is able to capture the dominant
dynamics and has been somewhat successfully used in a slightly modified form
in glycaemic control trials in the critically ill [Chase et al., 2005a; Wong et al.,
2006a].
Further models of glucose kinetics usually combine more complex kinetics,
such as a circulatory model by Mari [1998], accounting for mixing of injected glu-
cose in the circulation. More complex simulation models include those presented
by Lehmann and Deutsch [1992] or Arleth et al. [2000]. These models include
many more physiological effects, such as gastric glucose uptake through meals,
liver feedback, and renal clearance thresholds. In particular, the glucose surface
by Arleth et al. [2000] is built on knowledge and assumptions on the behaviour
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of the GLUT glucose transporters [Guyton and Hall, 2000], incorporating sat-
uration of glucose clearance. Its parameters are identified by fitting the model
to values gathered from a wide range of clinical studies of glucose and insulin
metabolism, resulting in a ‘glucose surface’ that allows prediction of metabolic
behaviour in a population sense.
To summarise, modelling approaches exist to capture most metabolic char-
acteristics of glucose. However, they are usually limited to tailored experimental
situations, overly simplified, or both. For a model to be useful in clinical settings
and regular screening, it should be readily identifiable with limited data, but
compromising only slightly on physiological accuracy to ensure the relevance of
the results.
4.2.2 Model Structure
The model structure chosen for this application is a mono-compartmental de-
scription, similar to the Minimal Model and the model used in previous glycaemic
control research at the University of Canterbury [Chase et al., 2005b]:
dG
dt
= −pG(G−GE)− SIG
Q
1 + αGQ
+
P
VG
(4.3)
The main advantage over a multi-compartmental description is its identifia-
bility using limited plasma samples, while still accounting for the dominant dy-
namics. This model has also performed well in a variety of insulin and nutrition
based glycaemic control trials, as well as in retrospective data fitting of critically
ill patients [Chase et al., 2005b; Hann et al., 2005b]. As the intended test is
much more dynamic, and frequently sampled, errors could be introduced by un-
dermodelling, such as assuming a mono-compartmental structure. The trade-offs
between the improved identifiability of a simplified model and potential errors
introduced by an over-simplification of the model need to be analysed carefully.
Recent studies sampling interstitial fluid (ISF) concentrations of glucose di-
rectly from the muscle tissue using a microperfusion technique [Regittnig et al.,
2003, 1999], found a mean delay of 22 min (SD 3 min) between a bolus injection
68 CHAPTER 4 GLUCOSE MODELLING AND IDENTIFICATION
of 20 g glucose and the equilibration of concentrations in plasma and ISF. This
delay explains the fast decay seen in IVGTT plasma glucose data during the
first 30 minutes, which causes an overestimation of Minimal Model SMMG when
it is used to fit a single exponential, as discussed in Section 4.2.1. An addi-
tional loss at these high glucose concentrations (∼ 14 mmol/l), not identified by
the researchers, could be a small glucose clearance by the kidneys, that have a
threshold of ∼ 10 mmol/l [Windhager, 1992].
Errors introduced by not accounting for the second mixing compartment
can be avoided if its causes and effects on the fitting algorithm are known. In
the proposed test, a lower glucose dose is intended, reducing the effect of renal
clearance and mixing during the first 10 minutes. By disregarding the first few
minutes after glucose administration in the fitting approach, any error introduced
by mixing can further be minimised. Any remaining error should thus be very
small, justifying the use of the simplified mono-compartmental description in this
case.
The saturation of insulin dependent glucose clearance, evident in long-term
hyperglycaemic individuals [Chase et al., 2004], is likely not evident in a fasted
state after a low dose injection of glucose [Prigeon et al., 1996], and is thus set
to αG = 0. Note that at higher insulin dosing saturation effects could affect the
estimation of SI , as both parameters trade off [Chase et al., 2004; Prigeon et al.,
1996].
Further enhancements are made to Equation 4.3 to include a more physiologi-
cal and complete description of the uptake and production mechanisms of glucose.
The resulting formulation is shown in Equation 4.4 and shown schematically in
Figure 4.4. The additions to the model and their physiological justification are
explained in more detail in the following sections.
dG
dt
= −(pGU + pGS)(G−GE)− SIGQ−
GUG
VG
+
EGPIb
VG
+
EGPGE
VG
+
P
VG
(4.4)
where pGU (min
−1) is the insulin independent rate of glucose uptake, pGS (min
−1)
the insulin independent rate of suppression of EGP, GUG (mmol/min) the con-
stant insulin independent glucose uptake by the brain and central nervous system,
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EGPIb (mmol/min) the fraction of EGP compensating glucose uptake at basal
insulin concentration Ib, EGPGE (mmol/min) the fraction of EGP accounting for
the constant glucose uptake by the brain (equal to GUG), and P (mmol/min) the
exogenous glucose administration.
Figure 4.4 Schematic of full glucose PK and PD model. Shown are all exogenous (P ) and
endogenous (EGP) inputs, the constant loss GUG, the insulin independent losses pGU and pGS ,
and the insulin dependent loss mediated by SI .
4.2.2.1 Insulin-Dependent Uptake
Insulin-dependent glucose uptake, mostly by muscle and adipose tissue cells, is
dependent on the product of peripheral insulin Q, total glucose concentration
G and insulin sensitivity SI , as seen in the second term of Equation 4.3. This
assumption is physiologically valid and widely accepted. It has also been iden-
tified and observed in many studies [e.g., Bergman et al., 1979; Jefferson and
Cherrington, 2001; Yang et al., 1989].
As the modelled insulin concentrations are absolute values and not those
above basal, as in the Minimal Model, the parameter SI includes a dynamic that
is included in SMMG in the Minimal Model, namely glucose uptake at basal insulin
Ib. This basal glucose uptake can be calculated from a steady state analysis of
Equation 4.3 at a fasting state (without saturation):
GUIb = −SIGEQb (4.5)
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where Qb is basal steady state interstitial insulin and can be estimated using
Equation 3.10. GUIb accounts for about 25% [Best et al., 1981; Cobelli et al.,
1984; Zierler, 1999] of basal glucose uptake. As this loss is included in the insulin
dependent term of the glucose model, the corresponding fraction of basal EGP,
EGPIb = −GUIb needs to be included in Equation 4.3 to keep a basal steady
state glucose balance.
4.2.2.2 Insulin-Independent Uptake
Insulin independent uptake in a basal state is primarily due to the brain and
central nervous system [Zierler, 1999], and to a lesser extent by some splanchnic,
well perfused organs. Most of this uptake is independent of glucose concentration
and can thus be seen as a constant loss, that is compensated by endogenous
production EGP to keep steady state levels. This uptake accounts for about
75% of basal glucose uptake and is in the magnitude of ∼ 1 mg/kg/min [Best
et al., 1981; Zierler, 1999]. Converted to mmol, this value results in the constant
irreversible loss rate:
GUG = 5.6× 10−3 mmol/kg/min (4.6)
This term needs to be compensated by the corresponding fraction of EGP,EGPGE.
Total EGP, insulin dependent and independent at basal state is thus defined:
EGPb = EGPIb + EGPGE (4.7)
In addition to insulin independent glucose uptake in the fasting basal state,
glucose can enhance its own uptake at hyperglycaemic levels and inhibit EGP
[Ader et al., 1997; Best et al., 1996; Jefferson and Cherrington, 2001]. These two
effects, uptake rate pGU and suppression rate pGS, are lumped into the parameter
pG of Equation 4.3 and in the Minimal Model parameter S
MM
G (along with GUIb).
Del Prato et al. [1997] studied the quantitative effects of glucose uptake and
inhibition of EGP during hyperglycaemic clamps at basal insulin and different
levels of glycaemia. Their results, interpreted in terms of pGU and pGS were
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pGU = 0.004 and pGU = 0.001 min
−1 for uptake in healthy, and diabetes subjects,
respectively, with a value of pGS = 0.005 min
−1 for suppression of EGP. These
rates are in good accordance with results from Best et al. [1996], who suggests
that all three effects (pGU , pGS, GUIb) are equally strong.
In similar studies employing an IVGTT at basal insulin on type 1 diabetes
subjects [Quon et al., 1994b; Regittnig et al., 1999], the slow decay of glucose at
basal insulin can be fit with values of pG = 0.0011 and pG = 0.0012 min
−1, re-
spectively, as shown in Figure 4.5. The same values were found for pGU in type 1
diabetes subjects in the study by Del Prato et al. [1997]. In the former study by
Regittnig et al. [1999], a tracer was employed, enabling the estimation of endoge-
nous glucose concentration during the test. Interestingly, this concentration does
not change significantly during the test, suggesting that the endogenous balance
is left unchanged, and only the additional injected tracer is taken up. With this
assumption, the above mentioned transport rates would equal to pGU alone, with-
out the effects of pGS and GUIb, which explains the relatively low values found
for pG, and matching the values found in Del Prato et al. [1997].
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Figure 4.5 IVGTT glucose data at basal insulin concentrations on type 1 Diabetes subjects.
Mean plots shown from Quon et al. [1994b] (left) and Regittnig et al. [1999] (right). Shown are
sampled data and single exponential fits between 50− 240 minutes.
Overall, these results using different clinical protocols, indicate that suppres-
sion of EGP due to elevated glucose alone is only apparent during prolonged
infusion of glucose, but not during a briefer, bolus-based IVGTT. Suppression
of EGP appears to be dependent mainly on elevated insulin levels. The insulin-
independent uptake at hyperglycaemia, represented by pG in Equation 4.3 is thus
much smaller than commonly found in Minimal Model fits, in line with the claims
of overestimation [Caumo et al., 1999].
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GUG and EGPGE cannot be measured directly without extensive clinical
testing. However, in fasting homeostasis or balance, they also cancel each other
and can be eliminated. EGPIb is dependent on SI and can be combined with
the insulin dependent term for easier identification. Finally, pGS can be taken
out as well, as its effect does not seem to be very strong during an IVGTT-type
test, especially as this test aims at a lower glucose dose. The model shown in
Equation 4.4 can thus be simplified, resulting in the final, shortened form of the
glucose pharmaco-kinetics:
dG
dt
= −pGU(G−GE)− SI(GQ−GEQb) +
P
VG
(4.8)
where Figure 4.6 shows the models of Equations 3.7-3.8 and Equation 4.8.
Figure 4.6 Schematic of final glucose and insulin models and their pharmaco-dynamic inter-
action.
4.3 Model Identification
Identification of model parameters is done using the integral-based fitting method
described in Section 3.1.3.3. Equation 4.8 is integrated in the interval [t0, t1], and
if the data resolution is good enough to usefully identify all parameters [Hann
et al., 2005a], pGU , SI and VG can be estimated:
4.3 MODEL IDENTIFICATION 73
G(t1)−G(t0) =
− pGU
∫ t1
t0
(G−GE)dt− SI
∫ t1
t0
(GQ−GEQb)dt+
1
VG
∫ t1
t0
Pdt (4.9)
In a dose response test, the volume of distribution VG can be estimated from
the distinct jump in concentration after a bolus input, as seen in the example of
Figure 4.7. In a clamp test or an infusion experiment, VG trades off with loss
parameters and can thus not uniquely be identified. A fixed parameter has to be
chosen, typically using an estimate based on body weight [DeFronzo et al., 1979;
Lotz et al., 2006a].
With less frequent data sampling than an IVGTT, for example using a first
post-input sample at +5 min, an integration error can be introduced if the sam-
ples are interpolated linearly between 0-5 min. Figure 4.7 shows this potential
error schematically. To overcome this limitation, VG needs to be estimated a-
priori by extrapolating back to t = 0 min from samples at ∼ 5 − 10 minutes.
This approximation also helps overcome any underestimation of the volume due
to mixing effects and is done similarly in the Minimal Model assessment of an
IVGTT [Bergman et al., 1981].
Insulin independent clearance pGU is difficult to estimate accurately without
specialised experimental protocols to suppress endogenous insulin response [e.g.,
Best et al., 1996; Del Prato et al., 1997; Quon et al., 1994b]. As explained in
Section 4.2.2, its effects are small in a short low dose bolus response test, and it
can thus be fixed a-priori to a mean value from the literature. Here a value of
pGU = 0.004 min
−1 is chosen in accordance with several studies [Del Prato et al.,
1997; Quon et al., 1994b; Regittnig et al., 1999].
Insulin dependent clearance, determined by SI , can be identified well, as the
test design is rich in information in this respect. By allowing most variability to
be captured by SI , the test also predisposes itself by design to capture the same
effects as a euglycaemic clamp. As a result, there is an increasing similarity and
correlation between them.
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Figure 4.7 Error introduced by interpolating between 0 and 5 min sample, when VG is not
known. Grey area shows underestimated area.
4.4 Summary
Many glucose models have been presented in previous research, ranging from one
to three compartments. Identification of glucose model parameters is difficult, as
endogenous glucose production (EGP) is difficult to measure in a clinical setting.
A single compartment description with minimal parameters can be used with
good performance if identified correctly.
The derived glucose model contains insulin-independent and insulin-dependent
glucose losses and accounts for endogenous and exogenous glucose input. By
analysing the physiology and problems encountered in previous similar approaches,
it is evident that some systematic sources of error can be eliminated by a bet-
ter understanding of the underlying assumptions in modelling and fitting errors.
This knowledge, combined with the modelled peripheral insulin from Chapter 3
and the customised integral-based fitting method, allows for a robust and fast
estimation of insulin sensitivity SI , as shown schematically in Figure 4.8. The
model and method is simple, requires minimal data and is thus well suited for
use in a clinical setting.
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Figure 4.8 The overall method of estimating the model-based insulin sensitivity SI . Mod-
elled peripheral insulin Q(t) and sampled glucose concentration data are combined in the glu-
cose/insulin pharmaco-dynamic model. Insulin sensitivity is estimated by fitting the model
with the integral-based fitting approach, as described in Section 4.3.
Chapter 5
Validation of Insulin Models
The insulin and C-peptide models and identification methods described in Chap-
ter 3 require validation on experimental data. Suitable data to validate all aspects
of the models are obtained from the published literature. The two main aspects,
endogenous insulin secretion (β-cell function) and insulin kinetics are validated in
separate steps to avoid tradeoffs between effects and parameters. The validation
of each model starts with details about the experimental data used and the per-
formance metrics chosen to assess model performance, followed by the validation
results and discussions.
5.1 Insulin/C-peptide Secretion
Model-based estimation of insulin secretion is validated on intravenous glucose
tolerance test (IVGTT) data. The IVGTT is ideal for validation, as it includes
the highly dynamic endogenous insulin secretion impulse response of the system
to a glucose bolus. Briefly, a glucose bolus is injected intravenously, triggering the
bi-phasic endogenous insulin response [Ferrannini and Mari, 2004]. The IVGTT
thus provides data from which both phases of β-cell function can be distinctively
identified, therefore providing the opportunity to measure and assess pancreatic
performance.
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5.1.1 Experimental Data
The C-peptide data from IVGTT studies used in this validation have been gen-
erously provided by Dr. Andrea Mari (Institute of Biomedical Engineering, Na-
tional Research Council, Padova, Italy) and Dr. Angelo Avogaro (Department of
Clinical and Experimental Medicine, University of Padova, Padova, Italy). The
data have been previously published [Mari, 1998], with a full description of the
subjects and experimental protocol. Key aspects relevant to this study are briefly
reproduced here for clarity.
The study was performed on 12 subjects, 5 with normal glucose tolerance
(NGT) (mean±SEM: age 24±2, weight 73±6 kg, fasting glucose 5.2±0.1 mmol/l,
fasting insulin 50± 5 pmol/l) and 7 with type 2 diabetes (type 2) (mean±SEM:
age 49 ± 5, weight 81 ± 3 kg, fasting glucose 8.6 ± 0.8 mmol/l, fasting insulin
125± 27 pmol/l). Pharmacological treatment in type 2 diabetic individuals was
stopped 3 days before the study to eliminate a confounding affect, and all subjects
received a 2000 kcal/day diet (50% carbohydrate, 35% fat, 15% protein) for at
least 30 days prior to the study, to standardise this aspect.
An insulin-modified IVGTT was performed on all subjects in the morning
after an overnight fast. After three fasting samples at -30, -15 and 0 min, a
0.3 g/kg glucose bolus was injected intravenously. At 20 minutes, insulin was
infused intravenously for 5 minutes, totalling 0.03 U/kg (NGT) and 0.05 U/kg
(type 2). For an 80 kg individual, these doses are 24 g glucose and 2.4-4 U of
insulin. Blood samples were collected at 2, 3, 4, 5, 6, 8, 10, 15, 20, 25, 30, 40,
60, 80, 100, 120, 140, 160, 180, 210, and 240 min, and analysed for C-peptide,
glucose and insulin concentrations.
5.1.2 Performance Metrics
Pancreatic secretion characteristics are compared, where available, to data esti-
mated in the original study by Mari [1998]. The performance metrics defined try
to capture all possible secretory characteristics of interest and include:
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1. First phase peak secretion rate (Smax): Missing samples in the first
minutes after the glucose input can lead to large errors in estimated peak se-
cretion rate, due to the slower observed increase in C-peptide concentration
that results.
2. Total insulin/C-peptide secreted in first phase, 0-10 min (AUC10):
The area under curve (AUC), or also described as acute insulin response
(AIR), is a common metric to describe the total insulin secreted during first
phase response [Ferrannini and Mari, 2004; Pacini and Mari, 2003]. It is
calculated by integrating the estimated secretion rate over 0-10 minutes.
3. Total insulin/C-peptide secreted between glucose and insulin in-
puts, 0-20 min (AUC20): As the exogenous insulin administered at
t = 20 min inhibits pancreatic insulin secretion, it could be of interest to
assess the total amount of endogenously secreted insulin until it is inhibited.
4. Total insulin/C-peptide secreted during the IVGTT (AUCtotal):
Calculated by integrating the insulin secretion rate over the complete test.
Expected error ranges introduced by the assay were assessed by Monte Carlo
analysis of the estimated secretion rate over 104 runs. The analysis utilised
data that was normally distributed, zero-mean random noise with a coefficient
of variation (CV) of 3%, which is the error reported for current state of the art
assays [Roche, 2005]. This value is a conservative choice for this analysis, as
older radio immunoassays have CVs up to twice this value [Clark, 1999]. These
larger CVs would result in even larger allowable errors from the reduced sampling
protocol. Hence, the smallest assay errors were utilised for comparison.
Statistical Analysis
Normality of results was assessed by the single sample Kolmogorov-Smirnov
(KS) hypothesis test with a significance level of 0.05. Where results were log-
normally distributed, the geometric mean (log-normal mean) and multiplicative
standard deviation [Limpert et al., 2001] are used, as noted in the respective
results.
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5.1.3 Reduced Sampling Intensity Approach
The very frequent sampling performed in this experiment immediately after glu-
cose administration allows an accurate assessment of the first phase secretory
peak. In clinical practice, sampling with such a high frequency is not feasible,
but a significant error could be introduced in Smax and AUC10 by not sampling
the concentrations in the first 5 minutes after the glucose bolus is administered.
To assess this error, these performance metrics are calculated for the case in
which the first two samples after glucose administration are at 6 and 10 minutes,
as glucose is administered between 0-1 minutes.
The error is introduced by an underestimated area under the concentration
curve in minutes 1-6, similar to the potential interpolation error in the glucose
curve shown in Figure 4.7. A proposed solution to this lack of data in a clinical
test is the introduction of an estimated peak concentration, placed 1 minute
after the administration of glucose, in this case at 2 minutes. This introduces a
faster rise in concentration in the interpolated profile, and thus a sharper peak
in estimated secretion rate.
The concentration profiles in this data set increase immediately after the
glucose bolus is administered and peak at approximately 2-3 minutes. The peak
concentration is slightly higher than the concentration sampled at 6 minutes.
A ’correction’ sample is thus introduced at 2 minutes, with a value 10% larger
than the sample taken at 6 minutes. This approach is shown for one subject in
Figure 5.1.
5.1.4 Results
Pre-hepatic insulin secretion rate was estimated well with the full data set using
the proposed integral-based method of Section 3.2. The overall result was the
stepwise constant endogenous insulin and C-peptide secretion profiles shown in
Figure 5.2. The qualitative shape of the secretory curves compare well to the
clinical data in the original publication [Mari, 1998].
Mean peak secretion rate is slightly higher in this study in both subgroups.
This difference may be due to the smaller stepsize (1 minute vs. 2 minutes)
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Figure 5.1 Errors potentially introduced by reduced sampling during the first 5-10 minutes
after glucose administration. Shown are the C-peptide profiles (left) and the Estimated secretion
rate (right). The grey area shows the original profile, the solid line (and diamonds) the profile
with only sampling at 6 and 10 minutes, and the dashed line (and squares) the results using a
corrected peak.
chosen for fitting in this study. Total mean amount secreted in the first 6 minutes
after glucose administration (ISR1 in Mari study) is virtually identical in NGT
(1659 pmol vs. 1667 pmol in Mari’s study), but larger in type 2 diabetes (655 pmol
vs. 430 pmol in Mari’s study). Further performance metric results are given in
Table 5.1.
Table 5.1 Performance metrics given as geometric mean and multiplicative standard devia-
tion.
NGT Type 2
Smax [pmol/min] 2628.1 (1.8) 871.4 (2.5)
AUC10 [pmol] 10456.4 (1.8) 4799.8 (2.5)
AUC20 [pmol] 15303.8 (1.7) 9791.3 (2.4)
AUCtotal [pmol] 42804.3 (1.4) 82536.1 (2.2)
Errors in the measured performance metrics due strictly to assay errors were
assessed by Monte Carlo analysis and are given as a CV for each metric, with the
median and 100% range over all 12 subjects:
• Smax: CV=5.47%, range 2.97− 11.01%
• AUC10: CV=4.10%, range 1.92− 9.39%
• AUC20: CV=3.13%, range 1.90− 4.26%
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Figure 5.2 Above: Mean C-peptide concentration in NGT (dashed) and type 2 diabetes
(solid) subjects. Samples from Mari [1998] are shown with error bars of ±2 SD. Below: Mean
estimated C-peptide secretion rate (ISR) in NGT (grey area) and type 2 diabetes (solid line)
subjects.
• AUCtotal: CV=1.11%, range 0.97− 1.25%
Within these CV ranges it is effectively impossible to determine whether a differ-
ence is due to models and methods or to simple assay error. Thus, in comparing
results to those in Mari’s study, these values are important.
Reconstruction of C-peptide concentrations from the identified secretion pro-
files resulted in the residuals shown in Figure 5.3. Residuals are given as rela-
tive values (decimal percentages). Deviations from the original sample set are
caused by smoothing of the estimated secretion profile or by errors introduced
through the linear interpolation used between samples in the integral-based fit-
ting method. The ideal goal is to have all variation within the dashed lines due
to assay error.
Estimated C-peptide secretion rate with only the 6 and 10 minute samples
after glucose administration, and with the correction peak introduced, are shown
in Table 5.2, as a relative difference to the original full sample set.
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Figure 5.3 Residuals introduced when reproducing the full C-peptide sample profile. The
solid line shows the mean residuals and the grey area the 100% range of residuals. The dashed
lines show the 95% range of residuals introduced by assay error, as estimated by Monte Carlo
analysis.
5.1.5 Discussion and Conclusions
Estimating pre-hepatic insulin secretion through modelling of C-peptide kinet-
ics has been a common methodology and it is relatively easy to perform in re-
search settings [Hovorka et al., 1996; Polonsky et al., 1986b; Van Cauter et al.,
1992; Watanabe et al., 1989]. In particular, the population method proposed by
Van Cauter et al. [1992] enables the estimation of insulin or C-peptide secretion
rate with a single experiment. By employing this method, model parameters are
consistent across studies, enabling a better comparison, as tradeoffs between es-
timated parameters and secretion rates are reduced. Nonetheless, the estimation
of peak secretion rate and insulin secreted during first phase is still highly depen-
dent on assay errors and sampling frequency during the initial minutes. Ideally,
sampling should be performed every minute to assess an accurate profile. How-
ever, such frequent sampling introduces significant labour and cost, and reduces
robustness of the method.
As the highly frequent sampling performed in this study is not feasible in
a clinical setting, the effects on estimated secretion rate of a reduced sampling
84 CHAPTER 5 VALIDATION OF INSULIN MODELS
Table 5.2 Deviations in performance metrics in the case of lacking samples immediately
after glucose administration. Shown are the case of sampling only at 6 and 10 minutes, and
the introduction of a correction peak at 2 minutes. Differences are given as percent, relative to
the full sample set.
NGT Type 2
Only sample at 6 and 10 minutes
∆Smax -38.9% (SD 2.9%) -35.8% (SD 13.8%)
∆AUC10 -12.4% (SD 1.2%) -10.6% (SD 8.8%)
Correction peak at 2 minutes
∆Smax -1.8% (SD 5.3%) -0.6% (SD 21.5%)
∆AUC10 -0.7% (SD 2.2%) -2.4% (SD 10.9%)
during the first phase secretion were assessed. Instead of using the full sampling
set (2, 3, 4, 5, 6, 8, 10 minutes), only samples at 6 and 10 minutes were used. Due
to the slower increase of the interpolated profile between 0 and 6 minutes, the
estimation of Smax was greatly reduced by ∼36%-39% in the NGT and type 2
diabetes subgroups, respectively. The effect on total secretion rate was not as
large, only underestimating AUC10 by ∼10%, which is still in the range of errors
attributable to assay errors. This minimal effect is due to the longer duration of
first phase secretion, compensating for the reduced peak, as seen in Figure 5.1.
By introducing a corrected peak at 2 minutes, the initial slope of the inter-
polated profile is matched to the initial slope seen in the full data set, and the
errors are thus minimised. This effect can be seen clearly in Figure 5.1, in which
the shape of the corrected secretion rate (dashed) closely matches the original
secretion rate (grey area). This approach can enable a more accurate estimation
of peak secretion rate, whereas the errors in AUC10 are not as large.
It is important to keep in mind that significant errors are also introduced
due to assay inaccuracy. For example, peak estimated secretion rate, Smax, has
a median CV=5.47% and can thus vary between ±11% (±2 SD), even with a
1-minute step sampling protocol. Most of the performance metrics are within, or
slightly outside of ±2 SD of assay error, meaning that they are in fact just within
the natural variability that can be identified [Clark, 1999].
Using the same model and the parameter estimation method from Van Cauter
et al. [1992], estimation of secretion rate has previously been proposed by deconvo-
lution [Eaton et al., 1980] and a more elaborate constrained regularisation method
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[Hovorka et al., 1996]. The main drawbacks of these methods are the individu-
alised method adjustments required for each subject, including knot placements
for cubic spline interpolations [Eaton et al., 1980], or a separate step to find the
optimal proportionality constant in each subject [Hovorka et al., 1996]. All of
these extra steps introduce time, computation and human variability into the
results, thus obviating a single consistent method.
In contrast, the integral-based method described in this study is a single step,
computationally convex and fast method that only requires linearly interpolated
data. By constraining the linear least squares estimation to non-zero values and
smoothing the estimated secretion rate, the resulting profile is physiologically
accurate and the effects caused by noisy data are reduced [Hann et al., 2005b].
First and second phase secretion characteristics were clearly identified, with slight
quantitative, but not qualitative deviations from the profiles reported originally
with this data. In addition, these smaller deviations can be readily explained
by the longer stepsize used in that study. Finally, the integral-based method is
consistently applied across all subjects and both subgroups.
From Figure 5.3 it can be seen that the C-peptide concentration profile is
reconstructed with the estimated and smoothed secretion rate within the expected
assay errors. The highest errors are apparent during 0-20 minutes, which is
attributable to the high rate dynamics that occur in this stage following glucose
administration. Measurement errors during this stage also have a relatively larger
effect on the estimation of secretion rate, thus magnifying the underlying errors.
Finally, the performance metrics show the typical characteristics that clini-
cally and physiologically differentiate NGT and type 2 diabetes subjects, further
validating the method. While in the NGT subgroup first phase secretion accounts
for about 25% of total secreted insulin, it is only about 5% in the type 2 diabetes
group, with the secretion rate only peaking at about a third of the value reached
by NGT subjects. Total secreted insulin is twice as high in type 2 diabetes as in
NGT. These metrics provide further important metabolic information about the
subject, which can be used clinically to supply a more complete picture of their
metabolic state of health.
Overall, the method to assess insulin secretion could be validated with very
good consistency on the IVGTT data. In addition, the IVGTT uses essentially
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the same perturbation of the pancreas as the intended test being developed.
Further metrics can also be derived from this method, in addition to insulin
sensitivity. Hence, the metabolic system and its status can be more completely
and accurately defined.
5.2 Insulin Kinetics
The primary goal of the insulin kinetics model validation is to assess the validity
of the general fitting approach described in Chapter 3. It is not to perform a
full parameter estimation. The objective is thus not a perfect model fit, but a
generic and simple approach that yields a good fit even on sparsely sampled data,
similar to the data density and requirements intended for a practical clinical test.
The fitting approach is considered appropriate if sampled data is matched within
measurement noise and parameter values obtained lie within a physiologically
valid range.
5.2.1 Experimental Data
To fully validate the insulin model, frequently sampled plasma and interstitial
insulin concentrations are required. However, interstitial fluid measurements are
difficult to perform and rarely available in most clinical studies. Therefore, sep-
arate validation of these two insulin compartments is performed.
To validate the fast and slow components of the decay curve, frequently sam-
pled insulin concentrations are required. This requirement is especially true in the
first 10 minutes after a sudden change in input. In addition, endogenous insulin
secretion should be captured either through C-peptide sampling or suppressed
through somatostatin infusion [Jefferson and Cherrington, 2001; Wahren et al.,
1977]. This highly frequently sampled insulin data with complete knowledge of
endogenous insulin input are difficult to obtain and have been rarely performed
in the past.
In this study, validation is performed using published data from a study
investigating the systemic delivery rate of insulin that was performed by Polonsky
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et al. [1986a]. In Polonsky et al. [1986a], three different insulin administration
profiles were applied to the same group of subjects. These tests allowed all the
insulin kinetics to be accurately delineated.
Interstitial insulin kinetics are validated with published data from two differ-
ent studies. In these studies, the insulin concentration was sampled from muscle
interstitial fluid during an OGTT [Sjostrand et al., 2005a] and during a two step
euglycaemic clamp [Gudbjornsdottir et al., 2003]. These latter studies allow the
interstitial fluid kinetics of the insulin model to be validated.
Plasma Insulin Data
Data used in this validation were taken from a published study by Polonsky et al.
[1986a]. Full experimental data could not be obtained from the authors and the
three mean concentration plots from page 115-117 of [Polonsky et al., 1986a] were
utilised instead. The high frequency sampling in this study make the data ideal
to validate the fast component of insulin kinetics.
The study was performed on 8 normal males within 10% of their ideal body
weight. More detailed characteristics are not given in the study description, so
a mean weight=75 kg, height=1.80 m and age=30 years were chosen to estimate
kinetic parameters. These characteristics approximately match a normal male in
the cultural setting in which the study was performed. During all three protocols,
a background infusion of somatostatin was administered to suppress endogenous
insulin secretion. The three studies reported were performed as follows:
1. Bolus injection of insulin (1.5 U) and subsequent sampling for 120 minutes
(1 min frequency during the first 10 minutes).
2. Constant infusion of insulin for 60 minutes (1 mU/kg/min) and frequent
sampling, after which the infusion is stopped and insulin sampled for an-
other 60 minutes (1 min frequency during the first 10 minutes).
3. Variable rate infusion of insulin, starting at 0.28 mU/kg/min and pro-
gressively increased in 5 min intervals up to 2.14 mU/kg/min by 35 minutes.
After 15 minutes at this rate, the infusion was reduced in 10 min steps to
reach the initial rate after 60 minutes.
88 CHAPTER 5 VALIDATION OF INSULIN MODELS
Interstitial Fluid Insulin Data
The first data set used in this validation were taken from a study published by
Sjostrand et al. [2005a]. Full experimental data could not be obtained from the
authors and the mean concentration plots from page 154 of [Sjostrand et al.,
2005a] were utilised instead. Brief study details are reproduced here for clarity.
Further details are described in [Sjostrand et al., 2005a]. Note that this publica-
tion was later retracted [Sjostrand et al., 2005b] due to a data handling mistake,
which is accounted for in this validation, thus not affecting the results.
Oral glucose tolerance tests were performed on 10 lean (5 male, 5 female,
BMI=23 (SD 0.6) kg/m2, age=39 (SD 4) years) and 10 obese (5 male, 5 female,
BMI=33 (SD 1.2) kg/m2, age=41 (SD 3) years) individuals. After an overnight
fast, an oral glucose load (75 g) was ingested and plasma and interstitial insulin
sampled every 15 minutes for a total of 120 minutes.
The second data set used were taken from a study employing the same ISF
sampling technique during a euglycaemic clamp test [Gudbjornsdottir et al.,
2003]. A two-step clamp was performed, the first step at an insulin infusion of
120 mU/min/m2, and the second step at an insulin infusion of 240 mU/min/m2.
Both clamp steps were held for 120 minutes. The study population consisted of
10 lean male subjects with BMI=23 (SD 2.8) kg/m2 and age=26 (SD 5) years.
Interstitial fluid measurements were performed by means of a microdialysis
technique [Sjostrand et al., 1999]. More specifically, interstitial fluid is sampled
directly at muscle tissue. This approach is more accurate than earlier interstitial
insulin studies sampling lymph concentrations [i.e. Steil et al., 1996; Yang et al.,
1989].
5.2.2 Methods
Plasma Insulin Kinetics
Plasma insulin concentrations from the three protocols in Polonsky et al. [1986a]
are fitted as described in Chapter 3, using the reported infusion profiles as input
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uex. As no C-peptide data are available, only the parameter nL is estimated from
the data. To account for an incomplete suppression of endogenous insulin by
somatostatin [Toffolo et al., 1980; Wahren et al., 1977], a low constant infusion
of 4 mU/min (∼25% of fasting basal secretion) is assumed and included as uen.
Interstitial Fluid Insulin Kinetics
To validate interstitial insulin kinetics, Equation 3.8 is solved with the measured
and interpolated plasma insulin concentration I(t) used as input to the equation.
In the OGTT study, I(t) cannot be modelled independently, as insulin appearance
in these tests is from pancreatic secretion, which cannot be estimated from the
data sampled in this study. In the clamp data, the insulin infusion protocol is
known, and plasma insulin can be modelled along with ISF insulin Q(t).
The parameters to be validated are nI and nC . This task is done with a
sensitivity analysis on γ = QSS/ISS, which defines the concentration gradient to
be reached, and nI , which defines the speed at which this gradient is reached.
Note also that nI also appears in Equation 3.7 that defines plasma insulin ki-
netics. This analysis therefore yields information on the robustness of the use of
population parameters.
5.2.3 Results
Plasma Insulin Kinetics
Just estimating hepatic clearance nL from data, while holding VP , VQ, nK , nI
and nC at population parameter values from Table 3.1, resulted in a very good
fit in all three cases. This result can also be seen in Figure 5.4. Estimated cohort
values for nL were 0.19, 0.17 and 0.16 min
−1 for protocols 1-3 respectively. This
limited variation is within expected natural variability [Duckworth et al., 1988;
Ferrannini and Cobelli, 1987b] and also within the variability that might be seen
from assay errors. The fit could potentially always be improved by fitting more
parameters, but that would require an unacceptable compromise in computation,
robustness and simplicity. The goal was to validate the described identification
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method, not to achieve a perfect fit. A fit was considered good if most data
points were matched within measurement noise and the key dynamic aspects of
the data were reproduced reasonably well.
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Figure 5.4 Experimental protocols from Polonsky et al. [1986a] (Protocol 1-3, from top to
bottom). Insulin input (left) and resulting plasma insulin concentration with model fit (solid)
and modelled interstitial insulin Q(t) (dashed) (right).
Interstitial Fluid Insulin Kinetics
In the validation of interstitial fluid kinetics, the mean steady state concentration
gradient γ (with ± 10% error) is 0.65 (0.58 - 0.71) and 0.55 (0.5 - 0.6) in the lean
and obese groups of the OGTT, respectively. In the clamp data, γ is 0.55 (0.5 -
0.6). Maintaining this ratio is important, as a variation outside of the 20% band
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reported would achieve inaccurate steady state values. Parameter nC thus needs
to be bound to nI through γ, as defined in Equation 3.11.
In the OGTT studies, the value of nI calculated a-priori results in a profile of
interstitial insulin Q(t) that is well within measurement error. The parameter is
not very sensitive, as can be seen by the calculated profiles shown in Figure 5.5.
Multiplying and dividing nI by a factor of 2 and 3 still achieves reasonably good
data fits of Q(t). A factor of 2 is mostly still within measurement error.
In the clamp study, the plasma insulin concentration profile could be mod-
elled in addition to the ISF profile, resulting in a good fit as shown in Figure 5.5.
Estimated hepatic clearance was similar to the values identified in the plasma in-
sulin validation, nL = 0.15. The effect of nI on plasma insulin is shown by the two
dotted lines around the plasma insulin profile shown in Figure 5.5, representing
an increase and a decrease of nI by a factor of 3.
ISF insulin concentrations during the first 90 minutes could not be matched
by the model fit, as the concentration gradient is significantly lower at γ =∼ 0.2.
This lower gradient is identified by the authors of the study as a methodological
sampling problem at lower insulin concentrations, and is thus not considered a
modelling error in this study [Gudbjornsdottir et al., 2003]. The last sample
of this first clamp step, at 120 minutes, is in line with the assumed γ = 0.55,
as well as the remaining samples during the second clamp step. Increasing and
decreasing nI by a factor of 2 and 3 results in good model fits. The value of nI
has the biggest impact during the first 10 minutes, in which the insulin infusion
loading protocol causes a very fast increase in concentrations.
5.2.4 Discussion and Conclusions
Plasma Insulin Kinetics
The insulin kinetics model, with the parameter estimation approach presented
in Chapter 3, shows very good performance in fitting the frequently sampled
plasma insulin data of Polonsky et al. [1986a]. This is a relatively remarkable
performance, as only one parameter, the hepatic clearance nL, is estimated from
the data. All the other parameters are calculated from a-priori known subject
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Figure 5.5 Sensitivity analysis on nI performed on mean plots of lean (upper left) and obese
(upper right) subjects from [Sjostrand et al., 2005a], and on the clamp data from [Gudbjorns-
dottir et al., 2003]. Average values for γ are used in each case, with γ = 0.65 used for the lean
OGTT, γ = 0.55 for the obese OGTT and the clamp subgroups. Shown are plasma insulin
samples and linear interpolation in OGTT or modelled insulin in clamp (solid), interstitial
insulin concentration samples (diamonds) and modelled interstitial insulin, with nI = 1×nI
(dash-dot), 2×nI and 1/2×nI (grey area) and 3×nI and 1/3×nI (outer dashed lines). The
dotted plasma insulin profiles in the clamp plot show the modelled profiles at 3×nI and 1/3×nI .
characteristics using population values or equations.
With more elaborate fitting approaches, and by allowing more parameters
to vary, the fits could potentially be further improved, but only with significant
additional effort. This is not desired in this study, as the methods are designed
to be applicable on sparsely sampled experiments, and the model performance
shown in this chapter is more than adequate for such an application. Note that
an over-fitting of the data can potentially also reduce accuracy and increase
variability, as is the case in the Minimal Model, in which SMMG is overestimated
and SMMI underestimated, as discussed in more detail in Chapter 3.
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Estimated nL varied slightly during the different protocols, but not exceeding
a natural physiological variability or assay error. The values were lower in the
infusion protocols than in the bolus injection, which could have been caused
by a different suppression of endogenous insulin secretion in the different types
of insulin administration. In addition, hepatic extraction has been shown to
be highly variable and saturable when exposed to high insulin concentrations,
particularly over time [Ferrannini and Cobelli, 1987b; Thorsteinsson, 1990; Toffolo
et al., 2006], a dynamic that was not accounted for in this validation study.
It should be noted that the plasma insulin data used in this validation can
be much more variable than just the assay errors. The study by Polonsky et al.
[1986a] was performed over 20 years ago, when insulin assays were not necessarily
very accurate and had a high cross-reactivity to proinsulin [Chevenne et al., 1999;
Robbins et al., 1996]. Even today, the insulin assay is not completely standardised
and large inter-laboratory variations persist [Sapin, 2003].
To conclude, the insulin kinetics model and the a-priori parameter estimation
approach described in Chapter 3 could be validated sufficiently well with the
presented data. The variable protocols of an impulse response, a step increase
and a gradual increasing infusion consistently show very good model performance.
Frequently sampled plasma insulin samples allow validation of the fast and the
slow components of insulin kinetics.
Interstitial Fluid Insulin Kinetics
Validation of interstitial insulin concentration modelling shows good performance
and robustness. The key parameter to estimate in this case is the steady state
concentration gradient γ = QSS/ISS, which is in the reported range of 0.5-0.7.
Estimating this parameter in individual tests would require separate sampling of
interstitial fluid, which is not viable in a simple clinical test. Thus, fixing the
parameter to a value within this range provides a reasonable and simple method
to identify the model within physiological plausibility.
Testing robustness by modifying nI by a factor of 2 and 3 results in the plots
shown in Figure 5.5. As the data is very noisy, especially at lower concentrations
[Gudbjornsdottir et al., 2003; Sjostrand et al., 2005a], a change by a factor of
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2, shown by the grey area in the plots, does not compromise the quality of fit
significantly. A further increase by a factor of 3 does not affect the plot as strongly
as a reduction by a factor of 3. The parameter thus seems to be more robust on
the high side, and as long as a large enough value is chosen, model performance
is within expected bounds.
The interstitial insulin measurements done by Sjostrand et al. [2005a] and
Gudbjornsdottir et al. [2003] are a novel and still experimental technique, requir-
ing complicated calibration methodology [Gudbjornsdottir et al., 2003; Sjostrand
et al., 1999]. Further validation of these methods are necessary until more accu-
rate results are obtainable. Nonetheless, the parameters of interstitial fluid insulin
kinetics result in very reasonable data fits, suggesting that they are potentially
very close to the true values.
5.3 Summary
In the validation performed in this chapter, insulin and C-peptide models and
identification methods presented in Chapter 3 could be satisfactorily validated.
Pancreatic insulin secretion can be estimated with high accuracy and performance
on bolus dose response data as found in an IVGTT. Plasma insulin kinetics can
be estimated very accurately with the a-priori parameter identification proposed
and by estimating only one parameter from data. Interstitial kinetics are well
represented and robust with the population values estimated a-priori.
The insulin model and its parameter estimation method, mostly employ-
ing population parameters, thus provide not only a physiological insulin kinetics
model, but also a method to identify its parameters with minimal data require-
ments. This approach performed very well as validated on the data in this chap-
ter. Overall, the simplicity, robustness and physiological validity of the proposed
approach make it ideal for use in an application designed for a clinical setting.
Chapter 6
Euglycaemic Clamp Validation
The euglycaemic-hyperinsulinaemic clamp [DeFronzo et al., 1979] is the gold
standard to assess insulin sensitivity. Model validation is performed on clamp
data to verify how the model-based metric for insulin sensitivity SI compares to
the clamp derived metric ISI. The correlation of both metrics gives an indication
of the performance of the overall model, including the insulin, C-peptide and
glucose components.
The clamp test is described in more detail in Chapter 2, but is briefly outlined
here for improved clarity. The clamp test consists of a constant infusion of insulin
and a variable infusion of glucose to maintain euglycaemia. The result is an
eventual suppression of endogenous insulin and glucose with the goal to reach a
metabolic steady state. The first hour of the test is highly dynamic in glucose
concentration, as the system needs to be stabilised, which is achieved by proposed
formulae [DeFronzo et al., 1979; Ferrannini and Mari, 1998] and/or experience
from medical staff. The second hour is the steady state and ideally constant
insulin and glucose concentrations are achieved, which are used for the calculation
of ISI.
6.1 Experimental Data
The clamp data used in this validation have been kindly provided by Dr. Kirsten
McAuley and Prof Jim Mann from the Edgar National Centre for Diabetes
Research, Dunedin, New Zealand. The data have been previously published
[McAuley et al., 2002], with full description of subjects and experimental proto-
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col. Key aspects are briefly reproduced here for clarity.
The data consist of euglycaemic-hyperinsulinaemic clamp tests performed by
McAuley et al. [2002] during a study assessing insulin resistance in normogly-
caemic individuals before and after a 16 week lifestyle intervention. The study
population was randomised into control, moderate and intense intervention sub-
groups. The subgroup results are not relevant in this validation and the cohort
is thus simply split into the pre- and post-intervention groups. Cohort data are
given in Table 6.1.
Table 6.1 Description of the intervention study population from McAuley et al. [2002]. ISI
is the clamp based metric of insulin sensitivity.
Mean (SD) Range Mean (SD) Range
Age (All N=146) 46.8 (8.9) 30-68
pre-interv. (N=73) post-interv. (N=73)
Fast. glucose [mmol
l
] 4.9 (0.6) 4.0-6.8 4.8 (0.6) 3.5-6.9
Fast. insulin [mU
l
] 19.9 (12.1) 6.6-84.3 17.2 (11.2) 5.7-65
BMI [ kg
m2
] 34.4 (4.9) 24.5-45.2 33.2 (5.0) 23.6-44.8
Weight [kg] 96.7 (15.3) 67.9-140.8 93.4 (15.5) 62.5-142.4
ISI [mg/kg/min
mU/l
] 3.03 (0.9) 1.16-5.15 3.79 (1.3) 1.74-8.37
HOMA-IR [ mU
mmol
] 4.4 (3.2) 1.4-24.4 3.8 (3.0) 0.9-19.9
The clamp was performed after an overnight fast, and was run over 120 min-
utes. The protocol infused insulin (Actrapid) at 40 mU/m2/min between 10 and
120 minutes and tried to maintain the blood glucose levels at a goal of 4.6 mmol/l.
An insulin loading protocol was applied during the first 10 minutes, starting at
127 mU/m2/min with an 11% reduction per minute, as described by DeFronzo
et al. [1979]. The glucose infusion was adjusted at 10 minute intervals. Glucose
concentration was sampled every 10 minutes and insulin at 0, 60, 90, 120 minutes.
Further details are described in [McAuley et al., 2001].
Glucose clearance (M -value, mg/kg/min) is the average glucose infusion dur-
ing the last 60 minutes, with a space correction to compensate for deviations
in glucose concentrations between 60 and 120 minutes [DeFronzo et al., 1979;
McAuley et al., 2001]. The insulin sensitivity index ISI is M divided by the
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average measured plasma insulin concentration during the last 60 minutes:
ISI =
M
I60+I90+I120
3
(6.1)
6.2 Methods
6.2.1 Comparison of Insulin Sensitivity Metrics
When comparing ISI and SI , it is important to first understand the extent of
similarity between these two measures of insulin sensitivity to avoid a comparison
of “apples and oranges”. The ISI calculation of the clamp is the steady state
ratio of glucose infusion rateM per kg body weight (mg/kg/min), divided by the
average plasma insulin concentration (mU/l) at a balances homeostatic state.
It is assumed that during the clamp steady state all endogenous glucose and
insulin secretion is fully suppressed, and that all glucose and insulin in the body
is being infused externally [Bergman et al., 1985]. The test metric thus tells the
clinician how much glucose the body can metabolise at a given plasma insulin
concentration. More importantly, it assumes all glucose uptake to be mediated by
insulin and that the uptake rate is proportional to plasma insulin concentration.
This assumption is not physiologically accurate, as it neglects insulin inde-
pendent glucose uptake. This uptake can be dependent on glucose concentration
or can be constant, as is the uptake by the brain and central nervous system,
which at ∼100 mg/min is quite substantial [Baron et al., 1988; Zierler, 1999].
The mean glucose infusion rate in this study population is 890 mg/min, so brain
uptake accounts for over 10% of the infused glucose.
A further physiological misassumption in the clamp calculation is the lack
of glucose clearance saturation [Chase et al., 2004; Natali et al., 2000; Prigeon
et al., 1996]. At the high rate of glucose and insulin infusion, glucose clearance
saturation is very likely, thus resulting in an underestimation of true insulin
sensitivity. As saturation and insulin sensitivity trade off and cannot uniquely
be identified on data from one test [Natali et al., 2000], the model saturation
parameter is set to αG=0 to match the clamp assumption. This dynamic should
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thus not further cause additional bias between ISI and SI .
The model-based SI (l/mU/min) is in principle similar to ISI, as it relates
the rate of glucose uptake to an insulin concentration. The main difference is
that insulin in interstitium, Q(t), instead of insulin in plasma, I(t), is used. This
approach is physiologically more accurate, but results in a systematic shift when
comparing absolute metrics.
A further important difference is the fact that the glucose model accounts
for additional glucose uptake that is not dependent on insulin, such as glucose-
only dependent uptake, pGU , and constant uptake, GUG. As these two effects are
physiologically valid and included in the model used in this research, they are also
used to validate the model against the clamp, to improve comparability between
the metrics attained in both tests. Removing these two effects, and relating all
glucose uptake to insulin dependent effects, results in more similar assumptions
to the clamp and thus likely in a tighter correlation.
When comparing the units of both metrics, it is evident that a correction is
necessary to compare absolute values. In this example, ISI is corrected to match
the units of SI :
ISI
[
mg · l
kg ·min ·mU
]
× weight
GclampVG
[
kg
mg/l · l
]
= SI
[
l
mU ·min
]
(6.2)
where the weight/VG term is used to normalise to body mass and volume. Sim-
ilarly, the 1/Gclamp term normalises the clearance to the steady state glucose
value achieved. This is a common approach to reduce the dose dependency of
the clamped glucose level and to correct for tests that deviate slightly from this
clamp goal [Bergman et al., 1985].
As can be seen in Equation 6.2, further variability can be introduced by
the unit conversion. The volume VG cannot be measured nor estimated from
the clamp data and an estimation of its value has to be made. A common
choice is VG = 0.19×weight [DeFronzo et al., 1979]. Using a weight-dependent
volume causes the effect of weight and volume to cancel out of Equation 6.2, and
merely introduces a constant factor. A more conservative choice is to estimate
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the volume dependent on the estimations for insulin distribution, VP and VQ, as
this decorrelates weight and volume and simulates a more realistic situation.
6.2.2 Parameter Estimation
Fitting of data was performed with the integral-based fitting method described
in Chapter 4. In addition to the parameters identified a-priori, VG was set to
VG = 1.2 · (VP + VQ), as the clamp data are not dense enough to allow a unique
identification. A 20% larger volume than the total insulin distribution volume
was chosen, as apparent glucose distribution volume has been found to be larger
than the total distribution volume for insulin, due to fast hepatic storage and
non-insulin dependent uptake by the brain [Despopoulos and Silbernagl, 2003;
Waterhouse and Keilson, 1972].
Hepatic insulin clearance nL is estimated as a constant over 120 minutes.
Glucose uptake at basal insulin, pGU , cannot be estimated from these data, as
a high insulin concentration is present throughout the test and was fixed at a
constant value of pGU = 0.004 over 120 minutes, as described in Chapter 4.
Insulin sensitivity, SI , is fitted as a constant over each 60-minute period to assess
any differences during transient SI−TR and steady SI−SS states.
During a clamp test EGP is reduced and eventually suppressed by the high
infusions of glucose and insulin [Bergman et al., 1985]. As the profile of EGP
cannot be measured from the available data, an assumption of its profile is made.
The assumption is a linear suppression during the transient 0-60 minutes and
full suppression thereafter, in line with observed metabolic responses during this
test [DeFronzo et al., 1979; Ferrannini and Mari, 1998]. If this assumption is
physiologically feasible, SI−TR and SI−SS should be very similar. In contrast, if
no suppression of EGP is actually the case, SI−SS will likely be overestimated by
seeing more glucose removal than actually occurs.
The goodness of the model fit at steady state is assessed as the relative
difference between ISI values calculated from experimental data and ISI values
calculated from glucose and insulin levels simulated by the model, given as a
percentile root mean square error (RMSE). Errors in fitted glucose and insulin
profiles are given to assess fit accuracy at transient states.
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6.2.3 Correlation Analysis
Modelled insulin sensitivity parameter SI is correlated (Pearson correlation co-
efficient) to clamp derived ISI, normalised by the average plasma glucose con-
centration during the final hour steady state (ISIG = ISI/G) [Bergman et al.,
1985]. ISI is normalised to account for trials in which a steady state glucose
concentration is not fully attained and the mean steady state value deviates from
the target of 4.6 mmol/l. It also matches the units for ISIG and SI , making
comparisons clearer, per Equation 6.2.
For the steady state comparison, SI during the last 60 minutes (SI−SS) was
used, as ISIG is calculated over the same interval. The transient value of SI
is fitted over 0-60 minutes (SI−TR) to assess the potential of the model for a
dynamic insulin sensitivity test. Pearson correlation coefficients were obtained
for the whole data set and the pre- and post-intervention subgroups.
Statistical Methods
Probability distributions of the insulin sensitivity parameters could not be as-
sumed to be normal, as assessed with the Shapiro-Wilk test. To assess the sig-
nificance of the correlations, their 95% confidence intervals (CI) in the form of
percentile intervals were calculated using the nonparametric bootstrap, which
does not require a parametric distribution model for the data [Efron and Tibshi-
rani, 1993]. Where data are log-normally distributed, the geometric mean and
multiplicative standard deviation (MSD) are used to describe the spread [Limpert
et al., 2001].
6.3 Results
Mean SI at steady state was SI−SS = 4.85× 10−4 (MSD 1.54) l/mU/min and at
transient state SI−TR = 4.82 × 10−4 (MSD 1.51) l/mU/min. The mean values
and distributions of steady state and transient state SI are statistically equal
(P = 0.71). In contrast, assumption of no suppression of EGP resulted in a
larger SI during steady state, SI−SS = 7.34 × 10−4 (MSD 1.48) l/mU/min, as
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compared to the transient state, SI−TR = 6.01 × 10−4 (MSD 1.43) l/mU/min,
as hypothesised. Both SI values were significantly different in the unsuppressed
EGP assumption case, as assessed by the Wilcoxon rank sum test (P < 0.001).
The root mean square error (RMSE), shown in percent, between clamp ISI
from experimental and modelled data for all 146 tests was 1.8% (MSD 2.8).
The expected error in the calculation of ISI, due to error propagation of sensor
errors and device inaccuracies, was calculated from the data as 6.8% (SD 0.45%,
range 6.24 - 9.32%) over all 146 tests. The RMSE between experimental and
modelled glucose and insulin values were 2.9% (MSD 3.5) and 3.9% (MSD 3.4),
respectively. Hence, all ISI errors are within measurement error propagation.
Mean estimated hepatic insulin clearance rate was nL = 3.68 × 10−2 (SD
2.04× 10−2) min−1. Further estimated parameters are given in Table 6.2 for the
pre- and post-intervention subgroups. A sample model fit is shown in Figure 6.1.
Table 6.2 Parameter estimates from clamp data fit, given for the pre- and post-intervention
subgroups. Data given as mean and SD and geometric mean and multiplicative SD (MSD)
where noted specifically.
Mean SD Mean SD
pre-interv. (N=73) post-interv. (N=73)
VG [l] 12.22 1.06 11.99 1.08
VP [l] 4.52 0.37 4.46 0.36
VQ [l] 5.67 0.54 5.54 0.57
nK [10
−2 min−1] 6.00 0.24 5.95 0.28
nL [10
−2 min−1] 3.24 2.14 4.12 1.84
nI [10
−2 l/min] 27.56 2.70 26.90 2.86
nC [10
−2 min−1] 4.86 0.06 4.86 0.06
EGPb [mg/kg/min] 1.47 0.29 1.51 0.29
SI−SS [10
−4 l/mU/min] 4.25 MSD 1.54 5.54 MSD 1.49
pGU [min
−1] 0.004
Correlation between clamp derived ISI and steady state SI−SS is r = 0.953
(95% CI: 0.933 - 0.968), and transient state SI−TR is r = 0.920 (95% CI: 0.881 -
0.950). To reduce variability introduced by a deviation from the clamped glucose
concentration, ISI is commonly normalised by the steady state glucose concen-
tration [DeFronzo et al., 1979; Ferrannini and Mari, 1998], denoted ISIG. ISIG is
further unit-corrected to reduce variability introduced by model assumptions for
VG and to match the units of SI (l/mU/min). The resulting correlation between
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Figure 6.1 Example of a clamp data model fit and corresponding samples. Shown are glucose
concentration (upper left), insulin concentration (upper right) with plasma I(t) (solid) and
interstitial Q(t) (dashed) concentrations, infusions (lower left) of glucose (solid) and insulin
(dashed), and profile of EGP.
ISIG and steady state SI−SS is r = 0.995 (95% CI: 0.992 - 0.997). At transient
state SI−TR the correlation is r = 0.924 (95% CI: 0.887 - 0.951), thus lower and
with a broader CI. Both regression lines have a y-intercept indifferent from zero
and a slope of 0.52 and 0.51 for steady and transient state, respectively. The
slopes are very close to γ = Qss/Iss = 0.5, the expected ratio between ISIG and
SI . Correlations for the steady and transient states are shown in Figure 6.2 for
all 146 clamp tests.
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Figure 6.2 Correlation of ISIG and SI−SS (left) and ISIG and SI−TR (right).
As steady and transient state SI are nearly identical, fitting the data with
a constant value of SI over 120 minutes should result in an equally good fit.
The RMSE between experimental and modelled glucose and insulin values were
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slightly larger at transient state (3.8% (MSD 3.2)), but equally accurate at steady
state (3.9% (MSD 3.4)). Correlation between ISIG and SI in this case is r =
0.981 (95% CI: 0.971 - 0.988). This result is more accurate than the transient
only correlation, as the steady state data are taken into account in the fitting. In
addition, SI would be physiologically expected to be constant over a 2-hour test.
Pre- and post-intervention subgroups showed a similar trend when analysed
independently. More specifically, there were higher correlations at steady state
and at post-intervention. These results are given in Table 6.3, along with correla-
tions of ISIG. Finally, correlations to log-HOMA, the logarithmic transformation
of HOMA-IR, are also shown, given its wide clinical use [Wallace et al., 2004b].
Note that the logarithmic transformation of HOMA-IR is required to enable a
comparison of the linear trend between both metrics, as described in Section 2.2.
Table 6.3 Results of correlation analysis for the whole population and the pre- and post-
intervention subgroups, given for steady and transient states.
Metric All (95%CI) Pre (95%CI) Post (95%CI)
SI−SS 0.995 (0.992-0.997) 0.988 (0.978-0.995) 0.998 (0.997-0.999)
vs. ISIG
SI−TR 0.924 (0.889-0.950) 0.912 (0.869-0.951) 0.922 (0.873-0.955)
vs. ISIG
∆SI−SS 0.990 (0.984-0.995)
vs. ∆ISIG
∆SI−TR 0.897 (0.833-0.938)
vs. ∆ISIG
log-HOMA -0.48 (-0.59- -0.35) -0.49 (-0.64- -0.32) -0.44 (-0.60- -0.25)
vs. ISIG
A further analysis is done to see how the model captures the change in in-
sulin sensitivity after the intervention, as compared to the clamp ISI. This
result is also shown in Table 6.3. Correlation of ∆SI−SS, between pre- and post-
intervention, and ∆ISIG is r = 0.990 (95% CI: 0.984 - 0.995), and between
∆SI−TR and ∆ISIG is r = 0.897 (95% CI: 0.833 - 0.938). The regression lines
have y-intercepts indistinguishable from zero, and slopes of 0.54 and 0.50 in steady
and transient states, respectively, where a slope of 0.5 is expected due to γ = 0.5.
The correlation plots in steady and transient states are shown in Figure 6.3.
Relative changes in ISIG and SI−SS are shown in Figure 6.4, along with
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Figure 6.3 Correlation of ∆ISIG and ∆SI−SS (left) and ∆ISIG and ∆SI−TR (right).
relative changes in log-HOMA. These plots clearly show the accuracy of SI in
capturing the change in insulin sensitivity as compared to a common and typi-
cal fasting measure (log-HOMA) that clearly does not capture the trend. Note
that log-HOMA is also one of the clinically highly regarded fasting measures
[Ferrannini and Mari, 1998; Monzillo and Hamdy, 2003].
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HOMA (bottom).
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6.4 Discussion and Conclusions
The error in modelled vs. calculated ISI over all 146 trials is well within the
expected accuracy from assay errors and reflects the ability of the model to match
the glucose and insulin dynamics during steady state. The mean fitting error of
the glucose profile of 2.9% (MSD 3.5) shows that the model also captures the
transient dynamics in glucose during the first 60 minutes. Errors in modelled
glucose are attributed to highly dynamic metabolic changes at the beginning of
the clamp, such as EGP, which are likely not fully captured by the model.
The assumption of a steady reduction of EGP during the transient state
and full suppression during steady state proved to be a physiologically sensible
approach. The difference in transient and steady state SI is statistically in-
significant, validating this approach. This result is further confirmed with the
good correlation of SI (r = 0.98) when fitted as a value constant over the whole
120 minute trial.
The fact that the model fit with constant parameters is within measurement
noise, validates the model dynamics. In particular, it shows that all variability
can be accounted for by its structure leaving only measurement error. Hence,
these results validate the overall model, its structure, and the fitting methods,
values and assumptions. A separate fitting of the transient state is still important
to validate the model’s transient performance. This value assesses the estimation
of SI when only transient data are considered. Such a transient form of data
would be the case in a simple clinical test.
When EGP is kept constant throughout the clamp, estimated SI is increased
during steady state, which is a result of overestimating modelled glucose input.
In particular, small deviations of γ from the expected or ideal value γ = 0.5 could
be attributed to errors or deviations in the 60-minute, linear EGP suppression
assumed. However, the overall good validation results obtained indicate that this
assumption is also not far from reality in the absence of better data that are
typically not available.
The insulin profile in steady state was captured by fitting only one parameter
of the insulin kinetics equations, hepatic clearance nL. The mean fitted value of
nL = 3.68×10−2 (SD 2.04×10−2) min−1 results in a hepatic metabolic clearance
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rate of 4.6 ml/min/kg (range 2.7-6.9), which is slightly lower than the reported
range of 5.0-8.5 ml/min/kg found by others [Ferrannini et al., 1983; Sherwin
et al., 1974]. This lower clearance could be caused by various factors, such as
heavy saturation of the liver being exposed to such large supra-physiological
concentrations [Thorsteinsson, 1990], reduced clearance in obesity [Valera Mora
et al., 2003], or incomplete suppression of pancreatic insulin during the clamp test,
resulting in an apparent lower clearance rate. None of these effects are accounted
for in the model or data fit and result in an underestimated nL. Incomplete
suppression of pancreatic insulin secretion is particularly likely, given the shorter
and lower dose method used in this specific clamp study [Ferrannini and Mari,
1998].
The goodness of fit for the first hour of the insulin profile could not be as-
sessed, as measurements were taken at only 0 and 60 minutes. However, the shape
of the modelled transient insulin profile matches profiles reported in similar stud-
ies [Bergman et al., 1985; DeFronzo et al., 1979]. The glucose profile was fitted
by estimating only one parameter, SI . The quality of fit is not compromised by
keeping pGU constant throughout the cohort. Estimation of pGU is not possible
on this data, as the insulin concentration is high throughout the test and does
thus not allow insulin-independent effects to be identifiable. Furthermore, the
effect of pGU is small in this study, as it is not effective near the basal glucose
concentrations, which are close to the clamped 4.6 mmol/l.
The mean value of SI−SS is higher than the unit-corrected ISIG (SI−SS =
1.59×ISIG). This factor is due to the difference in the assumptions of the two
calculations. The clamp calculation of ISI assumes all insulin in plasma (I(t)) is
active to enable glucose uptake by the cells. The model uses the modelled insulin
concentration in interstitial fluid, Q(t), which has been shown to be correlated to
glucose uptake in dogs [Miles et al., 1995; Yang et al., 1989] and humans [Castillo
et al., 1994]. It is also a more physiological assumption.
As the steady state insulin concentration gradient is γ = 0.5, ideally SI−SS
should be 2×ISIG if both metrics were otherwise equal. The further reduction
of this factor to 0.51 is caused by the constant glucose uptake GUG and the
suppression of EGP (discussed in detail in Section 6.2), which is included in the
model but not the clamp calculation. This constant uptake reduces the amount
of glucose that is to be cleared by insulin, thus reducing the value of SI .
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Correlations between ISIG and SI−TR at transient points in the trial are
useful to see how well the model performs in estimating insulin sensitivity when
the steady state assumptions of the ISIG calculation are not met and a steady
state is not yet reached. It provides a means to verify if the model-based SI
would be equally accurate if determined from a short 30-60 minute dynamic test.
Correlations between ISIG and SI−TR were slightly lower than at steady state,
but at r = 0.92 still very high and higher than similar dynamic metrics. As a
comparison, Table 6.4 shows various correlation coefficients of the similar model-
based IVGTT compared to the clamp. Different IVGTT protocols are shown
with a wide range of correlation values, mostly in the range of r = 0.5 to r = 0.7.
Table 6.4 Correlation coefficients reported in various studies comparing the IVGTT with
the euglycaemic clamp test. A standard IVGTT includes only a glucose bolus. A tolbutamide-
modified IVGTT additionally includes added tolbutamide to trigger pancreatic insulin secretion.
An insulin-modified IVGTT additionally includes an insulin bolus. Subgroups are normal
glucose tolerant (NGT), impaired glucose tolerant (IGT), obese (OB) and type 2 diabetes
(T2).
IVGTT Weak Strong Subjects Refs
Standard r = 0.44 12 NGT [Donner et al., 1985]
180 min r = 0.53 9 NGT, 3 IGT, 8 T2 [Foley et al., 1985]
r = 0.54 10 NGT [Beard et al., 1986]
Tolbut. r = 0.84 10 NGT [Beard et al., 1986]
180 min r = 0.89 5 NGT, 5 OB [Bergman et al., 1987]
r = 0.71 35 NGT [Saad et al., 1997]
Insulin r = 0.57 28 NGT, 13 OB, 15 T2 [Katz et al., 2000]
180 min r = 0.48 20 IGT [Saad et al., 1994]
r = 0.41 12 T2 [Saad et al., 1994]
r = 0.70 35 NGT [Saad et al., 1997]
r = 0.73 12 T2 [Coates et al., 1995]
Comparing the correlations between SI and ISIG in the pre- and post-
intervention subgroups in Table 6.3, a slightly better correlation can be seen
in both states after the intervention. This increase in correlation is very small
and not statistically significant (P < 0.001) A reduction in the correlations can
be seen when correlating the transient states, as would be expected due to this
highly dynamic perturbation. The correlations decrease to r = 0.91 in the pre-
intervention group, with a wider CI of r = 0.87 − 0.95. The still comparably
narrow 95% CIs in all subgroups highlight the positive correlations.
One reason for the lower correlations at transient state is a greater variabil-
ity in SI−TR, which compensates for endogenous insulin and glucose production
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insufficiently accounted for in the model. This estimation could be improved by
modelling or estimating endogenous insulin, through C-peptide measurements
[Van Cauter et al., 1992] and/or estimating a more correct hepatic glucose out-
put through tracer experiments [Vicini et al., 1999]. While the first option is
readily applicable without significantly adding to test complexity, tracer experi-
ments are too complex and expensive to perform without highly specialised and
trained personnel [Carson and Cobelli, 2001].
The effect of the intervention, measured as a change in insulin sensitivity,
was well captured by the model, with correlations of the change in sensitivity of
r = 0.99 and r = 0.90 in steady and transient states, respectively (Figure 6.3).
The regression line of the changes had a linear relationship with a y-intercept
very close to zero and slopes of 0.54 and 0.50, respectively. These slopes should
ideally be 0.5, and thus show very close similarity of both metrics. The deviation
from the ideal line is due to experimental problems resulting in insufficiently
clamping the steady state, thus resulting in incorrect clamp ISIs. In addition,
model assumptions about the suppression profile of EGP may play a small role.
How well the model captures the change in SI is visualised better in Figure 6.4, in
which the relative change in SI is shown in a sorted order. The change in SI−SS,
though more noisy than ISIG, captures the major trend in changing sensitivity
(Figure 6.4, upper right).
One of the more widely used surrogates for estimating insulin sensitivity in
clinical practice is the HOMA-IR measure [Wallace et al., 2004b]. This fasting
measure does not correlate as well with experimental ISIG in this population,
with r = −0.48 over all 146 tests. Other studies have reported a wide range of
correlations r = −0.2 to r = −0.8 in different subgroups [Bonora et al., 2000;
Lewanczuk et al., 2004; Mather et al., 2001], matching the wide 95% CIs in
Table 6.3. Figure 6.4 (lower plot) shows the change in sensitivity as assessed by
log-HOMA, which clearly does not capture the trend seen in the clamp ISI and
the model SI , rendering it clinically infeasible for such a study or use.
The results of this validation study, especially during the transient state of
the trial, show the performance of the validated system model when correlated
to the clamp derived ISIG. Unlike the clamp or IVGTT, which rely on a steady
state to assess insulin sensitivity, this model and fitting method has the potential
to perform similarly well as the clamp in a much shorter transient test. These
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results show great potential for the performance of the model in such a short,
dynamic test.
A key factor in the increased variability during transient state is incompletely
modelled dynamics, mainly endogenous insulin and glucose. They are a main
cause for previously reported over- and underestimation of the Minimal Model’s
parameters SMMG and S
MM
I [Caumo et al., 1999; Mari, 1997]. Errors in these
effects are lumped into SI−TR, causing a greater variability in the transient state.
However, for these clamp fits, with the assumed suppression profile of EGP, the
equality of SI in both states indicates these effects were captured sufficiently well.
Suppression of EGP is not as strong during a low-dose bolus injection of
glucose and insulin and should not have such an impact on SI estimated from
such a test [Jefferson and Cherrington, 2001]. Overall, these clamp validation
results show great model performance in this highly dynamic test and very good
correlations in insulin sensitivity metrics as compared to the gold standard metric,
even in a transient state.
6.5 Summary
In the validation performed in this chapter, the pharmaco-dynamic models and
identification methods presented in Chapters 3-4 could be satisfactorily validated
by fitting them to euglycaemic-hyperinsulinaemic clamp trials. Performance was
very good, with correlations between model- and experimental metrics for insulin
sensitivity of r = 0.92 and r = 0.99 in transient and steady states. Estimated
insulin sensitivity during steady and transient states was nearly equal, further
validation the modelling assumptions.
Correlation coefficients between this model’s SI and the clamp ISI are better
than in other insulin sensitivity tests. This better comparative performance is a
resulting consequence of the specific design aspects of this PD model. Overall, the
model performance validated in this chapter shows great promise for the intended
insulin sensitivity test.
Chapter 7
Proposed Insulin Sensitivity Test
The ability to sensitively and accurately identify individuals with insulin resis-
tance (IR) is critical for the implementation and assessment of intervention pro-
grammes in high risk groups. To diagnose IR in population studies and to be
applicable in clinical settings, a test has to be simple and cost effective. However,
it must also be accurate enough to assess small changes in IR or the progression
of treatment.
In this chapter, a clinical test protocol for a model-based assessment of insulin
sensitivity is proposed. The protocol applies the models and methods described
in Chapters 3-4 to estimate insulin sensitivity and β-cell function from clinically
sampled data. A Monte Carlo error analysis is performed on a simulated virtual
cohort to assess the expected accuracy in repeatability and in correlation to the
euglycaemic clamp test, in the face of clinical and assay noise.
7.1 Overview and Goal
The target environment for the proposed protocol is a clinical setting with com-
monly available blood sampling and assay facilities. The protocol should thus be
simple and not require specially trained personnel and equipment such as glucose
tracers [Caumo and Cobelli, 1993] or hand arterialisation equipment (i.e. heated
hand technique [Bergman et al., 1985; Godsland et al., 1993]). In essence, it must
be of low clinical intensity and effort.
A dose response test capturing the metabolic response to a glucose and in-
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sulin injection is very rich in information about the analysed system and less
noise-affected than a static or constant infusion sample. The impulse response
can be fitted with a model of the relevant physiology to derive metabolic infor-
mation from its parameters. Hence, a simple dose-response format has significant
potential in both a clinical and modelling scene.
The IVGTT with Minimal Model assessment is such a test, and is com-
monly used in research studies [Bergman et al., 1981]. The main disadvantages
of the IVGTT are its duration (3 hours), number of samples (22+ samples), non-
physiological dosing (20-30 g glucose, 2-5 U insulin), and triggering of regulatory
responses, such as suppression of EGP. Furthermore it usually requires arteri-
alisation of venous blood and very frequent sampling (1-2 minutes) during the
first 10-20 minutes. All these factors limit its use to highly controlled research
settings.
The Minimal Model identification of an IVGTT with commonly used fitting
methods [Carson and Cobelli, 2001] generally overestimates insulin independent
clearance SMMG and thus overestimates S
MM
I [Quon et al., 1994b]. The main
reason identified for this behaviour is the simplified description of glucose ki-
netics by a mono-compartmental model [Caumo et al., 1999]. As explained in
Section 4.2.1, this problem can be addressed by understanding the source of the
fitting error, namely trying to fit the fast decay in the initial minutes of the test
with an unsuitable model.
The proposed test is based on the same dose-response principle, but should be
significantly shortened in duration (< 60 minutes) and sampling (< 10 samples).
Dosing should be physiological (∼ 10 g glucose, ∼ 1 U insulin) to assess a more
accurate effect and minimise endogenous regulatory responses that can negatively
affect the results. No specialised knowledge or test equipment (beyond standard
clinical practice) should be required. The application of improved modelling and
fitting approaches should thus be able to improve test performance enough to
meet the clinical accuracy requirements.
Additional information about endogenous insulin response to glucose, or β-
cell function, can also be gathered in this type of data by sampling and modelling
C-peptide kinetics. To assess this response, a gap of at least 10 minutes is re-
quired between glucose and insulin administration, as exogenous insulin injection
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suppresses pancreatic insulin secretion [Jefferson and Cherrington, 2001]. The
key secretory response of interest after such a bolus injection of glucose is the
first-phase secretion of insulin [Ferrannini and Mari, 2004], which lasts approxi-
mately 10 minutes. Therefore, this very valuable diagnosis of β-cell function can
be easily obtained in addition to insulin sensitivity.
7.2 Protocol Design
7.2.1 Clinical Aspects
The test protocol is designed with physiological, computational and practical as-
pects in mind, and limited in time to be less than 60 minutes long. A more
extensive sampling and dosing protocol is proposed first, which is then simulated
before it is tested in a clinical pilot study. From this more extensive protocol,
shortened versions are derived in a further step in Chapter 9 and their perfor-
mance compared to the full protocol. The protocol is shown schematically in
Figure 7.1 and briefly defined in the following steps:
1. Inject a fixed dose of glucose (5 g, 10 g or 20 g) at 0 minutes.
2. Inject a fixed dose of insulin (0.5 U, 1 U or 2 U) at 10 minutes.
3. Sample blood at -10, 0, 5, 10, 15, 20, 25, 30, 35, 45 minutes and assay for
glucose, insulin and C-peptide concentrations.
4. Fit metabolic models of glucose, insulin and C-peptide to dose response
curves.
5. Determine insulin sensitivity from model parameter SI .
Sampling frequency is initially chosen in 5 minute steps during the more
dynamic stages and 10 minute steps during the initial fasting period and the
near-fasting condition at the end. A more frequent sampling directly after the
injections, as done in an IVGTT, is not clinically practicable. In addition, the
mixing process in plasma can take up to 10 minutes to complete [Bergman et al.,
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Figure 7.1 Schematic of the steps involved when applying the insulin sensitivity test.
1985; Caumo and Cobelli, 1993], and earlier measurements may thus be inaccu-
rate [Ader and Bergman, 1987].
Blood is to be taken from a venous access for increased safety and simpler
protocol. Arterialisation of venous blood, as performed in an IVGTT, should not
be a requirement, as specialised equipment would be needed. Sampling venous
instead of arterial blood has been shown not to affect Minimal Model parameters
in an IVGTT [Godsland et al., 1993].
Glucose and insulin dosing should be as small as possible to measure the
necessary effect without assay errors dominating the resulting profiles. However,
they should also be smaller than a standard IVGTT to minimise intensity and
counter-regulatory responses. These basic requirements ensure a less intense, yet
physiological test, as per Figure 2.7.
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Three fixed steps in dosing are chosen: 5 g/0.5 U, 10 g/1 U, 20 g/2 U glu-
cose/insulin respectively. The dosing of 10 g of glucose and 1 U of insulin is used
as the main option in the following study, as it is > 50% lower than the dose used
in an IVGTT, but likely yielding a better signal to noise ratio than the very low
dose (5 g/0.5 U). The protocol was also simulated with the low and high dose to
assess any differences in results and expected accuracy.
After two fasting samples, taken 10 minutes apart, the glucose is administered
as a bolus at t = 0 min. At t = 10 min, insulin is administered as a bolus. This
approach enables the separate information and assessment of a fasting situation,
the pancreatic insulin response after the glucose bolus, and the final decay of
glucose in the presence of exogenous insulin. The steps involved result in the
response profiles shown for glucose and insulin in Figure 7.2.
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Figure 7.2 Example of simulated profiles of glucose (left) and insulin (right) responses to the
low-, medium- and high-dose test protocols on the same virtual subject. Discrete measurements
are shown with error bars along with model fits (continuous curves).
7.2.2 Model Fitting
The model fitting of sampled glucose, insulin and C-peptide data is done as
described in Chapters 3-4. Some parameters need to be fixed, as the information
in the data does not allow a unique identification and inaccurately identified
parameters can affect accuracy of the others [Caumo et al., 1999; Chase et al.,
2004; Finegood and Tzur, 1996].
Insulin independent glucose clearance pGU cannot be estimated accurately
116 CHAPTER 7 PROPOSED INSULIN SENSITIVITY TEST
from the data, and is fixed to an approximate population value for healthy in-
dividuals, pGU = 0.004, as described in Chapter 4. It is also not a dominant
dynamic in the presence of low glucose doses and exogenous insulin [Natali et al.,
2000; Prigeon et al., 1996]. Equilibrium glucose concentration, GE, is set to the
fasting glucose level of each subject, as shown in the cohort description in Ta-
ble 6.1. Glucose clearance saturation is set to αG = 0, as the subjects are fasted,
and with the low dose insulin bolus saturation is not likely. This value also bet-
ter matches the assumptions in calculating ISI for the supra-physiological clamp
test [DeFronzo et al., 1979].
Parameters identified from the data are nL and xL for the insulin model and
SI and VG for glucose. The measured data are the plasma glucose, insulin and
C-peptide concentrations at each time point. The integral-based fitting method
employed is described in detail in Chapters 3-4.
7.3 Monte Carlo Error Analysis
To assess the expected accuracy and repeatability of the test, a Monte Carlo
analysis is performed on test simulations, taking into account significant errors
and potential unmodelled dynamics or effects. These errors include:
1. Errors in laboratory assays
2. Dilution of input solutions
3. Timing of samples
4. Errors due to unmodelled dynamics
Errors in unmodelled dynamics could include poorly or unmodelled endoge-
nous glucose production (EGP) and first-pass hepatic insulin extraction. The sim-
ulations are based on model-based insulin sensitivity (SI) values obtained from
fitting a cohort of 146 euglycaemic-hyperinsulinaemic clamp tests by McAuley
et al. [2002], covering a range of metabolic responses. Rather than assessing clin-
ical or physiological validity of the estimated insulin sensitivity value, this specific
7.3 MONTE CARLO ERROR ANALYSIS 117
study aims at validating the robustness of the proposed test in a noisy clinical
test environment.
The simulation procedure used is shown schematically in Figure 7.3, and
explained in more detail in this chapter:
1. Insulin sensitivity from 146 euglycaemic-hyperinsulinaemic clamp tests by
McAuley et al. [2002] is calculated from the test data (ISI).
2. A virtual cohort is created by fitting the metabolic model to the clamp
tests, resulting in a model-based insulin sensitivity for each subject (SI).
3. Monte Carlo simulations on the proposed test protocol are run on the virtual
cohort by adding random noise from published error levels to measurements
and inputs, and accounting for potentially unmodelled regulatory dynamics
in a randomised function.
4. The metabolic model is fitted to the simulated test profiles (glucose, in-
sulin and C-peptide concentrations), resulting in insulin sensitivity from
the Monte Carlo analysis of the proposed test (SI−MC).
5. Performance of the method is assessed by the coefficient of variation (CV) of
SI−MC and by correlating SI−MC with ISI and SI . Additional comparisons
are made to HOMA-IR.
7.3.1 Generation of Virtual Clamp Cohort
To simulate the proposed test and make it comparable to the clamp, a simu-
lation cohort was created using metabolic information estimated from a set of
clamp trials performed by McAuley et al. [2002] to study the effects of lifestyle
interventions on insulin resistance. The data consist of 146 trials performed on
73 individuals, once before and once after a 16 week intervention. The popula-
tion is identical to the data presented in the clamp validation in Chapter 6 and
described in more detail in that chapter. Population characteristics are given in
Table 6.1 on Page 96.
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Figure 7.3 Simulation procedure and performance metrics used in this Monte Carlo simula-
tion.
The clamp trials were fitted by the model described in Chapter 4 by estimat-
ing parameters SI and nL. Mean absolute errors of the fits were 5.9% (SD 6.6%)
for glucose and 6.2% (SD 6.4%) for insulin [Lotz et al., 2006a], as also described
in Chapter 6. Insulin sensitivity, SI , was estimated as time-varying, piecewise
constant during transient and steady state [Lotz et al., 2006b]. The steady state
value was taken for the subsequent simulations.
Mean nL estimated from the clamps was very low for this cohort compared
to that seen on dose-response tests. This result may be caused by various fac-
tors, such as heavy saturation of the liver being exposed to such large supra-
physiological concentrations [Thorsteinsson, 1990], reduced clearance in obesity
[Valera Mora et al., 2003] or incomplete suppression of pancreatic insulin secre-
tion during the clamp. None of these effects are accounted for in the model or
fitting methods, and result in an underestimated nL. Incomplete suppression of
pancreatic insulin secretion is particularly likely, given the shorter and lower dose
method used in this clamp study [Ferrannini and Mari, 1998].
To achieve a more realistic insulin profile, nL was thus increased by 0.1min
−1
for all individuals based on empirical testing on various dose-response data. This
increase results in a more realistic simulated insulin profile and does not affect
the performance of the insulin sensitivity value obtained. Thus, the outcome of
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the test and the performance of the simulations are not affected.
Due to the low resolution of the clamp data, further parameters had to be
identified a-priori in creating this virtual cohort, as described in Chapter 4. In
addition, VG was set to VG = 1.2 · (VP + VQ), as the clamp data are not dense
enough to allow a unique identification. A 20% larger volume than the total
insulin distribution volume was chosen, as glucose distribution volume has been
found to be larger than for insulin, due to fast hepatic storage and non-insulin
dependent uptake by the brain [Despopoulos and Silbernagl, 2003; Waterhouse
and Keilson, 1972]. This choice also does not affect the outcome of the study,
as SI and VG are subsequently identified from the test profiles, as described in
Chapter 4.
All of the model parameters derived from the clamp data and population
are summarised in Table 7.1. These parameter values are used in the models of
Equations 3.7-3.8 and Equation 4.8 to create the virtual cohort on which the test
protocol is simulated.
Table 7.1 Simulation model parameters calculated and estimated as described in Chapters 3-
4 to generate the virtual simulation cohort.
Mean (SD) Range Mean (SD) Range
pre-interv. (N=73) post-interv. (N=73)
VP [l] 4.52 (0.37) 3.98-5.93 4.46 (0.36) 3.90-5.96
VQ [l] 5.67 (0.54) 4.52-7.47 5.54 (0.57) 4.44-7.26
VG [l] 12.22 (1.06) 10.20-15.67 12.00 (1.08) 10.00-15.75
nK [10
−2 min−1] 6.0 (0.24) 5.3-6.4 6.0 (0.28) 5.3-6.4
nL [10
−2 min−1] 15 (2.7) 10-21 16 (2.2) 10-20
nI [10
−2 l/min] 28 (2.7) 22-36 27 (2.9) 21-36
nC [10
−2 min−1] 4.9 (0.06) 4.7-5.0 4.9 (0.06) 4.7-5.0
SI 4.25 (MSD 1.54) 1.37-8.63 5.54 (MSD 1.49) 2.22-13.95
[10−4 l/mU/min]
pGU [min
−1] 0.004 (fixed)
αI [l/mU] 0.0017 (fixed)
αG [l/mU] 0 (fixed)
Pancreatic insulin secretion is not known for this cohort, as C-peptide data
are not available. Insulin secretion can be suppressed or reduced by exogenous
insulin. However, full suppression is only achievable by a prolonged infusion of
large amounts of insulin [Ferrannini and Mari, 1998]. In the protocol for this
study, an insulin bolus is injected 10 minutes after glucose, thus not affecting
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the first phase endogenous insulin burst, but suppressing second phase insulin
secretion. Simulated total insulin secretion rate is thus reduced back to its basal
rate after the bolus injection of exogenous insulin [Argoud et al., 1987; Jefferson
and Cherrington, 2001; Lotz et al., 2005b].
Pre-hepatic endogenous insulin secretion can be simulated by a basal secre-
tion rate, superimposed by a first-phase burst. The burst peaks at a rate of
72 mU/min/m2·BSA [Eaton et al., 1980; Mari, 1998], which is dependent on
body surface area (BSA), and is followed by an exponential decay lasting 10 min-
utes. For the lower and higher dose protocol, this first-phase burst is halved and
doubled, respectively [Carson and Cobelli, 2001]. Basal endogenous secretion ub
is calculated from the steady state fasting insulin balance using Equation 3.7 with
basal insulin concentrations Ib and Qb = γIb (γ = 0.5), and a randomly generated
first pass hepatic extraction xL:
ub =
VP Ib
1− xL
(
nK +
nL
1 + αIIb
+
1
2
nI
VP
)
(7.1)
Total prehepatic endogenous insulin secretion is thus modelled as:
uen(t) =
{
ub + (72 · BSA)·e−0.3t 0 ≤ t < 10 min
ub t < 0 and t ≥ 10 min
(7.2)
First pass hepatic extraction, xL, is often approximated around 50%, but is
generally higher in the fasting state [Ferrannini and Cobelli, 1987b; Meier et al.,
2005; Toffolo et al., 2006], often reaching values of over 90% [Meier et al., 2005].
As a conservative choice, xL is thus determined from a uniform distribution of
values between 0.5 and 0.95 (almost complete extraction). Using this model, the
total insulin secreted and the peak during the first phase match values reported
in the literature [Eaton et al., 1980; Mari, 1998].
Basal endogenous glucose production EGPb (Equation 4.7) can be split up
into insulin dependent, EGPIb and insulin independent production, EGPGE. As
EGPGE is not affected by an exogenous input, as described in Chapter 4, only
EGPIb is taken into account. EGPb is thus calculated from the fasting steady
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state glucose balance in Equation 4.8, where Qb = (1/2)Ib and G(0) = 0:
EGPb = SIGE
1
2
Ib
1 + αG
1
2
Ib
(7.3)
where Ib is the basal plasma insulin concentration, αG is known in this case (or
assumed), and SI and GE are also known for the virtual cohort simulation via
the data summarised in Table 7.1.
7.3.2 Monte Carlo Simulation Method
The proposed protocol is simulated on the virtual cohort by generating noisy
glucose, insulin and C-peptide data and fitting the models to determine their
parameters.
Assay errors are assumed normally distributed with inter- and intra-batch
coefficients of variation (CVinter,CVintra) reported by the assay manufacturers.
Random intra-batch errors are generated for each sample of a test and added to
an inter-batch error, equal for all samples of a given test. As CVintra is assumed
to be included in the reported CVinter, the CV to be superimposed on CVintra
(CVadd) is calculated:
CVadd =
√
CVinter
2 − CVintra2 (7.4)
Errors in the timing of samples are caused by variations in blood sampling
procedure and are assumed to be normally distributed between ±30 seconds
around the sampling time. Due to anticipation of these small complications
during sampling, the sampling procedure in similar studies is usually initiated
early, thus sometimes resulting in early sampling.
Dilution errors can occur when drawing up glucose in a syringe or when
diluting insulin, which is typically distributed in highly concentrated form (e.g.
100 U/ml). Insulin has also been reported to bind to the inner walls of syringes
and tubes when being administered, causing a loss of insulin during the dilution
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process [NovoNordisk, 2002]. All of these issues are well known problems and
usually taken into account by the investigator and the choice of equipment. The
errors in this case are also assumed to be normally distributed around the mean.
Suppression of EGP is caused by increases in plasma insulin or glucose [Jef-
ferson and Cherrington, 2001]. The amount and efficiency of suppression is de-
pendent on the administered dose [Vella et al., 2003]. With the low dose this test
aims at, the suppression is likely not as large as during an IVGTT (∼ 75%−100%
[Nagasaka et al., 1999; Vicini et al., 1999]), but also cannot be neglected. Since
this level of suppression cannot be easily measured, a linear reduction of EGP is
assumed from the time of insulin input, reaching a randomly generated maximal
suppression EGPsuppr at the end of the test. It is defined:
EGP (t) =
{
EGPb
(
1− EGPsuppr ttend
)
0 min ≤ t < tend
EGPb t ≤ 0 min
(7.5)
where the maximal suppression, EGPsuppr, at the 10 g/1 U dose was chosen
randomly from a normal distribution from values between 25% − 75% with a
mean value of 50%. For the lower (5 g/0.5 U) and higher (20 g/2 U) dose variants,
EGPsuppr was shifted to 0%− 50% and 50%− 100%, respectively. Studies have
shown a direct dose-dependent relationship between glucose concentration and
suppression of EGP [Vella et al., 2003], validating this basic approach.
The random disturbances thus assumed in this Monte Carlo analysis are
summarised:
• Glucose assay errors: CVintra=1%; CVinter=2% [Wallace et al., 2004a]
• Insulin assay errors: CVintra=2%; CVinter=2.8% [Roche, 2004; Wallace
et al., 2004a]
• C-peptide assay errors: CVintra=3%; CVinter=3.4% [Roche, 2005]
• Glucose input error: CV=1.67%
• Insulin input error (dilution): CV=3.33%
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• Sample timing error: SD 10 seconds
• First pass hepatic insulin extraction: xL ∈ [0.50, 0.95]
• Mean maximal suppression of EGP: EGPsuppr=50%(10 g/1 U);
25%(5 g/0.5 U); 75%(20 g/2 U) (SD 8.3%)
The required number of Monte Carlo simulations was identified to be 500
in a convergence test, as the variability in the standard deviation (SD) of the
resulting SI value identified did not change significantly with more runs.
7.3.3 Monte Carlo Results
Performance of the method was assessed by correlation (Pearson correlation) of
the estimated insulin sensitivity SI with the gold standard clamp test ISI derived
clinically. Accuracy in the estimation of SI is given as its coefficient of variation
(CV=SD/mean). The distribution of SI can be assumed to be normal, as assessed
by the single sample Kolmogorov-Smirnov (KS) test.
Accuracy of ISI was assessed by Monte Carlo analysis with assay errors
as described above and a glucose infusion error of 10%. Accuracy of HOMA-
IR is also affected by assay errors, as well as pulsatile basal insulin secretion.
Therefore, the HOMA-IR criteria is also estimated for comparison using Monte
Carlo analysis with a CV of 10%, as reported byWallace et al. [2004b], accounting
for both assay and natural variability.
The model parameter for insulin sensitivity fit from clamp trials is SI =
4.85 (MSD 1.54) · 10−4 l/mU/min. This value is higher than clinically mea-
sured clamp ISI normalised by steady state glucose and corrected for units
(ISIG = ISI/G·weight/VG) ISIG = 3.23 (SD 1.16) · 10−4 l/mU/min. This
difference is due to the different compartmental insulin concentrations used in
the respective calculations. The clamp uses plasma insulin (I) and the modelled
SI uses interstitial insulin (Q). Clamp fitted SI and measured ISI correlate
r = 0.95. However, SI and ISIG correlate much better r = 0.995. The higher
correlation with ISIG is a result of the unit correction, which reduces variability
introduced by other parameters and imperfect clamping to a basal glucose level
[Bergman et al., 1985].
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Mean insulin sensitivity resulting from Monte Carlo analysis is SI−MC =
4.86 (SD 1.55) · 10−4 l/mU/min and thus identical to SI . Correlations with
clinically measured ISI and ISIG are slightly lower, at r = 0.91 (90% CI: 0.90-
0.92) and r = 0.98 (90% CI: 0.97-0.98), respectively. Figure 7.4 shows the
correlation plot of SI−MC and ISIG with the 90% CI’s of each metric over all
500 Monte Carlo runs, shown by the cross.
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Figure 7.4 Correlation of SI−MC and clinically measured ISIG with 90% CI’s of each metric
and mean regression line. The CI for SI is assessed by Monte Carlo simulation, the CI for ISIG
by error propagation calculation.
Intra-individual CV in SI−MC using the proposed low intensity test method
is CVSI=4.5% (90% CI: 3.8% - 5.7%). This value is larger than the CV for
ISI, CVISI=3.3% (90% CI: 3.0% - 4.0%), calculated by error propagation of
assay errors, but significantly lower than the CV for HOMA-IR, CVHOMA=10.0%
(90% CI: 9.1% - 10.8%). The three intra-individual CVs are shown in Figure 7.5
for all N=146 subjects.
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Figure 7.5 Intra-individual coefficients of variation for SI−MC (CVSI) at 10 g/1 U dosing,
ISIG (CVISI) and HOMA-IR (CVHOMA).
The increase in insulin sensitivity after lifestyle intervention [McAuley et al.,
2002] was captured by the model, with SI increasing from SI−MC(BEFORE)=4.34
(MSD 1.47) 10−4 l/mU/min to SI−MC(AFTER)=5.57 (MSD 1.48) 10
−4 l/mU/min.
This value matches the increase in ISI shown in Table 6.1. Correlation between
the change in SI−MC and ISIG, ∆SI−MC and ∆ISIG is r = 0.96 (90% CI: 0.96 -
0.97) with a mean regression line of ISIG = 0+0.48SI−MC . Note that the ∼ 50%
slope is due to the fixed γ = 1/2 ratio of insulin concentration in interstitium
(Q) and plasma (I) during steady state. Specifically, ISI is calculated using I
and SI is identified using Q.
The intra-individual CV of SI−MC decreased slightly from CVSI(BEFORE)=4.6%
(90% CI: 3.8% - 5.9%) to CVSI(AFTER)=4.3% (90% CI: 3.7% - 5.2%). A strong
correlation of r = −0.83 could be seen between a decrease in insulin sensitivity
ISI and increased intra-individual CV in SI−MC . Figure 7.6 shows the linear
relationships between ISIG and CVSI before and after intervention. A clear re-
duction in accuracy of estimated SI can thus be seen in subjects with very low
insulin sensitivities.
Re-simulating the low intensity test protocol with different doses of glucose
and insulin showed a clear dependence of accuracy of the method on the dose
employed, as can be seen in Figure 7.7. Administering 5 g glucose and 0.5 U
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Figure 7.6 Relationship between ISIG and intra-individual coefficients of variation CVSI
before and after intervention.
insulin resulted in CVSI=6.9% (90% CI: 4.9% - 9.9%). The high dose variant
with 20 g glucose and 2 U insulin resulted in a more accurate measure with
CVSI=3.6% (90% CI: 3.0% - 4.5%), which is very close to the accuracy of ISI.
Correlation of CVSI with ISIG was stronger in the low dose protocol (r = 0.90)
but showed a weaker linear relationship in the high dose variant (r = 0.46),
indicating the reduced effect of assay variation and other errors at higher doses.
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Figure 7.7 CVSI compared to CVISI and CVHOMA simulating the protocol with 5 g glucose
and 0.5 U insulin (left), and 20 g glucose and 2 U insulin (right).
Simulated hepatic insulin clearance nL and simulated first pass hepatic insulin
extraction xL were underestimated slightly in the Monte Carlo analysis, by -4.4%
(90% CI: -16.5% - 8.1%) and -2.2% (90% CI: -12.4% - 7.3%), respectively.
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Simulated glucose distribution volume VG was overestimated by 1.7% (90% CI:
0.7% - 3.5%). However, these results are relatively small and not likely to have
significant clinical impact.
7.4 Discussion
The test protocol presented is developed with the main goal to provide a clinically
useful, highly accurate method to diagnose insulin resistance (IR) that is highly
correlated to the gold standard euglycaemic-hyperinsulinaemic clamp. To be
clinically useful, a test must be accurate, short and simple. To correlate highly
to the clamp, a test must measure the same effects as the clamp and be equally
accurate. The most widely used and accepted tests developed so far (e.g. IVGTT,
OGTT and HOMA-IR), are all judged by their ability to correlate to the clamp.
This goal has been achieved only with some significant variability, yielding a wide
range of IVGTT-clamp correlations, for example, between r = 0.44 − 0.89 [e.g.
Bergman et al., 1987; Donner et al., 1985; Saad et al., 1994].
One major obstacle is that every test effectively measures a different effect
[Radziuk, 2000], as discussed in Chapter 2. The clamp relies on a steady state
glucose concentration during supra-physiological insulin and glucose infusions, in
which endogenous insulin and glucose are assumed to be completely suppressed.
Its metric for insulin sensitivity is the rate at which glucose is disposed in the
body with a given plasma insulin concentration. In contrast, the IVGTT fits
the Minimal Model [Bergman et al., 1979] to the glucose response curve after
a high-dose injection of glucose and insulin by estimating three model parame-
ters (p1, p2, p3), with insulin sensitivity being the ratio S
MM
I = p3/p2. Fitting
three parameters has the disadvantage that a longer test is required to allow
for enough resolution and data, and thus inter-subject variability is distributed
amongst these three parameters. In general, the IVGTT is considered the best
clamp-correlated method, with correlation values up to r = 0.89 being reported
[Bergman et al., 1987]. However, lower results, as low as r = 0.44, have also been
reported [Donner et al., 1985].
Other popular methods, widely used due to their simplicity, are surrogate
measures such as the OGTT (measuring the rate of glucose decay after an oral
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glucose load) and HOMA-IR (based on one fasting glucose and insulin sample).
These methods are far less correlated to the clamp [Monzillo and Hamdy, 2003], as
they too measure different effects. In particular, HOMA-IR can be very variable
due to a pulsatile secretion of insulin [Song et al., 2000] and assay inaccuracies,
leading to a CV > 10% [Wallace et al., 2004b].
The proposed low intensity protocol presented was designed to specifically
measure the same effects as the clamp in a much shorter and less intense transient
test. Variability is constrained to insulin dependent effects in the periphery,
controlled by the insulin sensitivity parameter SI . Modelled SI is lower than
clamp ISI, but it does not introduce additional variability. The difference is
consistent across all individuals, due to the fixed ratio of steady state plasma (I)
and interstitial (Q) insulin in the model. The model and fitting method employed
have been well validated [Hann et al., 2005b; Lotz et al., 2006a] and correlated
to clamp data in transient and steady state, resulting in very high correlations
(r = 0.92 in transient state, r = 0.99 in steady state) [Lotz et al., 2006b], as also
shown in Chapter 6.
The proposed method was able to estimate SI with high accuracy, given the
assay errors and unmodelled suppression of EGP. CVSI was slightly larger than
CVISI . This larger CV can be expected given the highly dynamic state of the
proposed test. Accuracy decreased drastically by 53% in the lower dose test
(5 g glucose, 0.5 U insulin), although accuracy was still better than HOMA-IR.
The higher dose test (20 g glucose, 2 U insulin) improved accuracy by 20%. As
suppression of EGP was adjusted to the dose accordingly, being higher in the
high dose test, the still improved accuracy suggests a strong dependence on the
signal to noise ratio of the test, with EGP playing a minor role.
In spite of the improved accuracy at a higher dose, this high dose is not as
practical for a simple clinical test, for a variety of reasons. As IV glucose is
commonly available in 50% solution, a 20 g bolus requires a 40 ml injection of a
very viscous solution, which can cause discomfort for the test subject. The 2 U
insulin dose also increases risk of hypoglycaemia, particularly in lean subjects.
Finally, an intravenous glucose bolus of 20 g is on the upper physiological range,
possibly triggering other glucose regulatory effects not accounted for in this model
and simulation, which could in a real clinical test worsen the results.
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The 10 g glucose and 1 U insulin dose is only slightly less accurate, but a lot
easier and safer to administer in clinical practice. Mean and range of CVSI are
greatly reduced in the step from low to medium dose, whereas the improvement
from medium to high dose is less pronounced. This decay is shown in Figure 7.8,
which illustrates that the medium dose of 10 g glucose and 1 U insulin appears
to be the best compromise in clinical practicability, safety and accuracy.
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Figure 7.8 CVSI with the 90% confidence intervals for the low (5 g glucose, 0.5 U insulin),
medium (10 g glucose, 1 U insulin) and high (20 g glucose, 2 U insulin) dose test variants.
A strong negative correlation was seen between a decrease in insulin sensitiv-
ity ISIG and a resulting increased CVSI . This correlation was even stronger with
the low dose test, but was markedly reduced in the high dose test. The origin of
this effect is likely physiological, as insulin-dependent effects are less dominant in
subjects with low insulin sensitivity, leading to a reduced signal to noise ratio. As
can be seen with the high dose test, this correlation can be reduced by increasing
the signal. In contrast, the correlation is stronger with a weaker signal as shown
in the low dose test.
Overall, the method is able to estimate the underlying insulin sensitivity
with high accuracy from the proposed test protocol. Whether the estimated
SI is a true marker of insulin sensitivity will require further clinical validation
with the clamp and other methods in a new data set. However, judging from
the accurate simulation of clinically observed dynamics, it is very likely that
the effect described by the model parameter SI is physiological and that insulin
sensitivity can be estimated with similar accuracy in clinical data. This result
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is supported by the high correlation between SI and ISI using clamp test data
[Lotz et al., 2006b]. More specifically, because the proposed low intensity test
was intentionally designed to measure the same physiological effect as the clamp
using highly correlated models and methods, the test should be highly correlated
to the clamp.
Even if the most prominent unmodelled dynamic (suppression of EGP) is
included in this Monte Carlo analysis, real results could still be affected by other
effects not simulated here. Inaccuracies in the simulated test protocol were iden-
tified in initial trials [Lotz et al., 2005b], such as in sample timing and imperfect
cannula flushing, or incomplete mixing of glucose and insulin in plasma during the
first 10 minutes. These effects are more likely in a clinical, non-research setting
with a simple protocol, where special considerations common in research settings
cannot be met. These factors have to be taken into account when designing a
robust clinical test.
Finally, additional variability could be introduced by less accurate assay
methods, especially for insulin and C-peptide. The assays used in this study
are run by the authors’ collaborating laboratory and are amongst the most ac-
curate methods to date. Less accurate insulin assays with more cross reactivity
to proinsulin are still widely used and could increase the test’s variability or
introduce a systematic error [Chevenne et al., 1999; Robbins et al., 1996].
7.5 Summary
The proposed test to assess insulin sensitivity is short and simple enough to be
applicable in a clinical setting. Factors and problems apparent in previous similar
attempts, such as the IVGTT, have been addressed and solved to improve overall
system performance. The method proved to be very accurate in Monte Carlo
simulation, and only slightly less accurate than the gold standard clamp test.
As a result of its design to measure the same effects as the clamp, it is highly
correlated to the gold standard clamp ISI metric.
The physiological dosing, simple and robust protocol and high accuracy make
the test very attractive for early diagnosis and monitoring of interventions. Ac-
curacy and correlation to gold standard tests must still be assessed in a clinical
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validation on a new cohort. However, this study has indicated that the proposed
test should possess the accuracy and robustness required, as compared to a large
cohort of clamp results.
Chapter 8
Clinical Pilot Test
The test proposed in Chapter 7 shows very good Monte Carlo simulation results
for diagnosing the underlying insulin sensitivity with great accuracy in a noisy
clinical test environment. To assess its performance in a clinical setting and
to find additional practical aspects to be optimised, a clinical pilot study on a
limited number of subjects is required. This chapter describes the study design
and presents its results.
The study was performed in collaboration with Dr. Kirsten McAuley and
Prof. JimMann from the Edgar National Centre for Diabetes Research in Dunedin.
Ethics approval for the study was granted by the Upper South A Regional Ethics
Committee. Tests were performed both in Dunedin and Christchurch.
8.1 Objectives and Design
The pilot study can yield information on effects of different dosing and on intra-
individual variability. It further provides an opportunity to assess practical as-
pects such as sampling procedure, ergonomics and comfort for the test subject.
Sources of error that have not been addressed in the simulation study can be
identified and the fitting algorithm optimised to improve overall method robust-
ness.
The pilot study is designed to investigate these aspects and produce insights
into the practical procedures, which can then be used to improve the protocol.
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8.1.1 Aims
The primary aims of the pilot study were to investigate the following aspects:
1. Assess difference in the clinically estimated insulin sensitivity SI at different
dosing of glucose and insulin.
2. Determine the minimum dose of insulin and glucose to produce adequate
resolution in the sampled data.
3. Assess intra-individual variability in SI at the same dose.
4. Obtain an initial estimate of the inter-individual range in SI and its relevant
diagnostic ranges.
5. Assess the overall clinical potential of the test prior to a full scale validation.
The study was performed on a range of normal and overweight men and
women over the age of 18 years, that were recruited from the general population.
Only those with a current major medical illness were excluded.
8.1.2 Study Design
The study is divided into two main parts, primarily to investigate Aims 1-3. Aims
4-5 can be evaluated on data gathered from all tests.
Part 1
Study Part 1 addressed Aims 1 and 2 (and 4-5), mainly the effect of different
dosing of glucose and insulin, and the minimum dosing required to minimise the
effect of noise in data. Recruited subjects had two tests on two occasions, no more
than two to three weeks apart. The test was performed as outlined in Chapter 7.2.
On each occasion, a different dose of glucose and insulin was administered. The
levels of glucose and insulin were defined in three steps for added simplicity. The
steps were as used in the simulation study in Chapter 7, namely 0.5 U/5 g (low),
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1 U/10 g (medium) and 2 U/20 g (high) of glucose and insulin, respectively.
These steps were chosen as they are still lower than a standard IVGTT dosing
[Bergman et al., 1981], and thus safer and more physiological.
As each subject was tested only twice, dosing steps for each subject were
chosen as either low + medium or medium + high. A systematic bias in estimated
SI is an indication of a different result obtained at different dosing. From the
noise in the resulting data and its affect on model fitting, a minimum dose for
the final test design can be chosen, that is more robust to noise. This aspect was
assessed in the Monte Carlo analysis in Chapter 7 and is initially validated on
the clinical data in this chapter.
Part 2
Study Part 2 assessed Aim 3 (and 4-5), mainly the accuracy in repeatability of the
same dose test on the same subject. The test was repeated on the same subject
two to three times, each test two to three weeks apart. Part 2 overlapped with
Part 1, as some of these subjects were simply tested a third time at one of the
doses already used in Part 1. This part yielded information on the variability to
be expected from the test. From model fitting performance, it could be estimated
if this variability is caused by computational or natural factors.
Additional Analysis
To investigate Aim 4, the test data gathered from Parts 1 and 2 were further
analysed computationally. The range of SI estimated in this test was compared
to the values obtained from the clamp population used in Chapter 6.
Further metabolic information that can be gathered from this test includes
the pancreatic secretory response to the glucose injection (β-cell function). These
data can be calculated from the estimated C-peptide secretion rate. Metrics of
interest are basal fasting insulin secretion rate, ub in mU/min, peak secretion rate
above ub after the bolus, Smax in mU/min, and total insulin secreted above basal
during the 10 minutes after glucose input, AUC10 in mU, calculated as area under
the secretion profile above the basal rate uB. All of these metrics have significant
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diagnostic merit and can be combined with the SI results obtained to provide a
more complete picture of the metabolic defect [Ferrannini and Mari, 2004].
8.1.3 Recruitment and Subjects
Recruitment of subjects was done in parallel in Dunedin and Christchurch by
the respective clinical research teams, mainly by advertisement flyers around
the university and the hospital. Interested subjects were informed about the
study and their characteristics and contact details recorded. Subjects were picked
from this list to obtain individuals within a wide range of age and BMIs. The
recruitment flyer used in Christchurch is shown in Figure 8.1.
Figure 8.1 Advertisement used to recruit volunteers for the study.
The test was performed on a total of 17 subjects, 7 in Christchurch and 10
in Dunedin. One subject in Christchurch came only once and could thus not be
further included in the analysis. The characteristics of the subjects included in
both parts of the study are presented in Table 8.1.
8.1.4 Test Procedure
All tests were performed between 9-11 am after an overnight fast from 10 pm.
The subject’s weight, height and blood pressure were taken. Before the first
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Table 8.1 Pilot study population in each study part. Age in years, weight in kg, BMI in
kg/m2, fasting glucose in mmol/l, fasting insulin in mU/l. ‘IFG’ denotes that the subject was
not previously diagnosed with type 2 diabetes but has elevated fasting glucose concentrations
qualifying for an ADA diagnosis of impaired fasting glucose (> 5.6 mmol/l) [ADA, 2006]. +
denotes geometric mean and multiplicative SD, as data has log-normal distribution.
Part 1
Subject Gender Age weight BMI Fast. G Fast. I Type 2
[years] [kg] [kg/m2] [mmol/l] [mU/l] or IFG
1 f 57 89 33.9 5.75 30.8 IFG
2 f 59 67 25.5 5.85 1.4 IFG
4 f 21 78 25.2 5 5.2
5 m 41 76 21.7 4 0.5
6 f 45 76 25.4 4.1 1.7
7 m 55 73 24.1 4.5 4.4
8 f 51 67 27.2 4.3 1.4
9 f 35 66 24 4.8 6.6
10 f 30 50 19.5 4.2 3.2
11 f 55 85 30.1 6.8 9.2 Type 2
14 f 41 111 41.3 4.5 3.9
15 m 29 84 25.9 5 2.5
16 m 49 105 35.1 6.3 16.6 IFG
17 f 25 60 25.3 4.5 3
mean 10 f/4 m 42.36 77.64 27.44 4.91+ 3.75+
SD 12.66 16.52 5.81 1.18+ 2.90+
Part 2
3 f 59 87 39.2 4.7 12.5
5 m 41 76 21.7 4 0.5
6 f 45 76 25.4 4.1 1.7
10 f 30 50 19.5 4.2 3.2
11 f 55 85 30.1 6.8 9.2 Type 2
13 f 48 91 33.4 5.2 9.5
14 f 41 111 41.3 4.5 3.9
15 m 29 84 25.9 5 2.5
16 m 49 105 35.1 6.3 16.6 IFG
mean 6 f/3 m 44.11 85.00 30.18 4.90+ 4.28+
SD 10.17 17.69 7.64 1.21+ 3.07+
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visit, informed consent was obtained and any medical history recorded. Tests
were performed in a seated, slightly reclined position.
Glucose was administered as a 50% solution. Insulin was diluted in two
steps to minimise dilution errors: First, 0.5 ml (50 U) of insulin (Actrapid,
NovoNordisk) is drawn in a 1 ml syringe and diluted with 49.5 ml saline to
obtain a 1 U/ml solution. From this result, the required amount for the test was
drawn (0.5 ml, 1 ml or 2 ml) in a 3 ml syringe.
A cannula was inserted into the antecubital fossa. Two baseline blood samples
(8 ml) were taken at t = −10 and t = 0 minutes. Glucose was administered at
t = 0 min and insulin at t = 10 min (just after the samples at those times). In
addition to the baseline samples, blood was sampled during the test at 5, 10,
15, 20, 25, 30, 35 and 45 minutes. Sampling and administration was performed
on the same cannula, which was flushed first with the subject’s own blood, then
with saline after each bolus input. This approach minimises errors due to insulin
and glucose binding to inner walls of tubes [NovoNordisk, 2002]. After the test,
the subject was given a snack.
Blood samples were centrifuged and plasma serum separated for insulin and
C-peptide analysis, and sent to the laboratory immediately or frozen at −80 ◦C.
Glucose was analysed by an enzymatic glucose hexokinase assay (Abbott). Insulin
and C-peptide were analysed with an ECLIA immunoassay (Roche Diagnostics
Elecsys).
The analysed data were fitted by the models and methods described in Chap-
ters 3-4 and insulin sensitivity determined from the glucose model parameter SI .
Further parameters estimated from the fitting are nL, xL and VG. Estimation of
VG is bound to a realistic range, between 15% and 25% body weight to avoid
misidentification by noisy data. The estimation of endogenous insulin secretion
rate was performed without the corrected peak proposed in Section 5.1.3.
8.2 Results
The experimentally sampled profiles of glucose, insulin and C-peptide were dis-
tinct enough in all dose options to achieve a good model fit. The model fits of
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glucose and insulin concentrations and estimated endogenous insulin secretion
rate on all subjects are shown in Appendix B. Where samples were within the
expected ranges and not affected by incomplete mixing or contamination, a stan-
dard fit with all data points and no weighting was possible. Likely erroneous
samples were evident in some tests and could result in incorrect estimation of
insulin sensitivity, unless identified and removed. Some typical examples of these
errors are shown in Figure 8.2.
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Figure 8.2 Errors in samples evident in some tests. Source of the errors could be incomplete
systemic mixing, assay error or contamination, especially in the unrealistically high values seen
in the two insulin plots.
Identified evident individual measurement errors in all 43 tests included:
1. Glucose
• 4 tests had the first one or two samples after glucose input still affected
by incomplete mixing, as shown in Figure 8.2 (B).
• 4 tests had first samples after glucose input that were affected by very
slow mixing or possible contamination, as shown in Figure 8.2 (A),
resulting in unrealistically high values.
• 2 tests had further samples later in the test that were larger than
physiologically possible. These were most likely contaminated.
2. Insulin
• 6 tests had the first sample after insulin input affected by incomplete
mixing processes.
• 5 tests had the first sample after insulin input outside of a realistic
physiological range, most likely due to contamination or very slow
systemic mixing, as shown in Figure 8.2 (C).
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• 3 tests had a sample later in the test larger than physiologically possi-
ble. These were most likely contaminated. An example of such a test
is shown in Figure 8.2 (D)
• Two tests, on subjects 6 and 9, had too noisy insulin profiles, caused
by unexplained contamination of samples, and were disregarded for
the further analysis, as the data did not allow a sensible model fit.
3. C-peptide
• No problems were evident in C-peptide samples.
As the first respective sample after glucose or insulin administration is usually
higher than expected by the model structure, a significant error can be introduced
by the fitting algorithm, as it tries to compensate for this difference. The dif-
ference is caused by incomplete mixing between plasma and interstitial fluid and
not accounted for by the model [Caumo and Cobelli, 1993; Regittnig et al., 1999].
As the goal for the algorithm is to be generic without prior manual filtering of
the data, an automated filtering of the samples is undertaken to minimise the
error introduced by noisy data. The automated filtering steps include:
• Replace the two fasting samples with their mean value.
• Remove first glucose sample after glucose administration at t = 5 min and
first insulin sample after insulin administration at t = 15 min.
• Further samples are expected to decay with time. If a sample is 10%
higher than the previous one, it is removed. This removes all samples that
are clearly contaminated.
This simple filtering eliminates all of the issues described in the ∼30 samples
noted (of 1290 total). The results presented for Part 1 and Part 2 were obtained
with this generic algorithm, without prior manual data analysis. As mentioned
before, two tests, one on Subject 6 and one on Subject 9, resulted in unreli-
able insulin data, due to unexplainable data errors and were excluded from the
subsequent analysis.
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8.2.1 Study Part 1
The study population for Part 1 consisted of 13 subjects, with the characteristics
shown in Table 8.1. 7 subjects had a low and medium dose test, 6 subjects the
medium and high dose test. The difference in estimated SI is shown in Table 8.2,
along with estimated parameters VG, nL and xL. In subjects with two tests at
the same dose, the mean value was taken.
Estimated SI is lower in 9/13 subjects at the higher dose test, but the
differences are not statistically significant (low/medium P=0.50, medium/high
P=0.52), as assessed by the two sample t-test. The volume VG is estimated with
high repeatability in all but 2 subjects (subjects 2 and 4). No relationship be-
tween the difference in VG and in SI is apparent. Hepatic clearance parameters
nL and xL were consistent in subjects, with significantly reduced clearance rates
in low SI subjects, in accordance with their hyperinsulinaemia [Ferrannini and
Cobelli, 1987a; Li et al., 2006; Valera Mora et al., 2003].
Pancreatic secretory metrics were consistent within individuals, within the
expected accuracy due to assay errors calculated in Chapter 5 (CV= 4%−10%),
and are given in Table 8.3. Basal secretion was consistently higher in subjects
with lower SI , as would be physiologically expected. Secreted insulin above basal
during the first 10 minutes after glucose input, AUC10, is increased at the higher
dose in all but one subject, with a wide range in changes of −7.1% − 213.8%.
The same is the case for the difference in maximal secretion rate, Smax, which is
in the range of −20.7%− 180.9%, and positive for all but two subjects.
8.2.2 Study Part 2
The study population for Part 2 consisted of 8 subjects, with 4 repeated for the
low dose test and 4 repeated for the medium dose test. Two subjects at the
medium dose had the test performed on three occasions, all others only twice.
Estimated SI and the error around the mean are given in Table 8.4, along with
the estimated parameters VG, nL and xL.
Errors in SI are in the range of 1.7%− 24.7% with a geometric mean value
of 6.0% (MSD 4.9). The volume VG was estimated consistently in all subjects
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Table 8.2 Results in estimated SI in study Part 1, effect of dosing. Also shown are further
estimated model parameters, nL, xL and VG, and the relative difference in SI at the higher
dose.
low/medium dose
Subject dose SI VG nL xL Diff SI
[l/mU/min] [l] [min−1] [-] [%]
4 5 g 13.39 15.85 0.16 0.78
10 g 16.49 11.70 0.11 0.75 23.14%
7 5 g 19.33 16.44 0.22 0.74
10 g 18.06 17.82 0.21 0.74 -6.60%
8 5 g 18.64 14.29 0.15 0.86
10 g 13.61 16.12 0.07 0.80 -26.98%
10 5 g 43.73 12.33 0.20 0.80
10 g 17.40 11.56 0.13 0.77
5 g 29.19 10.13 0.18 0.78 -52.27%
11 5 g 6.88 12.75 0.14 0.72
10 g 6.73 12.75 0.16 0.70
5 g 5.75 13.14 0.11 0.74 6.53%
15 5 g 8.28 16.57 0.16 0.78
10 g 7.39 16.45 0.12 0.78
5 g 8.99 16.81 0.17 0.79 -14.40%
16 5 g 3.27 15.75 0.09 0.77
10 g 3.17 15.75 0.05 0.75
5 g 3.16 15.75 0.05 0.81 -1.40%
mean 13.53 14.55 0.14 0.77 -10.28%
SD 10.34 2.24 0.05 0.04 24.33%
medium/high dose
1 10 g 3.13 13.35 0.05 0.74
20 g 2.69 13.35 0.06 0.67 -14.15%
2 10 g 19.47 16.19 0.10 0.82
20 g 13.43 12.95 0.15 0.75 -31.02%
5 10 g 26.45 16.04 0.21 0.81
20 g 25.07 18.19 0.34 0.74
10 g 19.97 16.96 0.13 0.79 8.02%
6 10 g 14.84 16.10 0.14 0.82
20 g 12.83 18.30 0.20 0.73 -13.56%
14 10 g 11.70 16.65 0.19 0.69
20 g 14.12 16.99 0.18 0.73
10 g 11.65 17.59 0.14 0.71 20.89%
17 10 g 36.85 14.21 0.20 0.52
20 g 12.60 12.25 0.12 0.70 -65.82%
mean 16.06 15.65 0.16 0.73 -15.94%
SD 9.06 2.04 0.07 0.08 30.51%
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Table 8.3 Results in estimated pancreatic secretion metrics in study Part 1, effect of dosing.
Also shown are the relative changes in AUC10 and Smax at the higher dose.
low/medium dose
Subject dose uB AUC10 Diff AUC10 Smax Diff Smax
[mU/l] [mU] [%] [mU/l] [%]
4 5 g 19.61 221.16 35.42
10 g 20.90 253.99 14.84% 42.08 18.81%
7 5 g 24.94 419.04 107.69
10 g 24.74 785.88 87.54% 152.82 41.91%
8 5 g 11.39 379.94 87.61
10 g 12.83 832.57 119.13% 190.98 118.00%
10 5 g 13.68 479.54 107.34
10 g 13.49 628.42 25.75% 149.70
5 g 15.62 519.90 122.65 30.18%
11 5 g 36.15 201.59 27.23
10 g 33.86 226.68 16.24% 29.22
5 g 42.18 188.43 31.72 -0.87%
15 5 g 20.00 399.71 114.45
10 g 20.80 648.11 69.42% 144.98
5 g 22.06 365.39 104.75 32.28%
16 5 g 62.70 244.98 43.03
10 g 66.22 577.64 213.77% 81.89
5 g 56.98 123.21 25.63 138.58%
mean 28.79 416.45 78.10% 88.84 54.13%
SD 17.42 212.44 71.67% 51.98 52.73%
medium/high dose
1 10 g 70.90 393.26 62.60
20 g 68.90 1027.10 161.18% 175.85 180.92%
2 10 g 8.94 174.78 32.51
20 g 12.02 225.09 28.79% 39.02 20.00%
5 10 g 14.28 410.45 76.09
20 g 10.85 564.21 48.55% 130.27
10 g 11.06 349.18 69.20 79.32%
6 10 g 17.04 344.69 63.39
20 g 17.16 554.53 60.88% 81.06 27.87%
14 10 g 21.05 696.51 183.96
20 g 19.13 666.65 -7.09% 144.39
10 g 25.75 738.51 180.18 -20.69%
17 10 g 9.62 383.14 111.86
20 g 11.43 607.46 58.55% 120.78 7.97%
mean 22.72 509.68 58.48% 105.08 49.23%
SD 20.56 228.66 56.27% 52.05 72.32%
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Table 8.4 Results of Part 2, accuracy in repeatability. Given are estimated parameters SI ,
VG, nL and xL, and the error around the mean SI .
low dose
Subject SI VG nL xL Diff SI
[l] [min−1] [-] [%]
10 43.73 12.33 0.20 0.80
29.19 10.13 0.18 0.78 19.94%
11 6.88 12.75 0.14 0.72
5.75 13.14 0.11 0.74 8.90%
15 8.28 16.57 0.16 0.78
8.99 16.81 0.17 0.79 4.13%
16 3.27 15.75 0.09 0.77
3.16 15.75 0.05 0.81 1.71%
medium dose
3 10.18 18.16 0.12 0.67
8.59 13.82 0.10 0.64
7.37 13.05 0.06 0.69 16.80%
5 26.45 16.04 0.21 0.81
19.97 16.96 0.13 0.79 13.95%
13 16.31 14.55 0.13 0.73
13.51 13.65 0.14 0.77
21.20 13.65 0.13 0.85 24.65%
14 11.70 16.65 0.19 0.69
11.65 17.59 0.14 0.71 0.22%
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but subject 3, in which the first test resulted in a much larger volume estimate.
Hepatic clearance parameters were also consistent across tests, with errors within
expected physiological variability.
Repeatability in pancreatic secretion metrics are given in Table 8.5. Error
in basal secretion rate ub was in the range of 2.6% − 11.7%, well within the
assay errors as estimated in Chapter 5. Total first phase insulin AUC10 was
estimated with high accuracy in repeatability, with a mean value of 9.5% and a
range of 2.9% − 33.1%. Only in one subject the deviation of 33.1% was larger
than the expected accuracy estimated by Monte Carlo analysis in Section 5.1.4.
Repeatability in maximal secretion rate, Smax, was good, with a mean error of
11% and only two errors above 15%.
Table 8.5 Estimated pancreatic secretion metrics from C-peptide data with errors around
their mean values.
low dose
Subject ub Diff ub AUC10 Diff AUC10 Smax Diff Smax
[mU/l] [%] [mU] [%] [mU/l] [%]
10 13.68 479.54 107.34
15.62 6.62% 519.90 4.04% 122.65 6.66%
11 36.15 201.59 27.23
42.18 7.71% 188.43 3.37% 31.72 7.62%
15 20.00 399.71 114.45
22.06 4.90% 365.39 4.48% 104.75 4.42%
16 62.70 244.98 43.03
56.98 4.78% 123.21 33.07% 25.63 25.34%
medium dose
Subject
3 34.08 1208.07 241.84
38.79 11.65% 1424.32 8.22% 270.62 14.43%
43.20 1316.04 315.99
5 14.28 410.45 76.09
11.06 12.71% 349.18 8.07% 69.20 4.74%
13 35.61 454.27 72.76
36.23 2.59% 544.59 11.86% 121.58 23.22%
34.10 593.89 101.68
14 21.05 696.51 183.96
25.75 10.03% 738.51 2.93% 180.18 1.04%
The distribution of estimated SI in the pilot has the same model assumptions
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as the clamp data fitting in Chapter 6 and its absolute SI values should thus be
comparable. The distributions of SI from the clamp and the lower dose in each
subject in this pilot study are shown in Figure 8.3 with log-normal distribution
fits. Geometric mean of the pilot SI = 11.7× 10−4 (MSD 2.3) and of the clamp
SI−clamp = 4.9×10−4 (MSD 1.5). Note that this figure is not meant to compare the
populations, just relate the ranges in SI metrics obtained in these two population
cohorts. The absolute values of SI have the same units and result from the same
model assumptions and should thus theoretically be comparable. The two cohorts
are different per design, the clamp cohort being specifically an insulin resistant
population, thus the tighter distribution at the lower mean value.
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Figure 8.3 Distribution of SI at the lower dose in each subject and corresponding log-normal
distribution (dashed), compared to the clamp population (n=146) from Chapter 6 (dotted).
8.3 Clinical Diagnostic Relevance
The diagnostic value of the proposed test is far greater than just one metric of
insulin sensitivity, as is usually the case with fasting or simple clinical tests. By
assessing the whole dynamic metabolic response and including the physiological
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models and methods, a broad picture of the state of the metabolic defect can be
derived. To visualise these aspects, the resulting glucose and insulin concentra-
tion profiles and estimated endogenous insulin secretion rates are exemplified in
Figure 8.4 for three subjects, with NGT, IFG and type 2 diabetes. All three tests
were performed at the medium dose (10 g glucose, 1 U insulin).
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Figure 8.4 Three exemplary tests (medium dose, 10 g/1 U), from top to bottom, a normal
glucose tolerant (NGT), impaired fasting glucose (IFG) and type 2 diabetes subject. Shown
are, from left to right, the blood glucose concentration, the plasma insulin concentration and
the estimated endogenous insulin secretion rate. Samples are given with error bars and areas
show the model fits.
The progression of the disease can be described well on these examples. The
NGT example, Subject 14, has an insulin sensitivity of SI = 11.7×10−4 l/mU/min,
a fasting glucose level of 4.5 mmol/l and fasting insulin level of 3 mU/l. Basal
insulin secretion rate is ub = 21.1 mU/min. The first phase β
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dogenous insulin secretion) to a bolus injection of glucose is very distinct and
large, peaking at Smax = 184 mU/min above the basal rate ub and releasing a
total amount of insulin above the basal rate of AUC10 = 697 mU. The first phase
insulin secretion lasts about 5-10 minutes, after which the secretion rate imme-
diately drops back to nearly its basal rate. This is a typical healthy metabolic
behaviour in all aspects.
The second example shows an IFG individual, Subject 16. The insulin sen-
sitivity is very low at SI = 3.2 × 10−4 l/mU/min, fasting glucose is elevated
at 6.3 mmol/l, and as a compensatory result, fasting insulin is also elevated at
16.6 mU/l. Basal insulin secretion rate is consequently three times as high as
in the NGT subject, at ub = 66.2 mU/min. In response to the glucose bolus,
the pancreas increases its output, but a distinct first phase secretion peak is not
pronounced anymore. Insulin secretion peaks at Smax = 82 mU/min above its
basal secretion rate ub and continues to produce at this rate until the end of
the test. The β-cells are producing at their limit but can only release additional
AUC10 = 578 mU over the basal rate during the first phase. The pancreas is not
able to fully compensate the low insulin sensitivity and blood glucose levels drop
slowly. This subject has probably been insulin resistant and IFG for some years
without being screened, and has now, as a result, significant damage in β-cell
function.
The third example shows Subject 11, who is diagnosed with type 2 di-
abetes. The insulin sensitivity is higher than in the IFG example at SI =
6.7 × 10−4 l/mU/min, which could be due to lasting effects of Metformin, a
sensitivity enhancing drug normally taken by this subject. The fasting glucose
level is at 6.8 mmol/l just below the type 2 diabetes diagnostic threshold of
7 mmol/l [ADA, 2006], and fasting insulin is elevated from normal at 9.2 mU/l.
Basal insulin secretion rate is ub = 33.9 mU/min and increased over the NGT
subject, but not nearly as high as the IFG subject, a sign of β-cell exhaustion.
Insulin secretion rate is slightly increased in response to the glucose bolus, but
only AUC10 = 227 mU are produced above the basal rate ub, with a secretion
peak of only Smax = 29 mU/min above the basal rate. The strongly diminished
β-cell function cannot compensate for the insulin resistance, resulting in fasting
hyperglycaemia.
These three examples show all the major stages in the progression from nor-
8.4 ADDITIONAL TESTS 149
mal glucose tolerance (NGT) to impaired fasting glucose (IFG) and type 2 dia-
betes. The information gathered from the test is able to describe and diagnose
all key metabolic defects. Note that although insulin sensitivity in the type 2
diabetic subject is twice as high as in the IFG subject, glucose uptake is still
slower due to the significantly deteriorated β-cell function in this subject. This
shows that the information from only one metric might not be enough to fully de-
scribe the metabolic defect [Ferrannini and Mari, 2004]. Similarly, an individual
could have a strong β-cell function that is able to compensate for a low insulin
sensitivity, resulting in normal fasting glucose levels and giving normal fasting
screening test results.
8.4 Additional Tests
Effect of Exercise
An additional test was performed on Subject 5 at the medium dose to assess
the difference in SI at a different level of exercise. The subject exercised regularly
and extensively during the time of the original three tests, but stopped exercising
due to injury and was tested again after three weeks of no exercise. Estimated
SI after lack of exercise was SI = 14.8 × 10−4 l/mU/min. This value represents
a 36% reduction from the mean SI = 23.2× 10−4 l/mU/min at the same dose in
two prior tests.
Effect of Systemic Mixing
The high errors on the first samples after glucose and insulin administration
suggest either contamination or incomplete mixing in plasma. It is known that
systemic mixing takes ∼10 minutes to complete [Bergman et al., 1985; Caumo
and Cobelli, 1993; Regittnig et al., 1999]. To further analyse these effects and
their impact on the fitting algorithm, the test was repeated a fourth time at the
medium dose on Subject 5, while sampling simultaneously from both arms. In
addition to the sampling protocol described above, samples were also taken at +7
and +17 minutes to increase the resolution in the first 10 minutes after glucose
and insulin administration. The resulting samples and model fits are shown in
Figure 8.5.
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Figure 8.5 Test samples obtained on Subject 5 by sampling from both arms during the test.
Double sampling was performed at +5, +7, +10, +15, +17 and +20 minutes. Shown are
samples from the arm of administration (circle) and model fit (solid), and from the other arm
(square) and model fit (dashed).
Samples taken from the arm of glucose and insulin administration (arm A)
are clearly higher than from the other arm (arm B) after the respective input,
but equalise after ∼10 minutes. The volume VG was overestimated in arm B
at VG−B = 19 l, compared to VG−A = 15.3 l, which matches the volume from
the previous tests on this subject. No differences are evident in the C-peptide
samples, which is expected as it is secreted by the pancreas and appears equally
diluted at both arms. Estimated SI are almost equal at SI−A = 18.9 × 10−4
l/mU/min and SI−B = 19.6 × 10−4 l/mU/min. This equal result is because the
algorithm accounts for noisy data within the first 10 minutes after administration
and is not sensitive to errors in estimated volume VG. This test thus further
validates the robustness of the overall method.
8.5 Discussion and Conclusions
The main goal of the pilot study was to assess the feasibility of the proposed test
in a clinical setting and to get a feel for practical aspects in performing it. The
study design consisted of two main parts, one to assess the effect of dosing and
the second to assess its repeatability. The test was performed a total of 43 times,
both in Christchurch and in Dunedin.
Overall the pilot study was successful and no major problems with tests or
8.5 DISCUSSION AND CONCLUSIONS 151
subjects occurred. The protocol and fitting algorithm proved to be reliable and
robust, and were able to produce results with considerable accuracy. The subjects
were comfortable with the procedure. Some subjects receiving the 20 g dose of
glucose complained about discomfort during the injection, which is understand-
able as it is a 40 ml injection of a rather viscous solution. Note that this is an
important advantage over tests such as the IVGTT, in which a glucose dose of
20-30 g is standard procedure.
One aspect that was evident in many tests when analysing the lab results was
the high noise in the first, and sometimes second, sample of glucose and insulin
after their respective administration. It was hypothesised that the reasons could
be mainly due to incomplete systemic mixing [Bergman et al., 1985; Caumo
and Cobelli, 1993; Regittnig et al., 1999] and/or contamination of the cannula
due to improper flushing, as it is well known that insulin binds to equipment
[NovoNordisk, 2002]. A reduction in this contamination was seen in studies in
which the cannula was flushed with the patient’s own blood before the saline flush.
A similar approach, adding 1% serum albumin to the solution, has been shown to
reduce binding [NovoNordisk, 2002; Polonsky et al., 1986a]. This method could
possibly not be applicable in a widespread clinical test, as the practice of re-
injecting a patient’s own recently drawn blood introduces further risk of blood
clotting and thus reduced safety. Instead, the algorithm thus needs to be robust
enough to account for these errors.
The effect of systemic mixing is seen very clearly in the tests performed on
Subject 5, in which blood was sampled from both arms. Mixing takes about
10 minutes to complete, which is in accordance with other studies [Bergman
et al., 1985; Caumo and Cobelli, 1993; Regittnig et al., 1999]. This factor points
out again, that samples taken between 0-10 minutes are not necessarily reliable.
This effect is also evident in the IVGTT with Minimal Model assessment and
was discussed as a cause of poor estimation in the Minimal Model in Chapter 4.
To overcome this problem, Caumo and Cobelli [1993] propose a two compartment
description of glucose kinetics, but as that approach imposes further identifiabil-
ity problems, it is not an option. Instead, as already mentioned to overcome
contamination, the algorithm needs to be able to perform without the 5 minute
sample. This limitation was imposed on the fitting method in the simple filtering
used in the pilot study data.
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In Part 1 of the study the effect of glucose and insulin dosing was analysed.
Some subjects received a 5 g / 0.5 U and a 10 g / 1 U test and some a 10 g / 1 U
and a 20 g / 2 U test. The dosing was chosen in these steps for practicality and
ease of used, and as they are all lower and more physiological than the commonly
used 20-30 g glucose and 2-5 U insulin used in the IVGTT. A dosing according to
body weight or BSA, which is commonly done [Bergman et al., 1985], was not used
as it would require individual adjustments and dilutions for each subject, which
is not practicable in a simple clinical test for widespread use where consistency
is important.
All doses were large enough to cause a significant rise in concentrations and
thus provided enough information for a model fit. Estimated SI was lower in
9/13 subjects in the higher dose test as compared to the lower dose test, but
the difference was not statistically significant. This effect has been reported
previously, where a significantly lower value in SI was found by Prigeon et al.
[1996] in an IVGTT performed at different doses. Injecting 2 U of insulin (in
an 80 kg individual) resulted in a 32% reduced SI value compared to injecting
4 U of insulin. The number of tests in this pilot study is likely too small to get
a significant result, and more controlled testing is necessary to isolate this effect
from other introduced variability.
Possible sources of error, such as insulin dilution errors, or insulin binding to
the equipment walls, can also cause a deviation in the results. These factors were
not closely monitored in this study, and will have to be addressed in any follow-
up study. Even if a systematic shift of the results is not significant, the effect
of dosing is apparent in the increased variability between doses, as compared to
the variability of repeated doses. This latter point is important to know when
comparing results obtained with the test, as they might vary at different dosing.
This effect of dosing has also been apparent in clamp tests performed at different
dosing, and has been attributed mainly to insulin saturation effects in glucose
uptake [Ferrannini and Mari, 1998; Prigeon et al., 1996].
The differences in SI were not attributed to a variability in VG or the hepatic
insulin clearance parameters nL and xL, which were very consistent in each sub-
ject, mostly unaffected by the dose used. An inter-subject difference was seen,
mainly a decrease in insulin clearance in obese and diagnosed type 2 diabetes
subjects, which is in line with the compensatory hypersecretion of insulin in re-
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sponse to an increased resistance [Ferrannini and Cobelli, 1987a; Li et al., 2006;
Valera Mora et al., 2003].
Pancreatic secretory metrics were not affected by mixing or contamination
issues, as they are estimated from C-peptide, which is secreted by the pancreas
and is thus well mixed by the time it is sampled. Basal secretion of insulin
was estimated consistently within each subject, within the expected assay noise
calculated in Chapter 5. Total first phase insulin, AUC10, was significantly larger
in all but one subject, and maximal secretion rate, Smax was larger in all but
two subjects. These results are also in accordance with the published literature,
confirming a dose dependance of insulin release [Jefferson and Cherrington, 2001].
Part 2 of the study aimed at assessing the repeatability by performing the
same dose test on each subject two or three times. The dosing was either low
or medium. The errors around the mean in each subject were in the range of
0% − 25%, with a geometric mean of 6.0% (MSD 4.9). The model fits were
good in most cases, and rarely affected by large noise in the data. The expected
accuracy assessed by the Monte Carlo simulation in Chapter 7 resulted in a
mean CVSI−MC = 4.5%. In other words, considering 2 SD, a mean 9% deviation
from the mean can be attributable to assay and protocol errors in ∼95% of the
subjects. The natural variability in SI , which was not included in the Monte
Carlo simulation, can be a source of additional variability in this pilot study
[e.g., Van Cauter et al., 1997]. The pilot results are thus in good accordance with
the Monte Carlo simulation results, possibly being slightly more variable due to
additional sources of variability.
The differences in estimated SI are not necessarily attributable to the method
itself, but can also be caused by natural variability, such as time of day [Van Cauter
et al., 1997], state of health [Hollenbeck and Reaven, 1987; Van den Berghe
et al., 2006], menstrual cycle [Trout et al., 2007] or exercise [Nishida et al., 2004;
O’Gorman D et al., 2006]. The effect of these factors would have to be assessed
in a separate study to further quantify them. However, that study is outside the
scope of this thesis.
One opportunity was taken to re-test Subject 5, who exercises regularly and
did so before each of his tests. Due to an injury, the subject had to cease all
exercise for over two weeks. The test showed a reduction in SI
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pared to the mean value at the same dose on two prior occasions. Even though
only one test was performed to assess this dynamic, the result is again in line
with published results of a very significant increase in insulin sensitivity during
exercise [Nishida et al., 2004; O’Gorman D et al., 2006]. It also further shows the
resolution of the test by capturing this change. Note that only one test cannot
be used as a reliable result and more validation of this effect is required.
Pancreatic secretory metrics were estimated with good consistency, within
the expected accuracy due to assay errors. This result shows that the greater
variability in Part 1 is mainly attributable to the different dosing used, rather
than the model, methods or protocol. These metrics also provide further diag-
nostic data, such as the increased basal endogenous insulin ub and blunted first
phase response AUC10 seen in low SI and diagnosed type 2 diabetes subjects, as
discussed in detail in Section 8.3. Combined with SI , a more complete diagnostic
picture of the metabolic defect can be drawn.
Estimated insulin secretion rate peak, Smax is likely underestimated, due to
the lack of samples during 0-5 minutes, as discussed in Section 5.1.3. By introduc-
ing a corrected peak at 1 minute, this metric could be estimated more accurately.
This approach was not applied in this pilot study, as the basic methodology was to
be tested. Even so, an inter-subject comparison is viable, as the introduced error
due to reduced sampling is systematic and should not add random variability.
The estimated insulin sensitivities can be compared to the distribution es-
timated from the clamp population in Chapter 6. The clamp study was per-
formed on insulin resistant individuals and the geometric mean is clearly lower at
SI−clamp = 4.9× 10−4 (MSD 1.5) l/mU/min than in this study SI = 11.7× 10−4
(MSD 2.3) l/mU/min, when only the lower dose tests on each subject are con-
sidered. Even if this comparison has to be considered with caution, as the clamp
values are highly dependent on assumptions of VG and EGP, the ranges seem to
be reasonably comparable.
More specifically, the type 2 diabetes subjects in the study have SI values
in the magnitude of 2-4×10−4 l/mU/min, or 5-6×10−4 l/mU/min for Subject 1
who was on Metformin, an insulin sensitivity enhancer. These latter values are
in the lower range of the clamp population, which is still normoglycaemic and
thus expected to be slightly less resistant. The range for normally sensitive
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people seems to be from ∼ 7 − 20 × 10−4 l/mU/min, and some highly sensitive
outliers show values up to over 40×10−4 l/mU/min. A complete validation of
this relationship will have to be done in a separate validation study against the
clamp, as the clamp results might also be affected by the higher dose or different
method of administration.
The final test on Subject 5, in which the effect of mixing was investigated, was
already discussed in part. One might consider changing the protocol to sample
from a different arm than the one in which administration of glucose and insulin
is done. In fact, this approach is what is done during an IVGTT [Bergman et al.,
1985] and in other similar research studies. For a simple clinical test, this option
would mean additional pain and stress for the person being tested and is also
not a good option in terms of clinical effort. As can be seen in the equal results
in SI from both sampling arms, the approach to disregard the first 10 minutes
is reliable and robust in dealing with this added noise. The contamination of
samples could also be reduced by adding serum albumin to the insulin solution
[NovoNordisk, 2002], or priming the equipment before use. In a final product, the
insulin would be pre-diluted and this issue will most likely not be a significant
problem.
Finally, the number of subjects and tests could have been larger to obtain
statistically more significant results, especially in assessing the effect of dosing.
Nonetheless, the study proved that the proposed test performs well and is very
accurate, mostly within the simulated accuracy calculated in Chapter 7. The
practical aspects learned from this pilot test allowed the fitting algorithm to be
adapted to account for unpreventable inaccuracies, such as contamination and
systemic mixing. The main sources of error were identified and accounted for by
the algorithm as well as possible, and their further effect was characterised.
Further testing is required to address possible protocol improvements to re-
duce possible sources of error, or to improve practical aspects, such as ergonomics
and sampling methods. A full validation study will also have to be performed to
finally validate the method against the gold standard clamp test. This full study
will yield experimental validation of the comparability of both metrics and the
overall correlation between both tests.
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8.6 Summary
The pilot study was designed as a proof of concept for the proposed insulin
sensitivity test. The aims were to assess the feasibility of the protocol and fitting
approach, the effect of different dosing of glucose and insulin and the accuracy in
repeatability at the same dose. A total of 43 tests on 17 subjects were performed,
both in Christchurch and in Dunedin.
The results show a greater variability in SI when different dosing is employed,
with an indication of a lower estimated SI at a higher dose test, a result that is
not statistically significant. Repeatability is very good, with accuracies within the
expected ranges simulated in Chapter 7. Accuracy and repeatability in pancreatic
secretory metrics ub, AUC10 and Smax were very good, all within the expected
accuracy defined by assay errors.
Overall, the test is accurate and the fitting method robust enough to account
for identified sources of error. The protocol is simple and short enough to be
useful in a clinical setting. Final validation against the euglycaemic clamp will
be required to completely validate the equality of both metrics.
Chapter 9
Test Optimisation
The test developed shows good accuracy and robustness, both in simulation and
in clinical testing. Optimisations of the test protocol can now be carried out to
improve practical or ergonomic aspects, and reduce the test duration and number
of samples. The overall goal is to improve its clinical applicability with no loss of
performance. In this chapter, possible steps to reduce test complexity and cost
are analysed. It concludes presenting some variations of the protocol that can be
readily implemented without a significant loss in accuracy or robustness.
9.1 Clinical/Diagnostic Improvement Goals
To optimise the insulin sensitivity test proposed in Chapter 7, the intended im-
provements, goals and acceptable compromises in accuracy need to be defined.
The key goals are:
Simplification of the protocol: For the test to be clinically practicable, it has
to be as simple and as short as possible without compromising its perfor-
mance. The proposed test is already simpler and shorter than the compara-
ble IVGTT, but any further simplification can greatly enhance its clinical
use. A systematic analysis is performed to assess the effects of targeted
sample reduction steps on outcome metrics. A reduction in samples has
the benefit of reducing assay costs, simplifying the protocol and reducing
overall time requirements for the subject and clinical personnel.
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Retain accuracy and clinical diagnostic relevance: With all possible sim-
plifications and cost reductions, an important aspect should be kept in
mind. This aspect is to not oversimplify the test and jeopardise its per-
formance, affecting its clinical diagnostic relevance and accuracy. Slight
variations in performance are acceptable, but should not alter the relevant
diagnosis obtained from the test.
Accuracy can be assessed as a relative deviation from the metrics obtained
from the full data set, and as a change in intra-individual repeatability.
The latter should be comparable to the assessed repeatability in the Monte
Carlo simulations of Chapter 7 and the pilot study results of Chapter 8.
Propose test protocol variations: The various simplified protocols do not
necessarily have to be regarded as a replacement for the original full sample
set, but rather as an expansion of the test’s applicability. Simplified test
protocols can be attractive for a clinical application that has cost or time
limitations, whereas if higher repeatability is required, such as in a semi-
research setting, a more complete sampling can be performed. A further
advantage is that the outcome metrics of these various alternative proto-
cols are equal and thus comparable. Clinical results can thus easily be
compared to research results and viceversa, an aspect that is not possible
with currently available methods [Ferrannini and Mari, 1998].
9.2 Sample/Cost Reduction
A reduction of the samples required has a triple benefit for the test. First, it
reduces complexity and stress for the clinical personnel performing it. Secondly,
assay costs can be reduced, making it more appealing for large population studies
and frequent use. Finally, it would reduce the stress on the patient being tested.
The cost reduction is based on current assay prices charged by the Canterbury
Health Laboratories, Christchurch, NZ (www.cdhb.govt.nz/chlabs). Inter-lab dif-
ferences in pricing are likely, particularly if comparing to larger U.S. or European
centres. However, relative differences between glucose, insulin and C-peptide as-
says are expected to be comparable. The price structure used is in NZ$ and
comprises:
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• Glucose: $ 2.50
• Insulin: $ 25.00 (10× glucose)
• C-peptide: $ 35.00 (14× glucose)
From these prices it is evident that any significant reduction in cost is only
possible if insulin and C-peptide samples can be reduced. A reduction of glucose
sampling would not significantly reduce costs, but could reduce complexity and
possibly the overall time required. Hence, insulin and C-peptide sample reduc-
tions impact on cost, while concomitant glucose sample reductions would then
reduce clinical intensity and improve ergonomics.
The current assay price for one test with 10 samples, as described in the
previous chapters, is NZ$ 625. Time required to perform the test, as simulated
and piloted (without overheads pre- and post-procedure), is 55 minutes. These
reference values will be used to evaluate the protocol optimisations suggested in
this chapter.
9.2.1 C-peptide Sample Reduction
Methods and Results
To minimise the number of C-peptide samples required to accurately describe
insulin secretion characteristics, it is crucial to identify key points of discontinuity
in the C-peptide concentration profile during this type of test. These points of
discontinuity are caused by sudden changes in the appearance of C-peptide, either
exogenous or endogenous. Identifying these critical points is important as they
include the key information about β-cell function. Missing these points results
in a loss of this important diagnostic outcome of the test. Common identified
changes in secretion during the clinical pilot results are illustrated in Figure 9.1
and defined:
1. Injection of glucose (D1): A sudden increase in plasma glucose triggers
a secretion burst of stored insulin (first phase) lasting 5-10 minutes that is
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often reduced or blunted in type 2 diabetes [Davies et al., 1994; Del Prato
et al., 2002]. In the C-peptide concentration profile, this dynamic is seen
as a very steep rise immediately after administration of glucose. As glucose
is administered between t = 0 and t = 1 minutes, a lag of one minute is
chosen here to account for glucose injection and initial pancreatic response
time.
2. Peak first phase secretion rate (D2): Peak C-peptide secretion rate
determines peak C-peptide concentration during the first 10 minutes post
glucose input. In the concentration profile, this point is the maximum value
CPmax, located at tCPmax, assumed between 0-10 minutes.
3. Injection of insulin (D3): A sudden increase in plasma insulin inhibits
pancreatic insulin secretion [Jefferson and Cherrington, 2001]. This re-
sponse can be significantly delayed or not evident in type 2 diabetes [Jef-
ferson and Cherrington, 2001]. In the concentration profile, this point can
be seen as a steepening of the negative downward slope soon after insulin
input. In these pilot tests, this point is not very pronounced due to the low
insulin dosing employed and might not be very critical for this study.
4. End of test (D4): The last sample is not back to the basal concentration
level in most cases due to the relatively short test duration after glucose
input. This sample thus provides an indication of the continuing secretion
after the insulin administration.
These points are typically very pronounced and consistent in healthy individ-
uals. However, they can be very gradual or blunted in individuals with diabetes,
who have an impaired first phase secretion and often have delays in pancreatic
response to glucose and insulin concentration changes. Figure 9.1 shows exam-
ples for a healthy and a type 2 diabetes subject from the pilot tests, with the
identified points of discontinuity.
Note that points D2 and D3 can be very variable in different individuals
and may introduce errors when generic points at specific times are chosen in
place of referencing the actual observed behaviour. In particular, healthy and
type 2 diabetes responses are very different in both shape and time to peak
concentration, as seen in Figure 8.4. Thus, identifying patients in transition
between these states, which is the goal of this test, requires the flexibility to
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utilise or estimate the actual dynamics and their variability. Diagnostically, this
requires any sample reductions to still account for these potential differences
without the excluded measurements.
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Figure 9.1 Example of points of discontinuity identified in the C-peptide profile during the
pilot test in healthy (above) and diagnosed type 2 diabetes (below) subjects.
The reduction of samples is done in five steps, to individually assess the
effect each step has on the final outcome. The steps are described and shown in
Figure 9.2, and specifically defined:
CP1. Only one instead of two fasting samples. All other samples remain un-
changed. This step reduces the total number of samples by one. However,
it also simplifies the protocol. Assay and natural variability can result in
different results due to this change, where two samples provided a better
baseline estimate.
CP2. The samples are reduced to 5 by limiting the samples to the points of
discontinuity. Both fasting samples are used.
CP3. A further reduction from Step CP2 to 4 samples by dropping D3, which is
not very distinct in most healthy subjects and may thus not provide too
important information for early diagnosis.
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CP4. A further reduction from Step CP3 by using only the first fasting sample.
This step uses only 3 samples.
CP5. This step uses only the first fasting sample, the points of discontinuity
D1 −D4 and the sample 10 minutes after insulin administration. This last
sample is important for the insulin profile and can thus also be analysed for
C-peptide. It can further improve accuracy in diagnosing and identifying
type 2 diabetes subjects.
The performance of each of these steps is assessed by analysing the difference
in performance and diagnostic metrics of the test, as compared to the full test
result. These metrics are SI , ub, AUC10 and Smax. The analysis is done using
the pilot data and simply excluding the selected points in the analysis. All other
methods are the same. The resulting differences are shown in Table 9.1.
Table 9.1 Difference in test results for C-peptide sample reduction Steps CP1-5. The first
column shows the number of samples (reduction from full set of 10), followed by the identified
SI , ub, AUC10 and Smax values. The difference is shown as a percentile relative change and
standard deviation (SD).
# CP Diff in Diff in Diff in Diff in
samp. SI (SD) ub (SD) AUC10 (SD) Smax (SD)
CP1 9 (-1) -0.02% (0.25) 0.56% (3.61) -2.07% (6.00) -1.97% (6.20)
CP2 5 (-5) -0.21% (1.94) 0.00% (0.00) -0.01% (0.05) 0.00% (0.00)
CP3 4 (-6) -0.44% (3.19) 0.00% (0.00) 2.43% (19.60) -2.99% (13.15)
CP4 3 (-7) -0.50% (3.14) 0.56% (3.61) 0.35% (22.71) -5.24% (15.33)
CP5 5 (-5) -0.03% (1.85) 0.56% (3.61) -2.07% (6.00) -1.97% (6.20)
The difference in intra-individual repeatability of the test introduced by the
sample reduction steps CP1-5 was not different to the original full set analysis
(6.0% (MSD 4.9)) in steps CP1 (6.0% (MSD 5.0)), CP2 (6.7% (MSD 4.2))
and CP5 (5.8% (MSD 5.1)). In the more extreme steps CP3 and CP4, the mean
repeatability was larger at 9.1% (MSD 2.8) and 9.1% (MSD 2.8), respectively, but
the MSD much tighter. The C-peptide sample reductions thus do not significantly
reduce accuracy in repeatability of the test as assessed on these pilot study data.
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Figure 9.2 Original C-peptide full sample set and C-peptide sample reduction Steps CP1-5.
Shown are the linearly interpolated C-peptide concentration samples (left) and the estimated
insulin secretion rate (right). The profile is representative of a healthy subject.
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Discussion and Conclusions
None of the five steps shown had a large effect on the estimated SI value. The
mean differences were insignificantly different from zero and the standard devia-
tions relatively tight. The same is the case for the introduced changes in accuracy
in repeatability in the different steps. Repeatability was not different to the orig-
inal full data set analysis in steps CP1, CP2 and CP5, and slightly less accurate
in steps CP3 and CP4. Clinically, these differences would have no diagnostic
impact.
The reasons for this lack of effect are that the estimated secretion rate is
only one input to the whole system. In addition, any errors in its estimation are
smoothed out by the subsequent fitting of insulin and glucose. These minimal
differences suggest that all five steps are viable alternatives if SI is the main result
of interest.
The estimated endogenous insulin secretion metrics ub, AUC10 and Smax, are
more affected by these steps, as they are directly calculated from the C-peptide
data. Basal insulin secretion, ub, is estimated from fasting information, and is
thus only affected by using one fasting sample, instead of the mean of two. The
effect on ub is thus very small and of a similar magnitude to the effect on SI . It
is also well within C-peptide assay errors, as shown by Monte Carlo analysis in
Section 5.1.4, and thus not significant.
The impact on AUC10 is not very large in steps CP1, CP2 and CP5, but
significantly larger for steps CP3 and CP4. In particular, steps CP1, CP2 and
CP5 include all samples in the first 10 minutes after glucose input (D2 and D3).
These 3 steps are therefore only affected by a change in ub, which is integrated
over this time period. In contrast, steps CP3 and CP4 do not include D3, a key
sample in some subjects. The differences are especially large in type 2 diabetes
subjects, for whom D2 is not a peak in concentration. For example, these errors
are especially large in Subject 16, but if Subject 16 is taken out of the calculation,
the SD of Step CP3 reduces to ∼15% and of Step CP4 to ∼18%. Hence, for
type 2 diabetes subjects, Steps CP3 and CP4 can introduce significant errors.
The same factors are important for Smax, as it is estimated from the same time
period immediately after glucose infusion. The standard deviations for steps CP3
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and CP4 are wide for Smax, which is again mainly caused by Subject 16. Without
this subject, they are reduced to 0.76% in Step CP3 and 5.4% in Step CP4, with
the mean values slightly improved.
The best overall approach is Step CP2, which is accurate in all metrics, but
uses only half the original samples. For practical sampling reasons, Step CP5
could be better, as it uses only one fasting sample and the 10 minute post insulin
sample, which is important for the insulin profile identification. This sample
could be dropped to further reduce the sample number to four, with no effect on
the pancreatic metrics and a slight, but not clinically relevant, difference in SI .
Overall, all steps work well for individuals with healthy pancreatic responses,
in which D2 is a clear peak in the concentration profile. In type 2 diabetes in-
dividuals, the differences in pancreatic metrics can be much larger, especially if
D3 is left out. The differences in SI are very small, and indicate that all of these
approaches are feasible if only insulin sensitivity is of importance. Clinically,
changes in endogenous insulin secretion rates may be important additional diag-
nostic markers of early insulin resistance. Hence, the choice of Step CP2 or CP5
represent the best options. Overall, the C-peptide assay costs can thus easily be
reduced by 50%− 60% (NZ$ 175-210) without compromising test accuracy.
9.2.2 Insulin Sample Reduction
Methods and Results
As with C-peptide, to minimise the number of insulin samples, the timing of key
samples in the dynamic profile have to be identified. There are two inputs to the
insulin system, exogenous insulin from the bolus and endogenous insulin secreted
by the pancreas. Thus, the considerations in reducing the number of samples
must be done by including the C-peptide sampling utilised. The important insulin
profile samples include:
• Fasting sample. Instead of using two fasting samples, one could be
dropped.
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• Two samples, 5 and 10 minutes post glucose input. These samples
are important if pancreatic secretory metrics are of interest. Dropping them
could also affect the quality of the estimated SI .
• 10 min post insulin sample. This sample is the first reliable sample that
is not affected by mixing after the insulin input. As the fast component of
insulin decay is not identifiable after 10 minutes, this sample is crucial.
• Last sample. The last sample shows how fast insulin concentrations return
to basal levels, and thus reflects insulin sensitivity and uptake, as well as
its effective removal rates via the kidney and liver.
If only these samples were used, the total number of samples could already
be reduced to 5, a cost improvement of 50% from the original 10 samples. How-
ever, the compromise in accuracy will have to be assessed, as a reduction in
diagnostic power of the test is not feasible. This tradeoff is also affected by the
assumptions or sample reductions made for C-peptide. In particular, eliminating
both insulin and C-peptide samples at specific time points will reduce blood draw
requirements.
A further possibility to reduce sampling numbers is to make use of steady
state assumptions and attempt to identify insulin kinetics with a fasting sample
of insulin and C-peptide. Since two kinetic parameters, nL and xL, are identified,
a further physiological dependency between them needs to be worked out to
achieve this goal. The parameter xL describes the fractional extraction of insulin
secreted by the pancreas, during the first pass through the liver before it reaches
the systemic circulation. It is thus the same effect as described by the hepatic
clearance rate nL.
These two parameters can be combined into one parameter by incorporating
hepatic blood flow, Fh, and total blood volume (plasma + haematocrit), VB. The
relationship between them can be defined:
xL = nL
VB
Fh
(9.1)
where the ratio VB/Fh (l/(l/min)) provides the fraction of blood flow through the
liver. The fractional extraction, xL, is thus related to nL by this constant.
9.2 SAMPLE/COST REDUCTION 167
Hepatic blood flow and blood volume can be estimated from the physiological
literature [Guyton and Hall, 2000]. Hence, blood volume can be defined:
VB = VP/(1− haematocrit) (9.2)
with mean haematocrit levels of 0.4 and 0.45 for female and male respectively
[Boron and Boulpaep, 2003]. Hepatic blood flow is defined [Guyton and Hall,
2000]:
Fh = 0.8 L/min/m
2 (9.3)
Pancreatic insulin thus appears in the plasma compartment at the rate
(1− xL)uen = (1− nLVB/Fh)uen (9.4)
where uen is the secretion rate estimated through C-peptide kinetics prior to
the first pass hepatic extraction. Rewriting Equation 3.7 in steady state form
(subscript ss) utilising these terms thus yields:
0 = −nKIss − nL
Iss
1 + αIIss
− nI
VP
(Iss −Qss) +
uex
VP
+ (1− xL)
uen−ss
VP
(9.5)
Incorporating γ = Iss/Qss and the relationship between xL and nL from Equa-
tion 9.1 with uex = 0, results in the relationship defined:
0 = −
(
nK + (1− γ)
nI
VP
)
Iss − nL
Iss
1 + αIIss
+ (1− nL
VB
Fh
)
uen−ss
VP
(9.6)
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For a fasted or measured steady state, the only unknown in Equation 9.6 is now
nL. Thus, nL can be determined analytically by rearranging that equation:
nL =
[
−
(
nK + (1− γ)
nI
VP
)
Iss +
uen−ss
VP
]1 + αI
(
Iss +
VBuen−ss
VPFh
)
Iss +
VBuen−ss
VPFh

 (9.7)
The hepatic clearance saturation αI is difficult to identify from this low dose
data, and likely has little or no effect at such low doses based on prior work
[Ferrannini and Cobelli, 1987a; Thorsteinsson, 1990; Thorsteinsson et al., 1987].
Hence, it was set to zero in the previous analysis. A good data fit could still
be achieved as the parameters nL and xL were identified accordingly. In this
case, αI = 0 results in an underestimation of insulin concentrations in 10/43
pilot tests, and is especially evident for those subjects with high fasting plasma
insulin levels, as found in IGT or type 2 diabetes. Increasing the saturation level
to αI = 0.0017, a mean value found in the literature [Thorsteinsson, 1990] and
used in glycaemic control studies [Chase et al., 2005a; Wong et al., 2006b], the
model fits are improved in the remaining subjects, with 40/43 insulin profiles
from the pilot tests within measurement error. The remaining three tests had
unreasonably large sample errors, greater than a multiple of normal assay error,
which were likely due to contaminated samples rather than realistic assay results.
The fasting identification of insulin kinetics results in similar, but increased,
values for nL and xL compared to the full data set identification. Two repre-
sentative fits are shown in Figure 9.3 for a NGT subject and a type 2 diabetes
subject. It is clear that the differences between fasting and full data identification
are clinically irrelevant.
An analysis to consider further sample reductions is performed by assessing
the reduced sample profiles in comparison to the fasting identification, due to its
minimal differences compared to the full data identification. Different options of
C-peptide profiles are also used to find an optimum, given the inter-relationship
of C-peptide and insulin. The five steps are defined:
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Figure 9.3 Two insulin profiles and modelled insulin identified with only one fasting insulin
and C-peptide sample (solid) and with the full data set (dashed). The example on the left is a
healthy subject, the one on the right a diagnosed type 2 diabetes subject.
INS1. The five critical insulin samples are used. These samples consist of only
one fasting sample, the two post glucose input samples (5, 10 minutes), the
10 minute post insulin sample (20 minutes), and the last sample. The full
10-sample C-peptide profile is used, to isolate any differences to changes in
insulin sampling alone.
INS2. The five insulin samples from Step INS1 are used. In addition, C-peptide
samples are only obtained at the same five points.
INS3. Insulin kinetics are identified using the fasting insulin and C-peptide sample
as described earlier in this section. No additional fitting of the insulin
concentration curve is done. The full 10-sample C-peptide profile is used,
to isolate any differences to changes in insulin sampling alone.
INS4. Insulin is only identified with its fasting sample, as in Step INS3. Addition-
ally, only the fasting C-peptide sample is used. A constant basal endogenous
insulin secretion rate is calculated from this sample and it is assumed to be
constant over the duration of the test. This approach obviously does not
capture pancreatic metrics, but it presents a low-cost, simple option if only
the value of SI is of interest.
INS5. This step uses the five insulin samples from Step INS1, but does not use any
C-peptide information. The insulin equation cannot be identified without
C-peptide information. Instead, plasma insulin is approximated from the
sampled data and interstitial insulin Q(t) is calculated using the approxi-
mated plasma insulin as the input to Equation 3.8. This option does not
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include pancreatic metrics, but it presents a further option if a C-peptide
assay is not available or too costly.
The resulting insulin and C-peptide profiles from these five sample reduction
steps are shown in Figure 9.4. The insulin profiles are qualitatively very similar
after the insulin bolus. A difference in the first phase insulin peak is seen in
Step INS4, in which the C-peptide concentration peak is not sampled and thus
endogenous insulin secretion is assumed to stay constant throughout the test.
The performance of the sample reduction steps is assessed by comparing esti-
mated SI , nL and xL. Pancreatic metrics ub, AUC10 and Smax are not applicable,
as they are calculated from C-peptide samples and are equivalent to the relevant
steps CP1-CP5 in Section 9.2.1. As the differences to the original sample set can
be quite large, especially during the fasting identification, a further comparison
is made in each step between the mean percentile repeatability in each subject
based on the clinical pilot test data in Chapter 8. The results are given in Ta-
ble 9.2. The repeatability metrics shown in Table 9.2 are absolute values and
are log-normally distributed. The multiplicative standard deviation (MSD) is
thus used to describe their spread. Standard deviation (SD) is used for all other
metrics, as they are normally distributed.
Table 9.2 Difference in test results for insulin sample reduction steps INS1-INS5. Given
are the number of samples (reduction from full set of 10) for both insulin and C-peptide, the
differences in SI , nL, xL, and the intra-individual repeatability. The difference is shown as
mean percent relative change and standard deviation. Repeatability is shown as mean absolute
percentile deviation and multiplicative standard deviation (MSD), as the data was lognormal
(P < 0.05).
# I # CP Diff in Diff in Diff in Repeat.
samp. samp. SI (SD) nL (SD) xL (SD) (MSD)
INS1 5 (-5) 10 (-0) -1.8% (14.9) 12.3% (51.0) -7.0% (10.2) 9.4% (2.5)
INS2 5 (-5) 5 (-5) -2.1% (15.2) 11.9% (49.9) -7.1% (9.9) 8.9% (2.6)
INS3 1 (-9) 10 (-0) -6.8% (17.4) 42.3% (66.4) 12.7% (12.7) 7.3% (1.9)
INS4 1 (-9) 1 (-9) 21.0% (30.0) 42.3% (66.4) 12.7% (12.7) 6.1% (2.3)
INS5 5 (-5) 0 (-10) -6.5% (14.1) - - 6.3% (6.7)
Original full sample set 6.0% (4.9)
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Figure 9.4 Original full sample set and insulin sample reduction steps INS1-INS5. The
plasma insulin model fits (solid) and interstitial insulin (dotted) are shown on the left, and the
linearly interpolated C-peptide concentration samples are shown on the right. The example on
the left is a healthy subject, the one on the right a diagnosed type 2 diabetes subject.
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Discussion and Conclusions
Insulin has much faster kinetics than C-peptide due to its multiple routes of
clearance. It is thus a much more dynamic peptide with larger time constants.
The insulin system has two inputs, one from an exogenous bolus injection and
the other from endogenous secretion by the pancreas. A reduction in samples
can thus not be performed without also considering C-peptide, which is used
to estimate the endogenous insulin secretion. Five different options of sample
reductions were analysed and their affect on SI assessed, both in difference to
the full sample set and in intra-individual repeatability over the cohort. All steps
were able to perform well, some with more accuracy than others.
The reduction to the five key samples identified (steps INS1 and INS2) re-
sulted in nearly identical results when either the full C-peptide sample set was
used (INS1) or just the same insulin sampling times (INS2). The mean deviation
in SI is close to zero, but the standard deviation of 15% is rather broad and may
have a clinical diagnostic impact. This result should be expected, as the insulin
decay curve is estimated from only two samples, which is much less robust to
sampling or assay error than a larger number of samples. Mean nL is slightly
overestimated, while mean xL is underestimated, both with similar SDs in both
steps INS1 and INS2.
Intra-individual repeatability is larger than in the original sample set, but
still very narrow at 9%. The multiplicative standard deviation in this case is
much tighter (2.5 vs. 4.9) than in the original set. This result indicates that
the reduced sampling set is not necessarily less accurate, even with the larger
variability, when SI is compared directly between methods. With a reduction in
insulin and C-peptide assay costs by 50% (NZ$ 300 reduction), the approaches
of steps INS1 and INS2 are very attractive.
The identification of insulin kinetics with just a fasting insulin and C-peptide
sample (steps INS3 and INS4), assuming a steady state during fasting, performs
surprisingly well given the generic assumptions used for hepatic blood flow Fh
and blood volume VB. When using αI = 0 some insulin profiles were slightly
underestimated. The largest deviations from sampled data appear to occur af-
ter the insulin bolus, when concentrations are high. When the insulin levels get
closer to their fasting values, accuracy increases. This result sug
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mation of clearance rates at high insulin concentrations with this approach, due
to the neglected saturation effect. Increasing αI = 0.0017 [Ellemann et al., 1987;
Thorsteinsson, 1990] improved the underestimated fits, while maintaining a very
good fit in the other subjects. The accurate patient-specific estimation of this
parameter is not possible on a normal low dose data set of this type. However,
merely including the effect using a population value is able to greatly improve
model performance.
The fasting ID approach of steps INS3 and INS4 is very attractive, not only
from a cost perspective (90% reduction in insulin assay cost), but also in terms
of the robustness of practical clinical aspects. Because no further insulin samples
are required, the method is completely unaffected by the often very error affected
plasma insulin samples immediately after the bolus insulin administration. These
samples were often contaminated or affected by incomplete mixing, as discussed
in Section 8.2.
The comparison of Step INS3 to the full sampling set shows larger errors in SI
and nL and broader SDs, which does not automatically invalidate the approach.
These deviations can also be caused by more variable original data due to sample
errors, which does not affect the fasting ID. In fact, the repeatability is improved
in this case, at nearly the same mean value, but with a much tighter MSD. The
subjects in which the between test variation is large in the original assessment,
mostly had large errors in portions of their sample sets. With the fasting ID, the
results were thus more consistent. The drawback of the fasting ID is that the
endogenous insulin input, estimated through C-peptide is still required. However,
a reduction of C-peptide to five samples should not affect the performance, as
can be seen in the result of Step INS2.
The two more extreme sample reduction steps, INS4 and INS5, were analysed
to test two special scenarios. These approaches can be necessary if, due to cost
or simplicity, only a fasting sample of C-peptide and insulin can be taken. The
rest of the samples are then only assessed for glucose (Step INS4). The second
case would occur if a C-peptide assay is not available and only insulin can be
sampled (Step INS5).
In Step INS4, in which endogenous insulin secretion is assumed to stay con-
stant throughout the test, the difference to the original assessment is largest due
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to completely missing any first phase β-cell response. Interestingly, the repeata-
bility is still very tight, even better than Step INS3 and much tighter than the
original set. This result may occur because the incorrect assumption on endoge-
nous insulin secretion is equally incorrect in all respective tests and may thus
effectively cancel. Because no dynamic assessment of C-peptide is performed, no
pancreatic insulin secretion metrics can be assessed. From a simplicity and cost
perspective, this option can be very interesting if only the value of SI is required.
Step INS5 has interesting results as well. In this case, no C-peptide sample is
taken. This simplification does not allow an insulin model identification, as this
significant endogenous insulin input to the system is not known. Nonetheless, the
insulin profile can be estimated with the same approach used in the integral fitting
method, as described in Chapter 3, and Q(t) calculated using the approximated
plasma insulin I(t) as input to Equation 3.8. The approach is very accurate, both
in relative SI and in repeatability, although slightly broader than the original set
in this limited pilot study.
To pick the optimal option, the requirements and facilities available have
to be determined. If cost is not relevant and good accuracy is required, more
samples can be included. As shown, a reduction to half the samples (5) can be
readily undertaken without compromising diagnostic performance (Step INS2).
Using only a fasting insulin sample (Step INS3, INS4) results in an increased
repeatability for SI , as compared to the original data set, but also in a reduction
of accuracy for other potentially useful clinical metrics. Overall, this analysis adds
to the robustness and versatility of the method by outlining all the potential
tradeoffs in terms of the test and thus clinical or diagnostic outcomes. From
these results, any form of the test could be created with an understanding of
the tradeoffs involved. In terms of economical aspects, the insulin and C-peptide
assay costs can now be reduced by at least 50%, thus creating an initial 40+%
reduction in assay costs from the full test.
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9.2.3 Glucose Sample Reduction
Methods and Results
The main incentive for the reduction of glucose samples is not cost as it was for
insulin and C-peptide sample reductions. Glucose sample reductions are analysed
to improve clinical practicality and shorten the overall test. The key samples for
the glucose profile are a fasting sample, the 5 or 10 minute post glucose input,
and two samples at least 10 minutes after that. The 5 minute sample is highly
affected by mixing and/or contamination, as was seen during the pilot test, and
is thus not considered to be always reliable. The 20 minute sample is chosen, as
sampling at this time is required to identify the insulin kinetics. A further sample
is needed, which can be either at 30 minutes or later, such as the last sample at
45 minutes.
This approach yields four key samples, at 0, 10, 20 and 30 (or 45) minutes.
To approximate the glucose concentration decay, a linear interpolation is not
reliable anymore, as not enough closely timed samples are available, which would
introduce larger errors to the integral-based fitting method. Instead, a single
exponential decay is approximated between the last three samples. In all the
following glucose sample reduction analysis steps, the four glucose samples are
used. In this analysis, different combinations of reduced insulin and C-peptide
sampling protocols are tested while using only these limited key glucose samples.
Six steps are assessed, as described here and shown in Figure 9.5:
G1. Glucose is sampled at t = 0, 10, 20 and 45 minutes. For insulin and C-
peptide the full data sets are used, to isolate the effect of glucose sample
reductions.
G2. Glucose is sampled at t = 0, 10, 20 and 45 minutes, but only five C-peptide
and insulin samples are used, as described in Step INS2. This approach is
clinically more practical and less intense, as sampling is only performed at
five time steps.
G3. Total test time is reduced, by replacing the 45 minute sample with the
30 minute sample. This is also done for insulin and C-peptide. Test time is
now only 30 minutes, a reduction of 25 minutes from the original protocol,
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with glucose sampled at t = 0, 10, 20 and 30 minutes, and insulin and C-
peptide at t = 0, 5, 10, 20 and 30 minutes.
G4. Glucose and C-peptide samples are sampled at t = 0, 10, 20 and 30 minutes,
but only a fasting insulin sample is used.
G5. Glucose is sampled at t = 0, 10, 20 and 30 minutes, but only one fasting
insulin and C-peptide sample is used. Insulin kinetics are identified from the
fasting samples and basal C-peptide secretion is assumed to stay constant
throughout the test as in Step INS3. This step introduces the option of
only one complete fasting sample and possibly only capillary glucose testing
thereafter. Thus, this test could remove the need for a cannula, as well.
G6. Glucose is sampled at t = 0, 10, 20 and 30 minutes. No C-peptide sample is
taken and insulin is interpolated between these five samples, as described in
Step INS5. This approach could be attractive for cases in which a C-peptide
assay is not available.
Test performance is again assessed by comparing the mean relative percentile
difference in estimated SI . As a further comparison, correlations between the
estimated SI values are calculated. Finally, the mean repeatability for SI in each
subject (Clinical pilot test Part 2, Chapter 8) is presented. The results are given
in Table 9.3. Correlation plots are shown in Figure 9.6. Estimated VG was equal
in all steps, and similar to the original full sample set, with a mean difference of
-0.85% (SD 3.8%).
Discussion and Conclusions
The sample reduction analysis steps for glucose show that only four samples are
necessary to achieve an almost equally good estimation of SI , if insulin and C-
peptide are fully sampled (Step G1). More samples could also be used, but enough
information is found in these four when compared to the original results. All six
steps were thus carried out with the same minimal glucose sampling protocol,
while the combinations with different reduced insulin and C-peptide sampling
protocols were tested.
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Figure 9.5 Original full sample set and glucose sample reduction steps G1-6. Shown are the
glucose (left) and insulin model fits in plasma (solid) and interstitial fluid (dotted) (middle),
and linearly interpolated C-peptide concentration samples (right).
178 CHAPTER 9 TEST OPTIMISATION
Table 9.3 Difference in test results for glucose sample reduction steps G1-6. Given are the
number of samples (reduction from full set of 10) for glucose, insulin and C-peptide, difference
in SI , correlation between SI and original full set SI and the intra-individual repeatability.
The difference is shown as percentile relative change and standard deviation. Repeatability is
shown as mean absolute percentile deviation and multiplicative standard deviation (MSD).
# G # I # CP Diff in Correl. Repeat.
samp. samp. samp. SI (SD) r (MSD)
G1 4 (-6) 10 (-0) 10 (-0) -10.6% (19.0) 0.96 7.0% (2.9)
G2 4 (-6) 5 (-5) 5 (-5) -6.3% (18.3) 0.96 8.8% (3.1)
G3 4 (-6) 5 (-5) 5 (-5) -6.9% (22.1) 0.89 10.5% (3.7)
G4 4 (-6) 1 (-9) 5 (-5) -8.7% (28.1) 0.80 6.8% (3.4)
G5 4 (-6) 1 (-9) 1 (-9) 15.3% (35.9) 0.81 4.9% (4.3)
G6 4 (-6) 5 (-5) 0 (-10) -7.8% (23.0) 0.90 7.3% (6.5)
Original full sample set 6.0% (4.9)
The deviations from the original set get larger as less insulin and C-peptide
samples are used. This result is expected, as errors accumulate from model to
model, and the glucose model is affected by both insulin and C-peptide. This
effect can be seen in the correlations calculated in the different sets. Whereas the
correlation between the Step CP5 SI and the full set SI is r = 1.0, it is reduced
to r = 0.96 in insulin Step I2, and is still r = 0.96 in glucose Step G2. All
three steps use the same samples and accumulate their errors. The error in this
case is mainly introduced by reduced insulin sampling, with reduced glucose and
C-peptide sampling not having a large impact. These three specific correlations
are shown in Figure 9.7 for clarity.
The intra-individual repeatability is still very good in all steps. In particular,
most of the MSDs are even tighter than the original set. However, a tighter MSD
may only imply a more repeatable, but also potentially more erroneous result.
The mean repeatability values are larger than in the insulin steps, which is again
due to the additional model included in this case.
Due to the low number of tests, only two or three in each subject, it is difficult
to compare the intra-individual repeatability of these sample reduction steps to
the repeatability assessed by the Monte Carlo simulations in Chapter 7, as any of
these few tests could be an outlier. Nonetheless, a simple comparison is possible.
The mean CV in SI assessed in the 500 Monte Carlo runs was CVSI−MC = 4.5%,
meaning that ∼95% of SI values (2 SD) are within 9% of the mean and ∼100%
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Figure 9.6 Correlations between the original full sample set and glucose sample reduction
steps G1-6.
(3 SD) are within 13.5%. All the mean sample reduction steps G1-5 are within
3 SD of CVSI−MC , with only G3 at 10.5% larger than 2 SD. Note that although
the MSD’s are relatively large, no subject had a larger deviation than 28.9% in
all analysed sample reduction steps. This comparison shows that a large part
of the variability could potentially be attributable to assay and clinical protocol
errors.
The reduction in total test time to only 30 minutes in steps G3-G5 is very
attractive. In particular, this choice reduces personnel cost and subject time by
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full set SI . The left plot shows only C-peptide sample reduction Step CP5, the middle plot
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50% as compared to the full protocol. The effect of this reduction is clear when
comparing Step G3 to G2, as the only difference between them is the timing of
the last sample (45 vs. 30 minutes. Repeatability is slightly worse in G3, but this
result is within the expected variability introduced by assay errors, as a different
sample is used.
One drawback that is evident is a loss in robustness. Reducing the samples to
only the most critical four, leaves no redundancy if one of these is contaminated.
Such contamination error occurs in three tests in which the 30 minute sample is
clearly too high to be within expected noise, as discussed in Section 8.2. These
three tests are still included in the analysis, producing the increased deviation
in Step G3. Hence, a contaminated sample could effectively ruin the entire test
result.
In contrast, a source of error in Step G2 is an increase in glucose concentra-
tions if the test lasts too long and EGP begins to increase. In these cases, the
decay in glucose cannot be estimated by a single exponential decay, as the real
curve is affected by a changing EGP. This occurs only in highly insulin sensitive
individuals, but negatively affects the accuracy of Step G2. This artefact speaks
in favour of Step G3. However, it is clinically not critical as these individuals do
not match the target group for this test.
The steps using a fasting identification of insulin (steps G4-G5) are not af-
fected by contaminated insulin samples, as discussed in the insulin steps of Sec-
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tion 9.2.2, and are thus much more robust in some ways. While glucose samples
are still required, they appear to provide more stable SI results than the pilot
test. The deviations in SI in Step G4 are not larger than in the preceding steps
and the accuracy in repeatability is even increased. Even Step G5, which only
makes use of a fasting C-peptide sample is reasonably accurate in SI . Step G6
performs similar to G3, given the almost equal insulin information, and thus pro-
vides an option to perform the test with good accuracy without the need of a
C-peptide assay.
The correlations in the first two steps are very high at r = 0.96. As discussed
previously, this reduction from r = 1.0 seems to be attributable to reductions
in insulin sampling. When an earlier sample is taken as the last sample, this
correlation is reduced to r = 0.89, which reflects the measurement and mixing
noise seen in the data used. The same correlation is seen in Step G3, which is
expected because they share the same insulin sampling protocol. The two fasting
identifications, steps G4 and G5 are less accurate at r = 0.80 and r = 0.81.
The reasons for a reduced correlation for any sample reduction steps versus
the full pilot test case can be explained well when looking at Figure 9.6. As can
be seen, steps G4 and G5 include some high deviation points caused by outliers
in the high SI range of 20− 40× 10−4. As noted, this high range is not clinically
or diagnostically relevant. The accuracy in the normal to low range targeted by
this test is much tighter.
The compromises in accuracy are expected, given the heavy reduction of
samples. With the lowest correlation at r = 0.80, the steps are still relatively ac-
curate. More practically, these reduced protocols now provide a variety of options
for different variations in the test protocol, depending on the available resources
and expectations. Hence, these analyses provide not only cost and intensity re-
ductions, but propose different protocol options for the same test metrics. A suite
comprising a range of tests with varying degrees of intensity is thus presented,
that enables a direct comparison of outcome metrics between them, an aspect
that is not possible with other currently available tests [Ferrannini and Mari,
1998; Radziuk, 2000].
Overall, the further simplification of the test by reducing glucose sampling
along with insulin and C-peptide sampling resulted in acceptable accuracy. The
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losses in accuracy can be counterweighed by an increase in practicability and a
reduction in assay cost and time, where reduced test time also reduces the cost
of personnel. Even if higher accuracy is required, a 30 minute test with five
samples of glucose, insulin and C-peptide results in almost equal performance,
at half the cost and time, as long as no samples are contaminated. Finally,
even with the larger spread in some extreme sample reduction steps, clinical
diagnostic performance was not jeopardised. A diagnosis of an individual at risk
of developing type 2 diabetes would not have differed if any of these variations
in protocol were used.
9.3 Practical Aspects
Besides a reduction in samples, further aspects of the test can be optimised
to improve robustness and ease of use with the goal of ensuring more ready
acceptance by clinical personnel and subjects. Some aspects that came up in
discussions during and after the pilot test are described here, with an eye towards
possible test improvements:
Contamination and Systemic Mixing: As discussed in Chapter 8, samples
taken within 10 minutes after glucose or insulin administration are strongly
affected by mixing and sometimes contamination due to imperfect flushing.
Sampling from the other arm can reduce these sources of error and give
a more accurate picture of the true concentrations. This approach would
not be very practical, as the test subject would have both arms punctured,
making the test much more invasive. In a more research based setting,
this approach can be feasible. Alternatively, a heating of the cannulated
arm can be performed to improve blood flow and mixing [Ferrannini and
Mari, 1998]. To reduce contamination, flushing can be improved by methods
such as including serum albumin [NovoNordisk, 2002] or similar approaches.
Nonetheless, this issue is not a major problem as the algorithm is already
tuned to work without these samples if they are affected.
Dosing: The administration of glucose should be limited to ∼10 g or less. When
20 g of glucose was administered, many subjects complained of slight pain
or uneasiness. This affect is due to the fact that glucose is diluted in 50%
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saline and 40 ml of this very viscous solution is required. Hence, its bolus
injection is not always comfortable. The performance of the test method is
not affected by a dose lower than 20 g, as seen in the results of Chapter 8.
Sample Timing: Sample timing accuracy is important to achieve a good model
fit. If samples are timed too tightly, it becomes very difficult for clinical
personnel to adhere to accurate sample timing. Due to unexpected and
unpredictable delays in drawing the samples that were encountered in ini-
tial clinical practice, delays of 1-2 minutes can easily be introduced. The
recommendation is thus not to time samples less than 5 minutes apart. A
10 minute gap is more practical. To further improve robustness, the timing
should be linked to the respective administrations of glucose and insulin.
For example, it is easier to obtain a better timed sample if the timer is
restarted after the insulin is injected, as opposed to using the glucose bolus
at t = 0 as a baseline.
Combined Injection of Glucose and Insulin: Glucose and insulin could be
administered at the same time, ideally from the same syringe. Insulin is
not degraded if diluted with glucose [NovoNordisk, 2002] and the two could
potentially be mixed into a single bolus dose. This approach would increase
robustness and ease of use. A drawback is that due to the immediate rise
in exogenous insulin, no information about the initial first phase β-cell
response would be available. In contrast, if this information is not required,
the test time could be further reduced by 10 minutes to a minimum of only
20 minutes. How this method compares to the original protocol will have
to be validated in pilot testing, but it is an aspect worth pursuing as part
of a suite of such tests.
Capillary Glucose Sampling: If one of the fasting sample identified protocols
is used, such as Step G5, only one full sample needs to be drawn at fasting
state to assay for glucose, insulin and C-peptide. All other glucose samples
could potentially be drawn from capillary blood and analysed on the spot
with a home glucose monitor [Chase et al., 2006; Johnson and Baker, 1999].
The advantage would be that the fasting sample and the injections can be
done with a venous puncture, with no need of a cannula to be inserted for
the duration of the test. With only 3 additional glucose samples needed,
this approach is potentially very cost efficient, simple and attractive to the
subject. Differences in performance caused by capillary blood will have to
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be assessed in a separate validation, however the sample errors for such
devices are not too large [Johnson and Baker, 1999] to affect the basic
models and methods utilised. Again, this approach has significant merits
worth piloting clinically.
9.4 Summary
Possible optimisations of the test protocol were systematically analysed for all
three assays. The focus was mainly on cost reduction, improved robustness,
a simpler protocol and reduced overall test time. Special consideration was also
given to limited or special situations, such as where no C-peptide assay is available
or financial limitations only allow one sample of insulin and C-peptide.
The sample reduction analyses were carried out in a stepwise manner, first
analysing C-peptide, then insulin and finally glucose. This approach is important,
as the models build upon each other in that order in the fundamental methods
presented. These assays thus affect overall variability in that same order.
Total sample numbers, and thus assay costs, could be halved to only five,
without necessarily compromising test performance and thus diagnostic outcome.
A further reduction of the much more costly insulin and C-peptide samples was
presented, which identifies the insulin kinetic parameters with steady state anal-
ysis and only a fasting sample of both peptides. Financially limited scenarios can
thus be catered for with a simple and low cost, although slightly less accurate,
test.
By eliminating one of the fasting samples and the last two glucose samples,
overall test time could be reduced by 25 minutes to only 30 minutes. This ap-
proach requires no C-peptide sampling but thus yields only an insulin sensitivity
assessment SI and no additional pancreatic performance measures or diagnosis.
The compromise in accuracy is minimal and the correlation between SI values of
the full protocol and this reduced version is r = 0.96.
Further observations and suggestions for improvements experienced first hand
during the pilot study are also discussed. These suggestions improve the ease of
performing the test and overall test robustness. Overall, the results presented
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in this chapter greatly improve the clinical practicability and cost of the test,
without a great compromise in accuracy. The final result is effectively a suite
of tests with known tradeoffs in accuracy, robustness, repeatability, cost and
performance measures available.
Chapter 10
Conclusions
Diabetes has reached epidemic proportions worldwide. In particular, both the
total number of affected individuals and the level of associated complications is
growing for this chronic disease. Thus, the increasing number of major compli-
cations, such as polyneuropathy, blindness, kidney failure and limb amputations,
are beginning to consume a major and increasing portion of worldwide healthcare
costs.
One of the key pathological factors leading to type 2 diabetes is insulin resis-
tance (IR), an impaired ability of the body to make use of available insulin. IR
is evident up to 10 years before type 2 diabetes is diagnosed. Diagnosed early
enough, there is the opportunity to initiate appropriate treatment and lifestyle
interventions to prevent and significantly mitigate the effects of this disease. How-
ever, an accurate, yet simple, test to provide such early diagnosis of IR is not yet
available for practical use in a clinical setting.
This thesis aimed at developing such a test, that is both accurate and re-
peatable, yet simple, cost effective and short enough to be accepted in a clinical
setting. The test design incorporates physiological modelling and engineering
techniques to match clinical requirements and provide outcome metrics that can
support the clinician in a more complete diagnosis of metabolic defects associated
with IR and pancreatic β-cell function.
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Insulin Sensitivity Test and Technological Outcomes
A model-based test allows the estimation of metabolic states and defects with a
minimally invasive test protocol. This minimal test is achieved by compensating
for the lack of measured data with physiologically accurate models and param-
eters. A much more accurate and complete assessment of the metabolic system
is thus possible, than just analysing the raw data. A short clinical test that
was specifically developed by integrating practical clinical aspects and modelling
techniques has not yet been presented.
The PK and PD models presented in this thesis were developed specifically
to account for the key metabolic dynamics in glucose, insulin and C-peptide in
such a short test protocol. Paired with the identification methods presented,
physiologically valid parameters can be obtained that enable accurate metabolic
assessment. The identification methods combine a-priori knowledge, parallels
between C-peptide and insulin, and a novel convex integral-based fitting method
to enable unique physiological model identification on limited clinical data.
The models represent simplified descriptions of the much more complex un-
derlying system. When fitting them to clinically obtained data, unmodelled dy-
namics can affect the fitting process negatively and result in over- or under-
estimation of key model parameters. By identifying these unmodelled dynamics,
the fitting algorithm was optimised to only account for relevant sections of the
sampled data, thus improving robustness and repeatability of the overall method.
Model parameters that cannot be identified reliably on these short test data
were fixed to mean population values. These assumptions allow observed vari-
ability to be captured by only one key parameter, insulin sensitivity SI . This
approach also matches the assumptions of the gold standard euglycaemic clamp
test, which attributes all glucose uptake to insulin-dependent effects. The mod-
els are thus designed to correlate well to the gold standard test, as variability
in insulin uptake is only attributed to insulin. In fact, validating the models on
n=146 clamp trials, very good correlations of r = 0.92 and r = 0.99 were found
in transient and steady states, respectively.
The proposed test protocol was specifically designed with practical clinical
aspects in mind and was simulated in a Monte Carlo analysis prior to clinical pilot
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testing. The Monte Carlo results show expected repeatability accuracies close to
the clamp test. Clinical pilot testing confirmed these results. Mean repeatability
accuracy was close to that assessed in simulation and showed good resolution in
capturing different levels of insulin sensitivity. By including C-peptide sampling
to estimate pancreatic insulin secretion, a full picture of basal and first phase
β-cell response can be obtained. The fitting algorithm proved robust and fast in
fitting all test subjects, without any prior data analysis and intervention.
Finally, optimised test protocols were proposed by systematically re-analysing
sample reduced data sets of the pilot test data. Overall test time could be reduced
to only 30 minutes and the number of samples reduced to 5 or less, without
significantly reducing accuracy in repeatability in all metrics. The result is a
suite of test protocols, suitable for a wide range of clinical and research settings,
and providing a means of assessing overall metabolic state of insulin sensitivity
and β-cell function with just one short and cost efficient test.
This outcome is a substantial contribution to modelling knowledge and clin-
ical engineering, as the modelling work and protocol design were intentionally
guided by practical clinical requirements and aspects. The result is thus a very
robust test that can be performed by clinical staff without the need of prior data
analysis or modelling expertise. A similarly good test performance has not been
achieved previously in this field.
Clinical Outcomes
The clinical and diagnostic value of current clinical tests to assess IR is very
limited. Their resolution is crude, usually only allowing the use of a threshold
value as a cut-off point for the diagnosis. Due to this low resolution, a diagnosis of
IR and β-cell dysfunction is only possible once the pathology is well advanced and
significant irreversible damage has been occurred. Thus, current diagnostic tests
do not offer the opportunity to intervene before significant future complications
and costs become inevitable.
The insulin sensitivity test proposed in this thesis has the high resolution and
repeatability necessary to detect declining insulin sensitivity and β-cell function.
Furthermore, it could be used to monitor these metabolic markers in identified
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high risk populations and intervene early to prevent or delay the onset of further
complications. Hence, it offers this opportunity to prevent future complications
and costs.
The metabolic information that can be obtained from the proposed test is very
broad. Besides insulin sensitivity, SI , the test yields information about various
β-cell performance metrics. These metrics are important markers to assess the
progression of the disorder. The test thus draws a complete picture of the extent
and progression of metabolic disorder.
The intensity of the test is very low compared to similarly accurate tests.
Nonetheless, its intensity could be considered high for wider clinical settings
in which the lower resolution OGTT is the current test of choice. This slight
increase in intensity is the compromise required for the vast increase in accuracy,
resolution and metabolic information.
To simplify the test and broaden its field of application, different sample
reduction steps were proposed, minimising the clinical intensity without a signif-
icant loss in accuracy. Possible alternatives include a shortened version that re-
quires 30 minutes and five samples, or an option that only requires one full venous
sample and three additional capillary blood samples over the next 30 minutes.
Overall, a range of possible protocols were presented for different clinical
requirements and target settings. All tests measure the same effects and thus
yield comparable outcomes, a feature not available in any other test so far. Direct
comparisons between clinical and research study results are thus made possible.
Finally, the proposed insulin sensitivity test is repeatable and robust, yet
simple, short and cost efficient. The broad metabolic information obtainable
from the test can help the clinician to improve the diagnosis and thus improve
treatment. High risk populations can be diagnosed much earlier and the onset of
complications thus delayed, improving overall healthcare, saving lives and cost.
The contribution of this research outcome to the field of diabetes management
and diagnosis is substantial. Diagnostic outcomes previously only available with
complicated and intense tests in a research setting can now be made available to
routinely diagnose at risk individuals. This greatly improved diagnostic capability
can significantly change the way diabetes is currently managed.
Chapter 11
Future Work
The insulin sensitivity test presented in this thesis performs well and is prac-
tical enough for use in a clinical setting. Nonetheless, research and validation
have to be continued to fully validate the test performance and its comparison
against gold standard methods on different subgroups of individuals. Additional
optimisation can also be implemented to improve the practical aspects of all the
protocols presented and further simplify their eventual use.
11.1 Further Clinical Validation
11.1.1 Test Performance
Clinical validation is important to create confidence and credibility in the test.
Additional test validation is also necessary to strengthen the results in repeata-
bility and the effect of dosing obtained from the first pilot study presented in this
thesis. Particular important aspects include:
Effect of dosing: This aspect was tested in the pilot study presented in this
thesis, but the test and subject numbers were not large enough to obtain
a significant result. With a more controlled test environment and a larger
number of test subjects, the impact of outliers can be reduced and a more
clear result obtained.
Repeatability: This aspect was also tested in the pilot study and showed very
good results. Some outliers were still evident, and a validation with larger
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subject numbers and possibly more tests on each subject could yield more
confidence in the results. More controlled environmental aspects, such as
time of day, state of health, previous exercise, or stage of menstrual cycle
in female subjects should be observed to minimise variability in insulin
sensitivity introduced by a natural cause.
Wider range of insulin sensitivities: To obtain a comparable scale of ex-
pected insulin sensitivities, and an idea of at-risk ranges, a large number
of subjects from various subgroups and risk populations would need to be
tested. With a complete range of expected sensitivities, results obtained in
each subject could be classified in comparison to that scale.
11.1.2 Validation Against Gold Standard Tests
Clinical validation against gold standard tests is important to validate the test
metrics against established methods. The model has shown good performance
when fitted to euglycaemic clamp trial data, but a clinical validation, in which
each test is performed on the same individual will provide final confirmation of the
comparability of both test metrics. Additional validation should be performed on
further research tests, such as the IVGTT, or clinical tests, such as the OGTT.
These comparisons against established methods will create comparability
scales of each test metric for better inter-study comparison of results. This ability
to easily compare results is important, as many tests effectively measure slightly
different effects of insulin sensitivity and yield different direct or surrogate met-
rics.
11.2 Practical Clinical Improvements
11.2.1 Combined Administration of Glucose and Insulin
A simplification of the test in terms of time, protocol and intensity could be
achieved by combining the administration of glucose and insulin into one syringe.
This change would require only one injection and thus significantly simplify the
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protocol for medical personnel, and also reduce the intensity for the subject.
Mixing of insulin with glucose does not affect the stability of insulin [NovoNordisk,
2002], and is, in fact, common practice in some critical care units (Dr. Geoff Shaw,
personal communication).
One drawback from this approach is that assessment of the first phase re-
sponse of the β-cells would not be possible, as the simultaneous increase in both
concentrations would inhibit endogenous insulin secretion. Hence, assessment of
β-cell function would not be possible. The protocol could still be attractive, if
the focus is on only assessing insulin sensitivity, or the reduced test time is im-
portant. Validation of this protocol variation would have to be carried out to
assess any difference it might introduce to the outcome metric.
11.2.2 Reduce Fasting State Requirement
The fasting state requirement is a common aspect of all insulin sensitivity tests
and is necessary to eliminate the impact of any remaining postprandial glucose
or insulin appearance in plasma that could alter the results. This requirement is
a limiting factor for a more frequent application of the test, as all tests need to be
performed in the morning after an overnight fast. Further testing in the afternoon
is not possible, unless the subject fasts all day. This aspect could increase the
flexibility of a test, as it could be performed during any doctor’s visit without
significant prior preparation.
With the knowledge of the appearance rate of endogenous glucose and in-
sulin, the fasting state requirement could be eliminated. Insulin secretion by the
pancreas is not a problem, as it can be estimated well by sampling C-peptide.
Glucose appearance from the gut cannot be measured easily and would have to
be estimated. With moderate knowledge about the subject’s last meal or snack,
the appearance rate can be estimated within a reasonable range. By also knowing
the starting glucose value at the beginning of the test, the introduced variability
can be limited to the appearance rate.
This approach needs to be assessed in Monte Carlo simulation studies as well
as in clinical validation. It could be possible that a partial fasting of 2-4 hours is
still required, as by that time the postprandial glucose peak is mostly over and
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the glucose appearance from the gut is more stable and can be estimated more
robustly. Nonetheless, even a reduction to 2-4 hours of fasting would enable the
test to be performed at various times during the day, such as in the morning,
before lunch and later in the afternoon. This added flexibility could further
enhance the applicability of the test in a wider clinical or screening setting.
11.2.3 Practical Protocol Aspects
The practical aspects of the test, such as the technique to sample blood, admin-
ister the injections of glucose and insulin, and the timing of samples need to be
very robust to be reliable in a widely used clinical application. Market research
of possible blood sampling devices and methods has to be carried out to find the
least painful and most robust approach. One variation could be to use venous
punctures instead of a cannula. Multiple venous punctures could be more painful
for the subject than inserting a cannula once, but would also reduce potential
contamination and blood clotting. The sampling routine could also be simplified,
as no flushing of the cannula would be required.
The timing of samples and injections, which is critical for the computational
portion of the test, needs to be easy to accurately manage by a sole clinician or
nurse performing the test. One possible solution would be an electronic timing
device, similar to a calculator, with customised buttons to press after each sam-
pling step. A beeping signal could also be implemented to anticipate the next
sample. The timing of samples could be stored by the device and eliminate any
manual time keeping and logging, thus increasing reliability of this aspect of the
test.
11.3 Outlook - Potential Additional Applications
Besides providing a clinical diagnostic test for early diagnosis of IR and β-cell
dysfunction, this test offers opportunities for drug development and optimising
current therapeutics. Potential applications could be to test the effect of insulin
sensitisers [Gerstein et al., 2006; Kahn et al., 2006a], combination therapies, or
drugs promoting insulin release [Larsen et al., 2007]. By directly assessing the
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metabolic disorders being treated, instead of waiting for surrogate markers, such
as fasting glucose, to indicate a significant effect, dosing and drug selection of
hypoglycaemic agents could be improved.
Finally, the test developed in this thesis offers great potential for improved
diagnosis and treatment of the risk of type 2 diabetes and the disease itself.
Validation against currently accepted methods will provide confidence in the
test’s performance, and further optimisations in practical aspects can improve
its widespread clinical use. Additional potential applications of this test, such as
optimisation of dosing of medication and other treatments can further improve
overall diabetes care.
Appendix A
Current Insulin Sensitivity Tests
This appendix includes three tables summarising aspects of current insulin sen-
sitivity tests described in Chapter 2. The three tables on the following pages are
separated into intravenous, oral and fasting tests, respectively.
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Table A.1 Intravenous insulin sensitivity tests.
Test Time Samples Input Calculation Repeatability Use Notes
Subject: G: 12-24+ I infusion spreadsheet CV=6-10%1 research +gold standard
Clamp 180-300 min I: 4-8+ 40-1200 only +very repeatable
Staff: CP: opt. mU/min/m2 -supra-physiological
180-300 min var. G infusion -special equipment
-trained personnel
Subject: G: 13 ∼20 g G bolus spreadsheet CV=21%2 mainly +short, simple
IVGTT Kg 60 min I: 13 research/ -inaccurate in IR/
Staff: limited diabetes
60 min clinical
Subject: G: 12-30 ∼20-30 g G bolus computer CV=14-82%3 mainly +repeatability
IVGTT-MM 240 min I: 12-30 ∼2-4 U I bolus software research/ +broad information
Staff: CP: opt. optional limited -many samples
240 min tolbutamide clinical -long duration
Subject: G: 7 ∼8 U I bolus spreadsheet CV=7-31%4 mainly +short, simple
ITT 90 min research/ -high hypo risk
Staff: limited
90 min clinical
Subject: G: 5 ∼0.4 g/min computer CV=17-21%5 mainly +safe
CIGMA 90 min I: 5 G infusion software research/ +physiological model
Staff: CP: 5 for 60 min limited -inaccurate in IR/
90 min clinical diabetes
1 [DeFronzo et al., 1979; Mari et al., 2001; Monzillo and Hamdy, 2003]
2 [Galvin et al., 1992]
3 [Ferrannini and Mari, 1998; Mari and Valerio, 1997; Monzillo and Hamdy, 2003; Scheen et al., 1994]
4 [Gelding et al., 1994; Monzillo and Hamdy, 2003]
5 [Hosker et al., 1985; Nijpels et al., 1994]
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Table A.2 Oral insulin sensitivity tests.
Test Time Samples Input Calculation Repeatability Use Notes
Subject: G: 1 75 g oral G - CV=15-40%1 clinical +simple, safe
OGTT 2-h 120 min change in status +low cost
Staff: in 30-60% of cases ADA -low repeatability
20 min after repeat test2 recommended -surrogate metric
-lumped effects
Subject: G: 1-7 75 g oral G spreadsheet CV=7-15%3 clinical/ +simple, safe
OGTT 120-180 min I: 1-7 limited +more reliable
Matsuda Staff: research than OGTT 2-h
Stumvoll 20-100 min -low repeatability
Cederholm -inaccurate in IR/
Gutt, etc. diabetes
Subject: G: 20-25 75 g oral G/ computer CV=12-15%4 research/ +physiological admin
OMM 240 min I: 20-25 or meal software limited +broad information
Staff: CP: 20-25 clinical +repeatability
240 min (opt.) -long duration
-many samples
-costly
1 [Levy et al., 1999; McDonald et al., 1965]
2 [Ganda et al., 1978; Levy et al., 1999; Riccardi et al., 1985]
3 [Breda et al., 2001; Mari et al., 2001]
4 [Breda et al., 2001]
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Table A.3 Fasting insulin sensitivity tests.
Test Time Samples Input Calculation Repeatability Use Notes
Subject: I: 1 - - CV=20%1 clinical +simple, safe
FPI 5 min +good indication of IR,
Staff: even in normoglycaemic
10 min -surrogate metric
-not feasible in IR/diabetes
Subject: G: 1 - - - clinical +simple, safe
FPG 5 min ADA +recommended by ADA
Staff: recommended -diagnosis of IR too late
10 min -surrogate metric
Subject: G: 1 - spreadsheet CV=10-30%2 clinical/ +simple, safe
HOMA-IR 5 min I: 1 limited +includes insulin
Staff: research and glucose
10 min +many reference studies
-surrogate metric
-low resolution/repeatability
Subject: HbA1C: 1 - - CV=2-4%
3 clinical +not affected by
HbA1C 5 min concentration fluctuations
Staff: +indicative of mean
10 min glucose over 2-3 months
10 min +no fasting requirement
-diagnosis of IR too late
-surrogate metric
1 [Mather et al., 2001]
2 [Bonora et al., 2000; Matthews et al., 1985; Wallace et al., 2004b]
3 [Barr et al., 2002]
Appendix B
Pilot Test Model Fits
The 43 pilot tests of the proposed insulin sensitivity test are shown here. Shown
are glucose and insulin concentrations with the respective model fits, and the
estimated endogenous insulin secretion rate, obtained from the C-peptide con-
centrations.
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